Category: Blog

HealthEvidenceDigest offers evidence based coverage of FDA approvals, regulatory updates, clinical research, and drug safety communications. Posts focus on the data behind each decision and explain the potential impact on patient care and clinical practice.

Triple-Negative Breast Cancer Has Had No Good First-Line Option for Patients Who Cannot Take Immunotherapy. Trodelvy Just Became the First Advance in 20 Years for That Population and the New Standard for Those Who Can. Here Is What the ASCENT-03 and ASCENT-04 Data Shows.

The essentials: On June 24, 2026, the FDA approved two new first-line indications for Trodelvy (sacituzumab govitecan-hziy, Gilead Sciences) in adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC): Indication 1 (monotherapy): as a single agent for adults with unresectable locally advanced or metastatic TNBC who are not candidates for PD-1 or PD-L1 inhibitor-based therapy. Supported by ASCENT-03. Indication 2 (combination): in combination with pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for adults with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (combined positive score [CPS] at or above 10) as determined by an FDA-authorized test. Supported by ASCENT-04/KEYNOTE-D19. These are new first-line approvals; Trodelvy was previously approved for second-line and later treatment in TNBC (2020) and HR+/HER2-low breast cancer (2023). The clinical basis: ASCENT-03 (NCT05382299): 558 patients, first-line TNBC ineligible for PD-(L)1 inhibitors, randomized 1:1 to sacituzumab govitecan 10 mg/kg days 1 and 8 of a 21-day cycle versus physician’s choice chemotherapy. Median PFS 9.7 months versus 6.9 months; HR 0.62 (95% CI 0.50 to 0.77; p less than 0.0001); 38% reduction in risk of progression or death. Median DOR 12.2 months versus 7.2 months. ORR 48% versus 46%. OS data immature. ASCENT-04/KEYNOTE-D19 (NCT05382286): 443 patients, first-line PD-L1-positive (CPS at or above 10) TNBC, randomized to sacituzumab govitecan plus pembrolizumab versus physician’s choice chemotherapy plus pembrolizumab. Median PFS 11.2 months versus 7.8 months; HR 0.65 (95% CI 0.51 to 0.84; p=0.0009); 35% reduction in risk of progression or death. Confirmed ORR 61% versus 55%. OS not reached in either arm at data cutoff. Mechanism: sacituzumab govitecan is a Trop-2-directed antibody-drug conjugate (ADC) that delivers the topoisomerase I inhibitor SN-38 specifically to Trop-2-expressing cancer cells. Trop-2 is highly expressed in TNBC. Boxed warnings: severe neutropenia; severe diarrhea. Both are manageable with established protocols.

Triple-negative breast cancer is defined by what it lacks: no estrogen receptor expression, no progesterone receptor expression, and no HER2 overexpression. That combination of absences eliminates three of the most productive therapeutic targets in modern breast cancer medicine. There is no endocrine therapy. There is no HER2-directed antibody. For decades, the treatment toolkit for TNBC was essentially the same chemotherapy regimens that oncology had in the 1990s.

The arrival of pembrolizumab plus chemotherapy for PD-L1-positive TNBC in 2021 represented the last major first-line shift. But pembrolizumab only helps patients whose tumors express PD-L1 at adequate levels, roughly half of the metastatic TNBC population. For the other half, the patients with PD-L1-negative disease or contraindications to immunotherapy, the standard of care in 2025 was still first-line chemotherapy.

That remained true for more than 20 years after TNBC was first defined as a distinct subtype. As Dr. Javier Cortés, Head of the International Breast Cancer Center in Spain and principal investigator of ASCENT-03, put it: the ASCENT-03 outcome represents the first clinically meaningful advance for this patient population in more than 20 years.

The June 24, 2026 FDA approvals give Trodelvy (sacituzumab govitecan-hziy, Gilead Sciences) a first-line role across the full spectrum of metastatic TNBC, whether or not the patient is eligible for immunotherapy, based on two Phase 3 trials both published in the New England Journal of Medicine.

What Triple-Negative Breast Cancer Is and Why It Has Been So Hard to Treat

Breast cancer is not one disease. It is a collection of molecularly distinct subtypes with different drivers, different natural histories, and different therapeutic vulnerabilities. The most common subtypes, hormone receptor-positive breast cancers, are driven by estrogen and progesterone signaling and are treated with endocrine therapies that can maintain disease control for years. HER2-positive cancers are driven by HER2 amplification and are effectively treated with targeted antibodies and antibody-drug conjugates. Both subtypes have seen dramatic survival improvements over the past 30 years.

Triple-negative breast cancer accounts for approximately 10 to 15% of all breast cancers, but its clinical impact is disproportionate to its prevalence. TNBC is more common in younger women and is overrepresented in women of African descent, for whom the incidence rate is approximately double that of white women. It tends to grow rapidly and metastasize early. Unlike hormone receptor-positive disease, which can smolder for years before progressing, TNBC often spreads and becomes lethal within months of metastatic diagnosis.

The five-year survival rate for metastatic TNBC is approximately 12%, compared with 28% for other metastatic breast cancer subtypes. Nearly half of patients diagnosed with metastatic TNBC never receive a second line of therapy, making the first line of treatment the most consequential decision in their care. That clinical reality is the context within which both ASCENT-03 and ASCENT-04 must be understood.

The PD-L1 split that defines the treatment landscape

The 2021 approval of pembrolizumab plus chemotherapy (KEYNOTE-522) for PD-L1-positive metastatic TNBC was a meaningful advance, but it created a fork in the treatment pathway. To receive pembrolizumab, patients must have PD-L1 expression with a combined positive score (CPS) at or above 10, as measured by the PD-L1 IHC 22C3 pharmDx assay. Patients who are PD-L1-negative by this criterion, or who have contraindications to checkpoint inhibition (autoimmune conditions, organ transplantation, severe prior immune-related adverse events), have not been eligible for the pembrolizumab combination and have faced first-line chemotherapy alone.

ASCENT-03 is specifically designed for this PD-L1-ineligible population. ASCENT-04 targets the PD-L1-positive population and asks whether replacing chemotherapy with an ADC as the partner to pembrolizumab improves on the current standard.

The Science: What Sacituzumab Govitecan Is and How It Works

Sacituzumab govitecan is an antibody-drug conjugate (ADC): a targeted delivery vehicle that combines a cancer-specific antibody with a cytotoxic drug payload, connected by a chemical linker designed to release the payload preferentially inside tumor cells.

The three components of sacituzumab govitecan are:

The antibody: anti-Trop-2. Trop-2 (trophoblast cell-surface antigen 2) is a transmembrane glycoprotein that is highly expressed on the surface of many epithelial cancer cells, including the vast majority of TNBC tumors. Its expression in normal adult tissues is comparatively low, making it a useful tumor-targeting antigen. The anti-Trop-2 antibody in sacituzumab govitecan binds to Trop-2-expressing cancer cells and is internalized through receptor-mediated endocytosis, bringing the payload inside the cell.

The linker: hydrolysable. Unlike ADCs with stable, non-cleavable linkers that only release payload inside target cells, the hydrolysable linker in sacituzumab govitecan releases some active payload in the tumor microenvironment after internalization. This creates a “bystander effect”: neighboring cancer cells that may express lower levels of Trop-2 are also exposed to SN-38, potentially expanding the drug’s activity beyond the highest-Trop-2-expressing cells.

The payload: SN-38. SN-38 is the active metabolite of irinotecan, a topoisomerase I inhibitor. Topoisomerase I is an enzyme that relieves torsional stress in DNA during replication by creating temporary single-strand breaks. SN-38 traps topoisomerase I in a complex with DNA, preventing the breaks from being resealed. The result is irreversible DNA double-strand breaks during replication, triggering apoptosis. SN-38 is approximately 100 to 1,000 times more potent than irinotecan itself. The ADC delivery format allows higher intratumoral concentrations of SN-38 than would be tolerable with systemic irinotecan.

The drug-to-antibody ratio (DAR) of sacituzumab govitecan is approximately 7.6, meaning roughly 7 to 8 SN-38 molecules are attached per antibody. This high DAR, unusual among approved ADCs, contributes to the drug’s potency at Trop-2-expressing tumors.

ASCENT-03: The Monotherapy Indication

Design

ASCENT-03 (NCT05382299) was a Phase 3, multicenter, open-label, randomized trial enrolling 558 adults with unresectable locally advanced or metastatic TNBC who had not received prior systemic therapy for advanced disease and who were not candidates for PD-1 or PD-L1 inhibitor therapy. The enrollment criteria specifically required that patients either had PD-L1-negative tumors (CPS below 10) or had PD-L1-positive tumors but could not receive immunotherapy due to comorbidities.

Patients were randomized 1:1 to:

Sacituzumab govitecan 10 mg/kg IV on days 1 and 8 of a 21-day cycle
Physician’s choice chemotherapy (paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin)

The primary endpoint was progression-free survival (PFS) per blinded independent central review (BICR). Key secondary endpoints included overall survival (OS), objective response rate (ORR), duration of response (DOR), and safety.

Results

At a median follow-up of 13.2 months, sacituzumab govitecan demonstrated a statistically significant and clinically meaningful improvement in PFS compared with chemotherapy, with a median PFS of 9.7 months versus 6.9 months, representing a 38% reduction in the risk of disease progression or death (HR 0.62; 95% CI 0.50 to 0.78; p less than 0.0001). BioSpace

Endpoint	Sacituzumab govitecan	Chemotherapy (TPC)	Result
Median PFS (BICR)	9.7 months (95% CI 8.1 to 11.1)	6.9 months (95% CI 5.6 to 8.2)	HR 0.62 (95% CI 0.50 to 0.77); p less than 0.0001
Risk reduction in progression or death	38%	Reference	—
ORR	48% (95% CI 42% to 54%)	46% (95% CI 40% to 52%)	Comparable
Median DOR	12.2 months (95% CI 9.7 to 13.8)	7.2 months (95% CI 5.7 to 8.4)	Substantially longer with SG
Median PFS2 (time to next progression)	18.2 months (95% CI 15.9 to NR)	14.0 months (95% CI 12.5 to 17.4)	HR 0.70 (95% CI 0.55 to 0.90)
OS	Data immature (37% maturity at cutoff)	Data immature	No OS detriment observed

Source: Cortés J et al. Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer. NEJM. 2025. doi:10.1056/NEJMoa2511734. ASCENT-03, abstract LBA20, ESMO 2025.

The ORR was 48% with sacituzumab govitecan versus 46% with chemotherapy, with similar rates but a substantially longer median DOR with sacituzumab govitecan (12.2 months versus 7.2 months). The PFS benefit was consistent across prespecified subgroups, including patients with poor prognostic features such as disease recurrence within one year of prior curative therapy. FDA

The treatment discontinuation rate due to adverse events was lower with sacituzumab govitecan than with chemotherapy, a finding that supports the tolerability of the ADC relative to standard cytotoxic regimens in this population.

ASCENT-04/KEYNOTE-D19: The Combination Indication

Design

ASCENT-04/KEYNOTE-D19 (NCT05382286) was a Phase 3, multicenter, open-label, randomized trial enrolling 443 adults with locally advanced or metastatic TNBC who had not received prior systemic therapy for advanced disease and whose tumors expressed PD-L1 at a CPS of 10 or greater, confirmed centrally using the PD-L1 IHC 22C3 pharmDx assay.

Patients were randomized to:

Sacituzumab govitecan 10 mg/kg IV days 1 and 8 of a 21-day cycle plus pembrolizumab 200 mg IV on day 1 every 3 weeks (n=221)
Physician’s choice chemotherapy plus pembrolizumab 200 mg IV on day 1 every 3 weeks (n=222)

The primary endpoint was PFS by BICR.

Results

At a data cutoff of March 3, 2025, sacituzumab govitecan plus pembrolizumab led to a median PFS of 11.2 months (95% CI 9.3 to 16.7) versus 7.8 months (95% CI 7.3 to 9.3) with chemotherapy plus pembrolizumab, translating to a 35% reduction in the risk of disease progression or death (HR 0.65; 95% CI 0.51 to 0.84; p less than 0.001). Patient Care Online

Endpoint	SG plus pembrolizumab	Chemo plus pembrolizumab	Result
Median PFS (BICR)	11.2 months (95% CI 9.3 to 16.7)	7.8 months (95% CI 7.3 to 9.3)	HR 0.65 (95% CI 0.51 to 0.84); p=0.0009
Risk reduction in progression or death	35%	Reference	—
6-month PFS rate	72% (95% CI 65% to 77%)	63% (95% CI 56% to 70%)	—
12-month PFS rate	48% (95% CI 41% to 56%)	38% (95% CI 31% to 45%)	—
Confirmed ORR	61% (95% CI 55% to 68%)	55% (95% CI 48% to 62%)	—
Median OS	Not reached	Not reached	Immature; no OS detriment

Source: Tolaney SM et al. Sacituzumab govitecan plus pembrolizumab in first-line PD-L1-positive TNBC. ASCO 2025 / NEJM 2025. doi:10.1056/NEJMoa2511736. ASCENT-04/KEYNOTE-D19 NCT05382286.

An important contextual note: 43% of patients on the chemotherapy-plus-pembrolizumab arm crossed over to receive sacituzumab govitecan as a single agent in the second line, accounting for 81% of those who received subsequent treatment. The fact that the combination still showed statistically significant PFS benefit despite high crossover to the ADC in the control arm’s next line is a meaningful finding, because crossover typically dilutes the OS benefit in second-line crossover-heavy trials. Patient Care Online

Dr. Sara M. Tolaney, MD, MPH, chief of the Division of Breast Oncology at Dana-Farber Cancer Institute and principal investigator for ASCENT-04, described the combination as resulting in a statistically significant and clinically meaningful improvement in PFS in the first-line PD-L1-positive metastatic TNBC setting.

The Approval Framework: Two Indications Split by PD-L1 Status

The two new approvals create a rational treatment framework that mirrors how oncologists already stratify TNBC patients before initiating first-line therapy:

Patient profile	New first-line standard of care	Trial support
TNBC, not eligible for PD-(L)1 inhibitor therapy (PD-L1 CPS below 10, or contraindicated)	Trodelvy monotherapy (sacituzumab govitecan)	ASCENT-03
TNBC, PD-L1 CPS at or above 10 (confirmed by FDA-authorized assay)	Trodelvy plus Keytruda or Keytruda Qlex (sacituzumab govitecan plus pembrolizumab)	ASCENT-04

The key practical implication for oncology teams: PD-L1 testing using the 22C3 pharmDx assay is now a required step in first-line treatment planning for metastatic TNBC. This test was already standard of care at many centers for the pembrolizumab decision; the new approvals make it universal.

Ricki Fairley, co-founder and CEO of TOUCH, The Black Breast Cancer Alliance, noted that because so many patients may never receive subsequent lines of therapy, the ability to start with an effective option like Trodelvy with or without Keytruda in the first line is critical, particularly given TNBC’s disproportionate impact on Black women.

Trodelvy’s Complete Indication Picture After June 2026

Trodelvy now holds approvals across multiple settings in TNBC and beyond: Contagion Live

Indication	Approval date	Key trial
Previously treated (at or above 2 prior lines) metastatic TNBC	April 2020	ASCENT
Previously treated unresectable locally advanced or metastatic HR+/HER2-low breast cancer after endocrine therapy	February 2023	TROPiCS-02
First-line metastatic TNBC, not eligible for PD-(L)1 inhibitors (monotherapy)	June 24, 2026	ASCENT-03
First-line metastatic TNBC, PD-L1 CPS at or above 10 (plus pembrolizumab)	June 24, 2026	ASCENT-04

Safety: What Prescribers and Patients Need to Know

Sacituzumab govitecan carries a boxed warning for two serious adverse reactions, both attributable to the SN-38 topoisomerase I inhibitor payload.

Severe neutropenia (boxed warning): Grade 3 or higher neutropenia occurred in 43% of sacituzumab govitecan-treated patients in ASCENT-03. Neutropenia is the most clinically significant toxicity and requires proactive management. Granulocyte colony-stimulating factor (G-CSF) prophylaxis is strongly recommended and substantially reduces the severity and duration of neutropenic episodes. Complete blood count monitoring before each dose is standard. Dose reduction or delay may be required for severe neutropenia. Sanofi

Severe diarrhea (boxed warning): SN-38 causes significant gastrointestinal toxicity through its topoisomerase I inhibition in intestinal epithelium. Grade 3 or higher diarrhea occurred in 9% of sacituzumab govitecan-treated patients in ASCENT-03, compared with 16% with anemia in the chemotherapy arm. Management includes early loperamide at the first sign of loose stools and dose modification for persistent severe diarrhea. Patients with UGT1A1*28 homozygous genotype (reduced SN-38 glucuronidation) are at higher risk for both neutropenia and diarrhea and require dose reduction. Sanofi

Additional key safety information:

Safety item	Details	Clinical guidance
Severe neutropenia (boxed warning)	Grade 3 or higher neutropenia in approximately 43% in ASCENT-03; febrile neutropenia possible	G-CSF prophylaxis strongly recommended; CBC before each dose; dose modification per prescribing information
Severe diarrhea (boxed warning)	Grade 3 or higher in approximately 9%; early-onset (within days of infusion) common	Loperamide at first sign of loose stools; dose modification for severe or persistent diarrhea
UGT1A1 genotype	Patients homozygous for UGT1A128 (poor metabolizers) have reduced SN-38 clearance and higher toxicity risk	Starting dose reduction to 7.5 mg/kg recommended in homozygous UGT1A128 patients
Nausea and vomiting	Common; manageable with antiemetics	Prophylactic antiemetics recommended; anti-nausea medications as needed
Hypersensitivity and infusion reactions	Severe reactions including anaphylaxis reported	Premedication; monitoring during infusion; resuscitation capability required
Embryo-fetal toxicity	SN-38 can cause fetal harm	Effective contraception during treatment and for 6 months after last dose for females; 3 months for males
Pembrolizumab-related toxicities (combination indication)	Immune-mediated adverse reactions including pneumonitis, colitis, hepatitis, endocrinopathies; infusion reactions	Refer to Keytruda prescribing information for full immune-related AE management guidance
Serious adverse reactions in ASCENT-03 CheckRare	Occurred in 26% of patients; fatal adverse reactions in 2.5%	Close clinical monitoring; dose modification per prescribing information

What This Means for Patients and Oncology Teams

For patients with metastatic TNBC not eligible for immunotherapy

This population has had no meaningful treatment advance since TNBC was defined more than 20 years ago. ASCENT-03 represents the first clinically meaningful advance for this patient population in over 20 years, according to Dr. Cortés. The 38% reduction in progression risk, the nearly 3-month improvement in median PFS (9.7 versus 6.9 months), and the dramatically longer duration of response (12.2 versus 7.2 months) constitute a clinically significant departure from what chemotherapy alone has provided. Pfizer

For oncologists managing these patients: sacituzumab govitecan monotherapy is now an FDA-approved first-line standard for PD-(L)1-ineligible metastatic TNBC. The G-CSF prophylaxis requirement and the UGT1A1 genotype assessment should be part of the treatment initiation workup.

For patients with PD-L1-positive metastatic TNBC

The ASCENT-04 data establishes sacituzumab govitecan plus pembrolizumab as a new first-line option for patients with CPS at or above 10, with a 35% reduction in progression risk over the prior standard of chemotherapy plus pembrolizumab. The combination’s 11.2-month median PFS and 61% ORR represent a meaningful improvement over what was achievable in this setting.

The combination requires PD-L1 testing before initiation, coordination of the ADC and checkpoint inhibitor schedules, and management of both SN-38 toxicities (neutropenia, diarrhea) and potential immune-mediated adverse events from pembrolizumab.

The sequencing question and OS data

One important clinical caveat applies to both approvals: overall survival data were immature at the time of analysis for both ASCENT-03 and ASCENT-04. The PFS benefit is established and statistically significant, but whether first-line Trodelvy translates into longer overall survival will depend on mature OS data from ongoing follow-up. Given the high crossover rate in ASCENT-04 (43% of control arm patients received sacituzumab govitecan in the second line), the OS signal may be attenuated even if the drug provides genuine survival benefit. These are data to watch in updated analyses from both trials.

For patients and families navigating a new metastatic TNBC diagnosis: the National Breast Cancer Foundation, Susan G. Komen Foundation, and TOUCH, The Black Breast Cancer Alliance all maintain current patient resources including clinical trial locators and financial assistance navigation for Trodelvy access.

For related HED coverage on oncology ADC approvals and breast cancer treatment advances, see our prior coverage on Pomalyst (pomalidomide) and what the multiple myeloma treatment landscape looks like as generic competition arrives in the 2026 LOE series.

Sources

FDA approval announcement: FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer. FDA.gov. June 24, 2026.

Gilead press release: U.S. FDA approves Trodelvy for first-line treatment of metastatic triple-negative breast cancer. gilead.com. June 24, 2026.

ASCO Post approval summary: FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination With Pembrolizumab for First-Line Treatment of TNBC. ascopost.com. June 2026.

Pharmacy Times clinical review: FDA Approves Sacituzumab Govitecan for First-Line Treatment of Advanced Triple-Negative Breast Cancer. pharmacytimes.com. June 2026.

BioPharm International clinical summary: Trop-2-Directed ADC Sacituzumab Govitecan Earns FDA Approval in First-Line Metastatic TNBC. biopharminternational.com. June 2026.

CancerNetwork detailed clinical summary: Sacituzumab Govitecan Receives FDA Approval Across 2 TNBC Indications. cancernetwork.com. June 2026.

OncLive: ASCENT-04 primary analysis and Dr. Tolaney commentary: Dr Tolaney on the FDA Approval of First-Line Sacituzumab Govitecan Plus Pembrolizumab for TNBC. onclive.com. June 2026.

ASCENT-03 primary NEJM publication: Cortés J et al. Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer. New England Journal of Medicine. 2025. doi:10.1056/NEJMoa2511734.

ASCENT-03 ESMO 2025 abstract (LBA20): Cortés JC et al. Primary results from ASCENT-03. Presented at ESMO Congress 2025. October 19, 2025. Berlin, Germany.

ASCENT-03 trial registration: NCT05382299. ClinicalTrials.gov.

ASCENT-04 primary NEJM publication: Tolaney SM et al. Sacituzumab govitecan plus pembrolizumab in first-line PD-L1-positive TNBC. NEJM. 2025. doi:10.1056/NEJMoa2511736.

ASCENT-04 trial registration: NCT05382286. ClinicalTrials.gov.

ASCENT-04 PFS2 and subsequent therapy data: Kalinsky K et al. PFS2 and subsequent therapies in ASCENT-04. ASCO 2026.

ADC mechanism and Trop-2 biology: Antibody-Drug Conjugates in Cancer Therapy. PMC7734386.

Sacituzumab govitecan StatPearls: Sacituzumab Govitecan. StatPearls. NCBI.

TNBC overview: Triple-Negative Breast Cancer. StatPearls. NCBI.

Pembrolizumab plus chemo TNBC approval (KEYNOTE-522): FDA approves pembrolizumab for triple-negative breast cancer. FDA.gov.

ACS TNBC overview: Triple-Negative Breast Cancer. cancer.org.

Patient resources: National Breast Cancer Foundation | Susan G. Komen Foundation | TOUCH, The Black Breast Cancer Alliance | Gilead Trodelvy patient support

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Trodelvy (sacituzumab govitecan-hziy) carries a boxed warning for severe neutropenia and severe diarrhea. Treatment decisions for metastatic TNBC, including the choice between monotherapy and combination regimens and the role of PD-L1 testing in treatment planning, should be made in close collaboration with a board-certified medical oncologist experienced in breast cancer management.

June 30, 2026

Thyroid Eye Disease Has Had Only One Approved Treatment Since 2020. Lumvoa Just Became the Second, and It’s the First Proven to Work in Both Active and Chronic Disease. Here Is What the THRIVE Trials Show.

The essentials: On June 26, 2026, the FDA approved Lumvoa (veligrotug-vvze, Viridian Therapeutics) for the treatment of thyroid eye disease (TED) in adults. Lumvoa is the second FDA-approved pharmacologic therapy for TED, following teprotumumab (Tepezza, Amgen/Horizon), which was approved in 2020 for active TED. What makes Lumvoa distinct: it is the first FDA-approved treatment for TED with labeling that includes clinical data in both active and chronic TED, making it the first therapy with a regulatory basis for use across the full disease spectrum. Mechanism: veligrotug is a full antagonist of the insulin-like growth factor-1 receptor (IGF-1R), a humanized monoclonal antibody that completely blocks IGF-1R signaling. This distinguishes it from teprotumumab, which is a partial/mixed agonist-antagonist. Regulatory designations: Breakthrough Therapy Designation; Priority Review. Clinical basis: Phase 3 THRIVE (NCT05176639) in active TED and Phase 3 THRIVE-2 (NCT06021054) in chronic TED. Both trials met their primary endpoint and all secondary endpoints at week 15 with high statistical significance. THRIVE (active TED, n=113): Proptosis Responder Rate (PRR) 70% versus 5% placebo (p less than 0.0001); mean proptosis reduction 2.9 mm versus 0.5 mm; diplopia complete resolution 54% versus 12% (p less than 0.0001). THRIVE-2 (chronic TED, n=188): PRR 56% versus 8% (p less than 0.0001); mean proptosis reduction 2.34 mm versus 0.46 mm; diplopia improvement 56% versus 25% (p=0.0006); diplopia complete resolution 32% versus 14% (p=0.0152). Rapid onset: statistically significant proptosis reduction observed as early as week 3 (after one infusion) in both trials. Treatment course: 5 intravenous infusions administered every 3 weeks (infusions at weeks 0, 3, 6, 9, 12; primary analysis at week 15). Shorter infusion course than teprotumumab (8 infusions). Key safety: infusion reactions approximately 9%; hyperglycemia 12% including patients without pre-existing diabetes; hearing impairment (class risk); muscle spasms most common adverse reaction. Available now: commercial launch immediately following approval.

Thyroid eye disease is one of those conditions that sounds manageable until you understand what it actually does to the people who have it. The immune system targets the tissues behind and around the eye — the orbital fat, the extraocular muscles, the connective tissue. The result can include forward protrusion of the eyeball (proptosis) that makes it impossible to close the eye fully, double vision that prevents driving or reading or functioning normally, and pain behind the eyes that is present with every eye movement. At its most severe, the expansion of orbital tissue compresses the optic nerve, threatening permanent vision loss.

Before 2020, the only systemic treatment for TED was intravenous corticosteroids, which reduce inflammation but do not address the underlying disease mechanism. In 2020, teprotumumab (Tepezza) became the first drug approved specifically for TED, targeting the insulin-like growth factor-1 receptor (IGF-1R) and demonstrating that the proptosis and diplopia of TED could be substantially reversed pharmacologically.

Lumvoa (veligrotug-vvze, Viridian Therapeutics), approved June 26, 2026, is the second drug approved for TED — and the first with regulatory labeling that includes data across the full disease spectrum, both active and chronic phases. The THRIVE and THRIVE-2 Phase 3 trials demonstrated not only that veligrotug works in both phases, but that it works rapidly, producing statistically significant proptosis reduction after just one infusion in week 3, with diplopia improvements that are among the most robust data ever generated for any TED therapy.

What Thyroid Eye Disease Is and Why the Active/Chronic Distinction Matters

Thyroid eye disease is a rare autoimmune orbitopathy most commonly associated with Graves disease, a condition in which autoantibodies against the thyroid-stimulating hormone receptor (TSHR) drive overproduction of thyroid hormone. In TED, those same autoantibodies, along with antibodies to IGF-1R, activate fibroblasts in the orbital fat and extraocular muscles, triggering inflammation, glycosaminoglycan accumulation, and remodeling of the orbital soft tissues. The result is a progressive expansion of orbital volume that pushes the eyeball forward (proptosis) and impairs the function of the muscles that move it (causing diplopia and limiting motility).

TED affects approximately 16 to 19 adults per 100,000, primarily those with Graves disease, though it can occur in euthyroid or hypothyroid patients with autoimmune thyroid conditions. Women are more commonly affected than men.

The active and chronic phases: why they are clinically distinct

Disease phase	Definition	Characteristics	Clinical significance
Active TED	Clinical Activity Score (CAS) at or above 3/7; onset within approximately 15 months	Active inflammation; edema; periorbital redness; pain; rapidly changing proptosis	Amenable to anti-inflammatory intervention; spontaneous partial remission possible
Chronic TED	CAS below 3; disease onset more than 15 months ago	Fibrosis and remodeling dominate over active inflammation; proptosis is stable; diplopia is fixed	Less responsive to corticosteroids; fibrotic changes once thought irreversible; surgical intervention (orbital decompression, strabismus surgery, eyelid surgery) traditionally the primary option

This distinction has historically defined treatment options. Teprotumumab’s pivotal trial was conducted in active TED, and its label is primarily supported by data in this phase. Patients with chronic TED, who have passed through the active inflammatory phase into a state dominated by fibrotic orbital remodeling, have had essentially no systemic pharmacologic options except orbital decompression surgery.

The THRIVE-2 trial, conducted specifically in chronic TED, is the first global Phase 3 randomized controlled trial to demonstrate statistically significant improvement in both proptosis and diplopia in this population. That is the clinical significance of Lumvoa’s “both active and chronic” labeling.

The Science: Why IGF-1R Is the Target and What “Full Antagonist” Means

The IGF-1R/TSHR cross-talk mechanism

The pathogenesis of TED involves a synergistic interaction between two surface receptors on orbital fibroblasts: the thyroid-stimulating hormone receptor (TSHR) and the insulin-like growth factor-1 receptor (IGF-1R). These two receptors form a physical complex on the fibroblast surface and engage in molecular cross-talk: activation of one sensitizes or amplifies signaling through the other.

In TED, autoantibodies against TSHR and IGF-1R activate this fibroblast complex, driving: expansion of orbital preadipocytes into mature fat cells (hyaluronan-producing adipogenesis); differentiation of fibroblasts into myofibroblasts that produce the fibrous connective tissue that hardens the orbital fat; and production of hyaluronic acid and glycosaminoglycans that attract water, expanding orbital volume further. The combination of fat expansion, glycosaminoglycan accumulation, and fibrotic remodeling produces the characteristic proptosis, restricted ocular motility, and diplopia of TED.

IGF-1R inhibition interrupts this fibroblast activation cascade at the receptor level. By blocking IGF-1R, the downstream signaling pathways (PI3K/Akt, MAPK/ERK) that drive fibroblast proliferation, differentiation, and hyaluronan synthesis are suppressed. The anti-inflammatory effect follows: the cycle of immune cell recruitment driven by fibroblast activation slows, and the structural remodeling that produces proptosis is interrupted.

Full antagonist versus partial agonist-antagonist: the distinction from teprotumumab

Veligrotug is described as a full antagonist of IGF-1R. This is a specific pharmacological claim that distinguishes it from teprotumumab.

Teprotumumab acts as a partial agonist at IGF-1R in certain contexts: while it blocks much of IGF-1R’s downstream signaling, it also produces some residual IGF-1R activation through the receptor before its internalization and degradation. Veligrotug, by contrast, binds the receptor and completely blocks signaling without producing any agonist activation. The clinical relevance of this pharmacological distinction is an active area of investigation, but the theoretical benefit of full antagonism is the absence of any compensatory receptor activation that might limit or counterbalance the therapeutic blockade.

The “full antagonist” distinction is included in Lumvoa’s approved labeling, which is clinically notable. It is not a marketing description; it is a regulatory characterization of the drug’s pharmacological mechanism supported by preclinical and clinical evidence provided to the FDA.

The THRIVE and THRIVE-2 Trials: Complete Data

THRIVE: Phase 3 in active TED

THRIVE (NCT05176639) was a randomized, double-masked, placebo-controlled Phase 3 trial enrolling adults with moderate-to-severe active TED, defined by CAS at or above 3/7, proptosis at or above 3 mm, and disease onset within 15 months of screening.

Patients were randomized to veligrotug 10 mg/kg IV or placebo, administered every 3 weeks for 5 total infusions (at weeks 0, 3, 6, 9, and 12), with the primary analysis at week 15. The trial enrolled 113 patients (75 veligrotug; 38 placebo).

Endpoint at week 15	Veligrotug	Placebo	p-value
Proptosis Responder Rate (PRR by Hertel)	70%	5%	p less than 0.0001
PRR by MRI/CT	69%	9%	p less than 0.0001
Mean proptosis reduction	2.9 mm	0.5 mm	p less than 0.0001
Mean CAS reduction	3.4 points	1.7 points	p less than 0.0001
Diplopia complete resolution (in patients with diplopia at baseline)	54% (27/50)	12% (3/26)	p less than 0.0001
PRR statistically significant from week 3 (after 1 infusion)	Yes	—	p less than 0.0001

Source: Endocrine Practice THRIVE topline results abstract. 2025. PMC12545473. THRIVE NCT05176639.

The 70% proptosis responder rate at week 15 — compared to 5% for placebo — is a dramatic treatment effect. The 54% complete diplopia resolution rate in patients who had diplopia at baseline is particularly notable: more than half of patients with double vision resolved it completely within 15 weeks of treatment.

The rapid onset finding deserves specific attention. Statistical significance in proptosis reduction was achieved at week 3, after only a single infusion. This speed of response is faster than what was observed in the teprotumumab clinical trials and has direct clinical significance: patients and clinicians can assess whether treatment is working within the first month rather than waiting for the full course to complete.

THRIVE-2: Phase 3 in chronic TED

THRIVE-2 (NCT06021054) used the same treatment design but enrolled adults with moderate-to-severe chronic TED, defined as disease onset more than 15 months before screening and proptosis at or above 3 mm with any CAS value. The mean time since TED onset in enrolled patients was 69.8 months — nearly 6 years — making this a population in whom fibrotic remodeling had been accumulating for a substantial period. The trial enrolled 188 patients (125 veligrotug; 63 placebo) with a 2:1 randomization.

Endpoint at week 15	Veligrotug	Placebo	p-value
Proptosis Responder Rate (PRR by Hertel)	56%	8%	p less than 0.0001
PRR by MRI/CT	48%	3%	p less than 0.0001
Mean proptosis reduction	2.34 mm	0.46 mm	p less than 0.0001
Overall Responder Rate	56%	7%	p less than 0.0001
Diplopia improvement (Gorman scale; in patients with diplopia at baseline)	56%	25%	p=0.0006
Diplopia complete resolution (Gorman scale)	32%	14%	p=0.0152
CAS of 0 or 1 achieved (patients with CAS at or above 3 at baseline)	54%	24%	p=0.0060
PRR statistically significant from week 3 (after 1 infusion)	Yes	—	—

Source: Endocrine Practice THRIVE-2 publication. 2025. doi:10.1016/j.eprac.2025. NCT06021054.

THRIVE-2 is the first randomized controlled trial in chronic TED to demonstrate statistically significant improvement in both proptosis and diplopia. The finding that 56% of chronic TED patients achieved a proptosis response, in a disease phase previously considered refractory to systemic pharmacotherapy, challenges the historical assumption that fibrotic TED could only be addressed surgically.

The 32% complete diplopia resolution rate in chronic TED patients with diplopia is also clinically significant: for a patient who has had double vision for years, the possibility of complete resolution from a 12-week course of infusions represents a meaningful departure from the trajectory that orbital decompression, strabismus surgery, and eyelid surgery were previously the only path toward.

How Lumvoa Compares to Tepezza: A Clinical Summary

Teprotumumab (Tepezza) was the first drug ever approved for TED and established proof of concept for IGF-1R inhibition in this disease. Lumvoa enters the same mechanistic space with several clinically meaningful differences.

Feature	Lumvoa (veligrotug)	Tepezza (teprotumumab)
Mechanism	Full IGF-1R antagonist	Partial agonist-antagonist at IGF-1R
Active TED data	Yes (THRIVE Phase 3)	Yes (pivotal Phase 2 and Phase 3)
Chronic TED data	Yes (THRIVE-2 Phase 3; first RCT in chronic TED with positive diplopia data)	Limited; label primarily supported by active TED data
Number of infusions	5 infusions over 12 weeks	8 infusions over 21 weeks
Dose	10 mg/kg IV every 3 weeks	10 mg/kg first infusion, then 20 mg/kg every 3 weeks
Onset of proptosis response	Week 3 (after 1 infusion)	Week 6 (after 2 infusions)
Hyperglycemia rate	Approximately 12%	Approximately 10%
Hearing impairment	Reported (class risk; approximately 16% in THRIVE active TED)	Reported (class risk; approximately 10 to 29% in trials)
Chronic TED diplopia resolution	32% complete resolution (THRIVE-2)	Not established in a dedicated chronic TED Phase 3 RCT

Sources: Viridian THRIVE/THRIVE-2 data; Tepezza FDA approval and prescribing information.

The most clinically significant difference for prescribers is the combination of fewer infusions and the chronic TED data. From a patient experience standpoint, 5 infusions over 12 weeks is a substantially lighter treatment burden than 8 infusions over 21 weeks. Infusion center visits for a condition that already carries significant quality-of-life burden matter.

Dr. Michael Yen, MD, Professor of Oculoplastic Surgery and Ophthalmology at Baylor College of Medicine and an investigator in the THRIVE program, noted that the clinical data demonstrated meaningful improvements across the full spectrum of TED, including rapid reductions in proptosis and significant improvements in diplopia, in both the active and chronic disease settings.

An important note on indirect comparison: THRIVE and THRIVE-2 were not head-to-head trials against teprotumumab. The efficacy numbers from Lumvoa’s trials should not be used for direct numeric comparison against teprotumumab’s trials. Patient populations, trial designs, and baseline characteristics differed across programs. What can be said is that both drugs demonstrated substantial, statistically significant, clinically meaningful benefits in their respective trials, and that Lumvoa now adds a Phase 3 evidence base in chronic TED where Tepezza’s regulatory support was limited.

Safety: What Prescribers and Patients Need to Know

Lumvoa’s safety profile is consistent with the IGF-1R inhibitor class established by teprotumumab, with some differences in rate and pattern across specific adverse events.

Most common adverse reactions (occurring in 5% or more of patients):

Muscle spasms were the most common adverse event overall, reported in approximately 36% of veligrotug-treated patients versus 6% of placebo patients in THRIVE-2. While striking in relative frequency, the muscle spasms were predominantly mild in severity and rarely led to treatment discontinuation. Other common adverse reactions include headache, fatigue, diarrhea, nausea, nasopharyngitis, elevated creatine phosphokinase, dry skin, and hypertension.

Key warnings and precautions:

Infusion reactions: Infusion-related reactions occurred in approximately 9% of Lumvoa-treated patients in the THRIVE program. Most were mild to moderate. Premedication before infusions and clinical monitoring during administration are standard management. Patients should be observed during and after each infusion.

Hyperglycemia: Hyperglycemia was reported in approximately 12% of veligrotug-treated patients, including patients without pre-existing diabetes. IGF-1R inhibition affects insulin signaling, and glucose elevation is a class effect shared with teprotumumab. Blood glucose should be monitored before and during treatment, particularly in patients with diabetes or prediabetes. Dose modification or antidiabetic medication adjustment may be required.

Hearing impairment: Hearing impairment, including potentially permanent hearing loss, is identified as a risk in Lumvoa’s prescribing information. This is a class effect of IGF-1R inhibitors in TED. In the THRIVE trials, hearing-related adverse events were reported in approximately 13% to 16% of veligrotug-treated patients in the active and chronic TED trials, with a placebo-adjusted rate of approximately 9.6% in THRIVE-2. Patients should be counseled about this risk before treatment initiation. Audiologic evaluation before and during treatment is clinically appropriate, and patients should report any new hearing changes promptly.

Inflammatory bowel disease: The prescribing information includes a risk of inflammatory bowel disease exacerbation. Patients with a history of inflammatory bowel disease should be evaluated carefully before initiating Lumvoa.

Embryo-fetal toxicity: Based on its mechanism of action affecting IGF-1R signaling, Lumvoa may cause fetal harm. Females of reproductive potential should use effective contraception during treatment and for a specified period after the final infusion. Pregnancy testing before initiating treatment is appropriate.

Serious adverse events: Serious treatment-emergent adverse events in THRIVE were reported in 4 veligrotug-treated patients, all assessed as unrelated to treatment. Serious adverse events in THRIVE-2 occurred in 2% of veligrotug patients versus 3% of placebo patients. Treatment completion rates were high: 94% of veligrotug-treated patients in THRIVE-2 completed their full treatment course, a retention rate that speaks to the overall tolerability of the regimen.

What This Means for Patients and Clinicians

For patients with active TED

Lumvoa provides a second approved systemic pharmacologic option for active TED, alongside teprotumumab. The clinical discussion with an ophthalmologist or oculoplastic surgeon experienced in TED should now include both options, weighing the specific clinical profile, the shorter infusion course, the full antagonist mechanism, and individual patient factors including diabetes status, hearing risk, and infusion access.

For patients who have previously received teprotumumab and experienced disease recurrence or inadequate response, Lumvoa’s distinct pharmacological profile as a full antagonist represents a mechanistically differentiated alternative. Whether prior IGF-1R therapy exposure affects veligrotug response is a question that ongoing clinical experience will address. The THRIVE trials excluded patients who had received prior anti-IGF-1R therapy, so the evidence in this subgroup is not yet established.

For patients with chronic TED

This is the population for whom Lumvoa’s approval is most transformative. Until now, patients in the chronic phase of TED with established proptosis and fixed diplopia faced a choice between living with these manifestations or pursuing surgical correction: orbital decompression for proptosis, strabismus surgery for diplopia, and eyelid surgery for cosmetic and functional restoration. These surgeries are effective but carry their own risks and often require sequential procedures.

The THRIVE-2 data demonstrates that pharmacologic reversal of chronic TED manifestations is achievable in a meaningful proportion of patients. A 56% proptosis response rate and 32% complete diplopia resolution in a population with a mean TED onset of nearly 6 years challenges the assumption that fibrotic orbital changes are irreversible. For patients and clinicians managing chronic TED, a conversation about whether a 12-week course of Lumvoa infusions might reduce or eliminate the need for surgical intervention is now evidence-supported.

Christine Gustafson, Founder and Executive Director of the TED Community Organization, noted that a new treatment option could benefit many patients living with the physical and emotional burden of thyroid eye disease. The psychosocial burden of TED is well-documented: disfiguring proptosis, double vision that impairs independence, and pain with eye movement contribute to depression, social withdrawal, and reduced quality of life that persist well beyond the active inflammatory phase.

Practical access and administration

Lumvoa launched commercially on June 26, 2026, the same day as FDA approval. Treatment requires intravenous infusion access, which means a certified infusion center or hospital outpatient setting. The 5-infusion schedule over 12 weeks, with infusions every 3 weeks, represents a meaningful reduction in infusion center visits compared to teprotumumab’s 8-infusion protocol. Viridian has established a patient support program to assist with access, insurance navigation, and infusion site coordination.

For related HED coverage on autoimmune and rare endocrine conditions, see our post on Tzield (teplizumab) approved as the first disease-modifying therapy for recently diagnosed Stage 3 type 1 diabetes and our post on Hympavzi (marstacimab) expanding to cover children aged 6 to 11 and inhibitor-positive hemophilia patients.

Sources

Viridian FDA approval press release: Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa (veligrotug-vvze) for the Treatment of Thyroid Eye Disease. BusinessWire. June 26, 2026.

Eyewire clinical summary: FDA Approves Viridian’s Lumvoa for Thyroid Eye Disease. eyewire.news. June 2026.

Pharmacally detailed clinical coverage: FDA Approves Veligrotug as First Treatment for Active and Chronic Thyroid Eye Disease. pharmacally.com. June 2026.

Ophthalmology Times (full safety and mechanism detail): FDA approves veligrotug-vvze (Lumvoa) for thyroid eye disease across active and chronic stages. ophthalmologytimes.com. June 2026.

Optometry Times: FDA approves Lumvoa (veligrotug-vvze) for active and chronic thyroid eye disease. optometrytimes.com. June 2026.

HCPLive BLA acceptance coverage: FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease. hcplive.com. March 2026.

THRIVE topline results (Endocrine Practice): Efficacy and Safety of Veligrotug, a Full Antagonist Monoclonal Antibody to IGF-1 Receptor, in Active Thyroid Eye Disease: THRIVE Phase 3 Topline Results. Endocrine Practice. 2025.

THRIVE PMC abstract: OR31-04 Efficacy and Safety of Veligrotug in Active TED: THRIVE Phase 3 Topline Results. PMC12545473.

THRIVE-2 primary results (Endocrine Practice): THRIVE-2 Phase 3 Trial of Veligrotug in Chronic Thyroid Eye Disease: Efficacy and Safety at 15 Weeks. Endocrine Practice. 2025.

THRIVE-2 topline press release (Viridian): Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial. ir.viridiantherapeutics.com. 2024.

THRIVE trial registration: NCT05176639. ClinicalTrials.gov.

THRIVE-2 trial registration: NCT06021054. ClinicalTrials.gov.

Viridian BLA acceptance and Priority Review: Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug. ir.viridiantherapeutics.com. 2025.

Teprotumumab FDA approval: FDA approves teprotumumab-trbw for thyroid eye disease. FDA.gov. January 2020.

IGF-1R biology: IGF-1R in autoimmune disease. PMC6126283.

Thyroid eye disease overview: Thyroid Eye Disease. StatPearls. NCBI.

Graves disease overview: Graves Disease. NIDDK.

Lumvoa prescribing information: LUMVOA (veligrotug-vvze) Prescribing Information. Viridian Therapeutics. 2026.

Patient resources: TED Community Organization | American Thyroid Association: TED patient resources | Viridian Lumvoa patient support

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Thyroid eye disease management, including the decision to initiate pharmacologic therapy with Lumvoa or Tepezza, requires individualized evaluation by a board-certified ophthalmologist, oculoplastic surgeon, or endocrinologist with experience in TED. Patients with active or chronic TED should discuss all systemic treatment options with their managing specialist before initiating therapy.

June 29, 2026

Severe Hypertriglyceridemia Has No Good Treatment Options. Tryngolza Just Became the First Approved Therapy Shown to Reduce Acute Pancreatitis Risk. Here Is What the CORE Trial Data Shows.

The essentials: On June 24, 2026, the FDA approved a new indication for Tryngolza (olezarsen, Ionis Pharmaceuticals) as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG: fasting triglycerides at or above 500 mg/dL). This makes Tryngolza the first and only therapy approved specifically to reduce the risk of acute pancreatitis in this population. Tryngolza was originally approved in December 2024 for adults with familial chylomicronemia syndrome (FCS), a rare monogenic form of sHTG affecting roughly 3,000 to 5,000 people in the U.S. The new sHTG indication covers approximately 3 million Americans who have severe hypertriglyceridemia from multiple non-monogenic causes. Mechanism: olezarsen is a GalNAc-conjugated antisense oligonucleotide (ASO) that targets apolipoprotein C-III (apoC-III) mRNA in hepatocytes, reducing apoC-III production. ApoC-III inhibits lipoprotein lipase (LPL), the enzyme responsible for clearing triglyceride-rich lipoproteins from the bloodstream. By reducing apoC-III, olezarsen restores LPL activity and promotes clearance of triglycerides through both LPL-dependent and LPL-independent pathways. The clinical basis: Phase 3 CORE-TIMI 72a (NCT05079919, n=617) and CORE2-TIMI 72b (NCT05552326, n=446), conducted with The TIMI Study Group. Mean baseline triglycerides: 1,116 mg/dL. Placebo-adjusted triglyceride reduction at 6 months: up to 72% (80 mg dose) in CORE, sustained through 12 months. Acute pancreatitis events: 85% reduction in pooled analyses; pooled rate ratio 0.15 (95% CI 0.05 to 0.40; p less than 0.001). Patients achieving triglycerides below 500 mg/dL: 86%. Primary NEJM publication: Marston NA et al. NEJM. 2025. doi:10.1056/NEJMoa2512761. Regulatory designations: Priority Review; Breakthrough Therapy designation (November 2025). Dosing: 50 mg or 80 mg subcutaneous injection once monthly via autoinjector. Available in the U.S. July 2026. Key safety considerations: injection site reactions; liver enzyme elevations; dose-dependent hepatic fat fraction increases; more thrombocytopenia with 80 mg dosing.

Hypertriglyceridemia is one of the most undertreated serious lipid disorders in clinical medicine. While elevated LDL cholesterol commands the vast majority of attention in cardiovascular risk management, very high triglycerides carry their own distinct and devastating clinical consequence: acute pancreatitis. When fasting triglycerides reach approximately 500 mg/dL and above, the risk of severe, recurrent, and potentially fatal pancreatitis rises substantially. At levels above 1,000 mg/dL, the risk becomes acutely dangerous.

And until June 24, 2026, no FDA-approved therapy had ever demonstrated that it could reduce the risk of acute pancreatitis in patients with severe hypertriglyceridemia. Fibrates, fish oils, and niacin lower triglycerides in this population, but none of them had generated the clinical trial evidence showing that their triglyceride reduction translated into fewer pancreatitis events.

Tryngolza (olezarsen, Ionis Pharmaceuticals) is the first. The Phase 3 CORE and CORE2 trials, involving 1,061 adults with fasting triglycerides at or above 500 mg/dL and a mean baseline level of 1,116 mg/dL, demonstrated an 85% reduction in acute pancreatitis events and up to 72% reduction in triglycerides compared to placebo — and did so with a once-monthly subcutaneous injection targeting the same molecular pathway responsible for the most severe form of this disease.

This post covers what severe hypertriglyceridemia is and why pancreatitis is its most feared consequence, how the apoC-III mechanism drives triglyceride accumulation and why targeting it with an antisense oligonucleotide represents a fundamentally different approach from existing therapies, what the CORE and CORE2 trials showed, the safety profile of olezarsen, how it relates to the original FCS indication, and what this approval means for the much larger population of Americans with severe hypertriglyceridemia.

What Severe Hypertriglyceridemia Is and Why It Causes Pancreatitis

Triglycerides are the primary form of dietary fat storage in the body. After meals, triglycerides are packaged into chylomicrons in the intestine and released into the bloodstream, where they are broken down by lipoprotein lipase (LPL). Between meals, the liver packages triglycerides into very low-density lipoprotein (VLDL) for transport and distribution. Under normal conditions, fasting triglycerides are below 150 mg/dL.

Severe hypertriglyceridemia is defined as fasting triglycerides at or above 500 mg/dL. At this level, the body’s triglyceride clearance machinery is overwhelmed: chylomicrons and VLDL remain in the circulation at pathologically elevated concentrations. The population affected in the United States is substantial, approximately 3 million adults, arising from combinations of genetic predisposition, metabolic conditions (type 2 diabetes, obesity, hypothyroidism), alcohol use, and medications that raise triglycerides (corticosteroids, certain antipsychotics, estrogens, beta-blockers).

Why hypertriglyceridemia causes pancreatitis

The mechanism by which very high triglycerides cause acute pancreatitis is not fully elucidated but involves the accumulation of triglyceride-rich lipoproteins (chylomicrons) in the pancreatic capillaries. Pancreatic lipase, the same enzyme that normally digests dietary fat in the intestine, hydrolyzes these accumulated triglycerides locally in the pancreatic microcirculation. The free fatty acids released from this hydrolysis are directly toxic to pancreatic acinar cells, producing the inflammatory cascade of acute pancreatitis. The pathological cycle is self-amplifying: local tissue damage increases vascular permeability, concentrating triglycerides further in the pancreatic bed.

Hypertriglyceridemia-induced acute pancreatitis differs from gallstone or alcohol-induced pancreatitis in several clinically important ways. Patients often present with more severe disease at initial diagnosis. The condition is highly recurrent: patients who have had one episode remain at high risk for subsequent attacks as long as triglycerides remain uncontrolled. Repeated episodes of acute pancreatitis cause cumulative damage including pancreatic fibrosis, exocrine insufficiency, and secondary diabetes. And the acute attacks themselves can be life-threatening, with mortality rates of 5 to 10% per episode from severe pancreatitis.

Why the existing therapies for hypertriglyceridemia have never been sufficient for this population Fibrates (fenofibrate, gemfibrozil), omega-3 fatty acids (Vascepa, Lovaza), and niacin all lower triglycerides to varying degrees in patients with sHTG. For mild-to-moderate hypertriglyceridemia, these agents are appropriate. For severe hypertriglyceridemia (triglycerides at or above 500 mg/dL), the problem is twofold: the degree of triglyceride reduction achievable with these agents is often insufficient to bring triglycerides below the 500 mg/dL danger threshold, and — critically — none of these therapies had ever demonstrated in a randomized controlled trial that their triglyceride-lowering translated into fewer pancreatitis events. They lower triglycerides. They do not have regulatory approval for reducing pancreatitis risk. For patients with sHTG who have been told to take a fibrate and a fish oil and watch their diet, this approval addresses the most important clinical gap in their management.

The Science: How apoC-III Drives Triglyceride Accumulation and Why Blocking It Works

Understanding olezarsen’s mechanism requires understanding the central role of apolipoprotein C-III (apoC-III) in triglyceride metabolism.

ApoC-III is a small apolipoprotein produced primarily in the liver. It acts as a major inhibitor of triglyceride clearance through two distinct mechanisms:

LPL inhibition: LPL is the enzyme that sits on the surface of capillary endothelial cells throughout the body and hydrolyzes the triglycerides in circulating VLDL and chylomicrons, releasing fatty acids for energy use or storage. ApoC-III, when present on the surface of these triglyceride-rich lipoproteins, directly inhibits LPL activity. When apoC-III levels are high, LPL cannot efficiently break down triglycerides, and triglyceride-rich lipoproteins accumulate in the bloodstream.

Impaired hepatic remnant uptake: Beyond LPL inhibition, apoC-III also blocks the hepatic receptors responsible for removing triglyceride-rich lipoprotein remnants from the bloodstream after partial hydrolysis. This means that even the breakdown products of VLDL and chylomicron hydrolysis accumulate in circulation when apoC-III is elevated.

In patients with sHTG, both mechanisms contribute to the massive triglyceride accumulation. Some patients have genetic variants that increase apoC-III expression directly; others have metabolic conditions that drive excess apoC-III production; all share the downstream consequence of overwhelmed LPL and impaired remnant clearance.

How olezarsen targets apoC-III: the GalNAc-ASO approach

Olezarsen is an antisense oligonucleotide (ASO) — a short, synthetic strand of modified RNA designed to bind to the messenger RNA (mRNA) that encodes apoC-III in the liver. When the ASO binds to its target mRNA, it recruits RNase H, an enzyme that degrades the bound RNA strand. With the mRNA destroyed, the ribosome cannot translate it into apoC-III protein. Hepatic apoC-III production decreases substantially and persistently.

What makes olezarsen a next-generation ASO is its GalNAc (N-acetyl galactosamine) conjugation. Three GalNAc molecules are attached to the olezarsen molecule in a triantennary arrangement. GalNAc is a high-affinity ligand for the asialoglycoprotein receptor (ASGPR) expressed almost exclusively on hepatocytes. When the GalNAc-conjugated ASO enters the bloodstream, hepatocytes recognize and rapidly internalize it through receptor-mediated endocytosis. The result: the drug is delivered with exceptional precision to the liver cells where apoC-III is produced, achieving equivalent apoC-III knockdown at doses far lower than first-generation ASOs that relied on non-targeted distribution.

The practical significance of the GalNAc targeting is not only efficacy. First-generation apoC-III ASOs like volanesorsen caused significant thrombocytopenia (low platelet counts) because systemic ASO distribution led to off-target interaction with platelets and the reticuloendothelial system. The GalNAc-mediated hepatic uptake of olezarsen reduces systemic ASO exposure substantially, greatly reducing platelet-related side effects. As a result, patients treated with olezarsen do not require the same intensive platelet monitoring that volanesorsen demanded, simplifying outpatient management considerably.

The CORE and CORE2 Trials: What the Data Shows

Trial design

CORE-TIMI 72a (NCT05079919) and CORE2-TIMI 72b (NCT05552326) were two Phase 3, global, multicenter, randomized, double-blind, placebo-controlled trials conducted in collaboration with The TIMI Study Group. Together they enrolled 1,061 adults (617 in CORE; 446 in CORE2) with fasting triglycerides at or above 500 mg/dL who were already on standard-of-care therapies for elevated triglycerides.

The extremely high baseline mean triglyceride level of 1,116 mg/dL in enrolled patients reflects the severity of sHTG being targeted. At baseline, 47% of CORE participants and 37% of CORE2 participants had fasting triglycerides at or above 880 mg/dL, well into the range where pancreatitis risk is acute.

Patients were randomized to olezarsen 50 mg once monthly, olezarsen 80 mg once monthly, or placebo via subcutaneous injection, for 12 months. The primary endpoint was placebo-adjusted percent change in fasting triglycerides from baseline to month 6. The results were published in the New England Journal of Medicine in November 2025.

Primary endpoint: triglyceride reduction

Trial	Dose	Placebo-adjusted TG reduction at 6 months	p-value	Sustained at 12 months
CORE	50 mg	63%	p less than 0.001	Yes
CORE	80 mg	72%	p less than 0.001	Yes
CORE2	50 mg	49%	p less than 0.001	Yes
CORE2	80 mg	55%	p less than 0.001	Yes

Source: Marston NA et al. Olezarsen for managing severe hypertriglyceridemia and pancreatitis risk. NEJM. 2025. doi:10.1056/NEJMoa2512761.

These are substantial reductions in a patient population starting from a mean triglyceride of 1,116 mg/dL. A 72% reduction from 1,116 mg/dL would bring the mean to approximately 312 mg/dL, below the 500 mg/dL acute pancreatitis risk threshold.

Secondary endpoint: acute pancreatitis events

The acute pancreatitis endpoint is the most clinically significant finding in the CORE and CORE2 program. At 12 months, in the pooled population across both trials:

Outcome	Pooled olezarsen	Pooled placebo
Acute pancreatitis events	7 events in 5 patients	22 events in 17 patients
Rate ratio (pooled)	0.15 (95% CI 0.05 to 0.40)	Reference
Reduction in acute pancreatitis events	85%	—
p-value	p less than 0.001	—
Patients achieving TG below 500 mg/dL	86%	—

Dr. Nicholas Marston, MD, MPH, cardiologist at Brigham and Women’s Hospital and Harvard Medical School, and principal investigator for the CORE program, noted that these were the first studies to show a significant reduction in acute pancreatitis events in sHTG, and that with most patients on olezarsen achieving triglyceride levels below the risk threshold for those potentially life-threatening episodes, the results represent a major advance for patients with recurrent pancreatitis.

Secondary lipid endpoints

Beyond triglycerides, olezarsen produced favorable changes across the broader lipid panel in CORE and CORE2:

Substantial reductions in apoC-III itself (the direct molecular target)
Reductions in remnant cholesterol
Reductions in non-HDL cholesterol
Reductions in VLDL cholesterol
Increases in HDL cholesterol (the protective lipoprotein)
Reductions in apolipoprotein B-containing lipoproteins

These secondary lipid findings are relevant to the question of whether olezarsen’s benefits extend beyond pancreatitis prevention to cardiovascular risk reduction, a question that the ongoing ESSENCE trial in moderate hypertriglyceridemia with established cardiovascular disease is designed to address.

Tryngolza’s Complete Indication Picture After June 2026

Indication	Population	Approval date
Reduce triglycerides in adults with familial chylomicronemia syndrome (FCS)	Adults with confirmed genetic FCS	December 19, 2024
Reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG)	Adults with fasting TG at or above 500 mg/dL	June 24, 2026

FCS is a rare monogenic disorder affecting 3,000 to 5,000 people in the United States, caused by biallelic loss-of-function mutations in genes encoding LPL or its essential cofactors, resulting in complete or near-complete absence of LPL activity. The sHTG population, now the larger approved indication, includes patients with polygenic triglyceride elevation, secondary causes, or a combination of genetic susceptibility plus metabolic or lifestyle factors.

The mechanistic basis for olezarsen’s efficacy across both conditions is the same: in both FCS and sHTG, apoC-III elevation contributes to insufficient triglyceride clearance. In FCS, LPL is absent or dysfunctional and apoC-III’s LPL-independent effects on remnant clearance are particularly relevant. In sHTG from other causes, restoring LPL activity by reducing apoC-III is the primary mechanism.

Dosing and Administration

Tryngolza is available in two doses: 50 mg and 80 mg, both self-administered once monthly via subcutaneous autoinjector. The injection can be administered in the abdomen, thigh, or upper arm.

The 80 mg dose produced somewhat greater triglyceride reduction in the CORE trials (72% vs. 63%) but is associated with more adverse effects including dose-dependent hepatic fat fraction increases and higher rates of thrombocytopenia. The appropriate dose for a given patient is a clinical decision based on baseline triglyceride level, risk stratification, and tolerability.

The once-monthly dosing schedule is a meaningful practical advantage. Standard-of-care fibrate therapy requires once-daily oral dosing (or twice daily for some formulations), and omega-3 fatty acids require 4 capsules daily. A single monthly injection removes the daily medication burden for the most critical component of triglyceride management in this population.

Tryngolza will be available in U.S. pharmacies beginning July 2026.

Safety: What the Prescribing Information and Trial Data Cover

The safety profile of olezarsen in CORE and CORE2 was generally favorable, with most adverse events mild in severity. Notably, serious adverse events were less frequent in olezarsen-treated patients than in the placebo group, likely reflecting the reduction in pancreatitis hospitalizations.

Safety item	Details	Clinical guidance
Injection site reactions	Most common adverse event; generally mild (redness, bruising, pain); consistent with the subcutaneous injection class	Rotate injection sites. Mild reactions typically resolve without intervention.
Liver enzyme elevations	ALT and AST increases observed; greater with 80 mg dosing	Baseline liver function testing; monitor as clinically indicated.
Hepatic fat fraction increase	Dose-dependent; greater with 80 mg; clinical significance of hepatic fat accumulation under long-term treatment requires monitoring	Discuss with patients who have pre-existing hepatic steatosis; liver function monitoring recommended.
Thrombocytopenia	More common with 80 mg than 50 mg; less severe than observed with volanesorsen (first-generation apoC-III ASO); clinically significant platelet declines were infrequent and reversible	Baseline platelet count; periodic monitoring during therapy, more vigilant with 80 mg dosing.
Hypersensitivity reactions	Serious hypersensitivity reactions requiring medical treatment have occurred	Contraindicated in patients with a history of serious hypersensitivity to olezarsen or any excipient.
Embryo-fetal toxicity	Animal studies showed adverse developmental effects; potential fetal harm	Females of reproductive potential: use effective contraception during treatment.

Contraindication:
Tryngolza is contraindicated in patients with a history of serious hypersensitivity reactions to olezarsen or any of the product excipients.

The GalNAc-conjugated design of olezarsen is clinically relevant to the thrombocytopenia profile. Volanesorsen, the first-generation apoC-III ASO approved in Europe for FCS, caused severe, sometimes immune-mediated thrombocytopenia that required intensive platelet monitoring and led to treatment discontinuation in a meaningful proportion of patients. Olezarsen’s hepatocyte-targeted delivery dramatically reduces systemic ASO exposure, and the lower platelet toxicity signal observed in CORE and CORE2 reflects this. Patients treated with olezarsen require monitoring but not the intensive surveillance that volanesorsen demanded.

What This Means for Patients and Clinicians

For the approximately 3 million Americans with severe hypertriglyceridemia

This approval provides the first therapy specifically shown in randomized controlled trials to reduce acute pancreatitis events. For patients who have experienced one or more episodes of hypertriglyceridemia-induced pancreatitis — a population that knows intimately what the hospitalization, pain, and recovery looks like — the 85% reduction in pancreatitis events in CORE and CORE2 is the most important number in this approval.

For patients currently on fibrates and fish oils with triglycerides still above 500 mg/dL: the addition of olezarsen as an adjunct to diet and existing therapy is now an evidence-supported option. The trials enrolled patients already on standard-of-care therapies, meaning the CORE and CORE2 data reflects real-world patients who had not achieved adequate control on existing agents.

For clinicians managing lipid disorders

The approval creates a new treatment algorithm decision point: patients with confirmed fasting triglycerides at or above 500 mg/dL, particularly those with a history of pancreatitis, should now be evaluated for Tryngolza as an add-on to current triglyceride-lowering therapy. The once-monthly subcutaneous autoinjector, the absence of significant drug-drug interactions with common triglyceride-lowering agents, and the favorable tolerability profile in CORE and CORE2 make this a manageable addition to complex lipid management regimens.

The liver function and platelet monitoring requirements are straightforward and consistent with standard care for patients on lipid-active therapies. The hepatic fat fraction consideration is worth discussing with patients who have pre-existing metabolic-associated fatty liver disease, a common comorbidity in the sHTG population.

The FCS distinction

Patients with confirmed familial chylomicronemia syndrome remain a distinct population. FCS, defined by biallelic loss-of-function mutations in LPL or essential cofactors with complete or near-complete absence of LPL activity, carries a more severe clinical course and is the population for which Tryngolza’s original December 2024 approval was granted. FCS patients may have different dose considerations and monitoring needs from the broader sHTG population; management in these patients should involve a lipidologist or endocrinologist with experience in genetic lipid disorders.

For the broader sHTG population without confirmed monogenic disease: Tryngolza is now available in both primary care and specialist settings where appropriate patient selection, baseline testing, and monitoring can be provided.

For related HED coverage on lipid management and cardiometabolic health, see our post on Foundayo (orforglipron), the first oral GLP-1 receptor agonist with no food or water restrictions, approved for obesity management in 2026, and our post on Januvia (sitagliptin) losing exclusivity and what generic sitagliptin means for the type 2 diabetes treatment landscape.

Sources

Ionis FDA approval press release: TRYNGOLZA (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia. Ionis Pharmaceuticals. BusinessWire. June 24, 2026.

Drugs.com approval news: Tryngolza (olezarsen) Approved to Reduce Triglycerides and the Risk of Acute Pancreatitis. drugs.com. June 24, 2026.

HCPLive clinical coverage: FDA Approves Olezarsen (Tryngolza) for Severe Hypertriglyceridemia. hcplive.com. June 2026.

Endocrinology Advisor clinical summary: Tryngolza Approved to Reduce Triglycerides and Pancreatitis Risk in sHTG. endocrinologyadvisor.com. June 2026.

Pharmacy Times clinical review: Olezarsen Receives FDA Approval to Reduce Triglycerides, Risk of Acute Pancreatitis in Severe Hypertriglyceridemia. pharmacytimes.com. June 2026.

AHA gastroenterology news: FDA approves olezarsen to reduce acute pancreatitis risk in severe hypertriglyceridemia. news.gastro.org. June 2026.

CORE/CORE2 primary NEJM publication: Marston NA et al. Olezarsen for managing severe hypertriglyceridemia and pancreatitis risk. New England Journal of Medicine. 2025. doi:10.1056/NEJMoa2512761.

CORE trial registration: NCT05079919. ClinicalTrials.gov.

CORE2 trial registration: NCT05552326. ClinicalTrials.gov.

CORE/CORE2 trial design and rationale: Bergmark BA et al. Design and rationale of the CORE-TIMI 72a and CORE2-TIMI 72b trials of olezarsen. American Heart Journal. 2025;286:116–124.

ESSENCE trial (moderate HTG, CV outcomes): Olezarsen in Moderate Hypertriglyceridemia. NEJM. 2025. doi:10.1056/NEJMoa2507227.

Olezarsen mechanism and GalNAc-ASO review: Olezarsen: A Next-Generation Antisense Therapy. Cureus. PMC12700839.

Olezarsen and FCS original approval review: Olezarsen: FDA approval and clinical impact in FCS. PMC12577896.

ApoC-III mechanism and TRL metabolism: JACC Focus Seminar on apoC-III and TRL-lowering therapies. JACC. 2021;78(18):1817–1830.

Triglycerides and metabolic syndrome overview: Blood Triglycerides. NHLBI.

Acute pancreatitis overview: Acute Pancreatitis. StatPearls. NCBI.

Thrombocytopenia: Thrombocytopenia. StatPearls. NCBI.

Tryngolza prescribing information: TRYNGOLZA (olezarsen) Prescribing Information. Ionis Pharmaceuticals. 2026.

Tryngolza approval history: Tryngolza FDA Approval History. drugs.com.

Patient resources: National Lipid Association (lipid.org) | American Heart Association: Triglycerides | FCS patient community: AMAG FCS Foundation | Ionis Tryngolza patient resources

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Decisions about initiating Tryngolza for severe hypertriglyceridemia or familial chylomicronemia syndrome should be made in consultation with a qualified clinician, such as a lipidologist, cardiologist, or endocrinologist, who can evaluate baseline triglyceride levels, liver function, platelet counts, and the full clinical context including history of pancreatitis and concurrent medications.

June 28, 2026

The Standard Nilotinib Pill and Acid Reducers Don’t Mix. For the 25% of CML Patients on PPIs, That’s Been a Real Problem. Cavhanza Just Solved It.

The essentials: Cavhanza (nilotinib, Cycle Pharmaceuticals/Flex Pharma) is a new orally disintegrating tablet (ODT) formulation of nilotinib, a second-generation BCR-ABL tyrosine kinase inhibitor (TKI), approved by the FDA for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Indications: newly diagnosed Ph+ CML in chronic phase, and Ph+ CML in chronic or accelerated phase with resistance or intolerance to prior therapy including imatinib (Gleevec). This is the same clinical indication as Tasigna (nilotinib capsules, Novartis) — the FDA approval of the ODT version was supported by the established efficacy and safety data from Tasigna’s well-controlled trials. What makes Cavhanza different: the nilotinib molecule is unchanged. The innovation is pharmaceutical delivery. The ElectroNanoSpray (ENS) proprietary technology used by Flex Pharma produces nanoparticle-sized drug particles with dramatically improved solubility and dissolution rate. The result: Cavhanza maintains bioavailability when taken with proton pump inhibitors (PPIs) or histamine H2 receptor antagonists (H2RAs) — acid reducers that substantially reduce Tasigna’s absorption and are currently contraindicated with it. No food effect: Cavhanza can be taken without regard to meals. Standard nilotinib capsules require fasting (no food 2 hours before and 1 hour after each dose) because food substantially increases absorption and can raise drug levels to toxic ranges. The clinical problem this solves: approximately 25% of Ph+ CML patients are co-prescribed PPIs or H2RAs for conditions such as GERD, peptic ulcer disease, or gastroesophageal reflux. With standard nilotinib, these patients face a choice between undertreating their leukemia (due to reduced TKI absorption) or undertreating their GI condition (by stopping the acid reducer). Cavhanza eliminates this compromise. Dosing: consistent with Tasigna: 300 mg orally twice daily for newly diagnosed CML-CP; 400 mg orally twice daily for resistant or intolerant CML-CP and CML-AP. Can be swallowed whole or allowed to dissolve in the mouth before swallowing; can be taken with or without water. Regulatory basis: 505(b)(2) NDA pathway, referencing Tasigna’s clinical efficacy data. The studies showed no difference in the rate or extent of nilotinib absorption whether the ODT was swallowed whole or dissolved in the mouth.

Chronic myeloid leukemia is one of the most remarkable success stories in oncology’s history. Before 2001, a diagnosis of CML in chronic phase carried a median survival measured in years. The discovery that the BCR-ABL fusion oncogene drives CML, and the subsequent development of imatinib (Gleevec) as the first targeted BCR-ABL inhibitor, transformed CML from a reliably fatal malignancy into a manageable chronic condition. Today, patients on first- or second-generation TKI therapy have survival rates that approach those of the general population.

But managing a chronic leukemia requires sustained, reliable drug exposure, and for a meaningful proportion of CML patients that has been harder to achieve than the simple instruction to “take your pill twice a day” implies. Nilotinib (Tasigna), one of the most effective second-generation TKIs, has two well-documented, compliance-limiting properties: it cannot be taken with food, and it cannot be taken with the acid-reducing medications that 25% of CML patients regularly need.

Cavhanza (nilotinib ODT, Cycle Pharmaceuticals), approved in June 2026, is the pharmaceutical engineering answer to both of those problems. The nilotinib molecule is unchanged. The delivery technology is entirely new. And the clinical consequence is that a patient who needs both a TKI and a proton pump inhibitor no longer has to choose between them.

What CML Is and Why the BCR-ABL Target Changed Everything

Chronic myeloid leukemia is a clonal myeloproliferative neoplasm caused by a specific and well-characterized genetic abnormality: the Philadelphia chromosome. The Philadelphia chromosome results from a translocation between chromosomes 9 and 22, creating the fusion gene BCR-ABL1. The BCR-ABL1 protein is a constitutively active tyrosine kinase: unlike normal ABL kinase, which requires external activation signals, BCR-ABL constantly fires, driving uncontrolled myeloid cell proliferation.

This single molecular event — a translocation creating a permanently active kinase — is the driver of CML in the chronic phase for virtually every patient with the disease. That singular, druggable target is what made CML the proving ground for precision oncology.

CML has three clinical phases, reflecting disease progression if untreated or inadequately treated:

Phase	Definition	Clinical characteristics
Chronic phase (CML-CP)	Less than 10% blasts in peripheral blood or bone marrow	Most patients at diagnosis; generally manageable with oral TKI therapy; good prognosis with treatment
Accelerated phase (CML-AP)	10 to 19% blasts; specific cytogenetic or hematologic criteria	Intermediate stage; higher risk of progression; still potentially responsive to TKI therapy
Blast phase (CML-BP)	More than 20% blasts; resembles acute leukemia	Rapid deterioration; TKI therapy less effective; often requires intensive chemotherapy

The goal of TKI therapy in CML-CP is to achieve and maintain major molecular response (MMR), defined as BCR-ABL1 transcript levels at or below 0.1% on the International Scale (IS). Achieving MMR correlates strongly with preventing progression to accelerated or blast phase, and deep molecular responses (MR4, MR4.5) are associated with the possibility of treatment-free remission (TFR) in a proportion of patients. The monitoring of BCR-ABL1 transcript levels by PCR is standard practice, typically every 3 months during the first year of therapy and every 3 to 6 months thereafter.

Where Nilotinib Fits in the CML Treatment Landscape

CML now has five approved BCR-ABL TKIs in the United States, each targeting the same fundamental kinase but with different potency profiles, off-target activity, side effect patterns, and approved indications:

Agent	Generation	FDA-approved indications (adults)	Notable features
Imatinib (Gleevec, generics)	First	Newly diagnosed CML-CP; imatinib-intolerant/resistant CML-CP/AP/BP	First-in-class; extensive long-term data; generic available
Nilotinib (Tasigna, Cavhanza)	Second	Newly diagnosed CML-CP; resistant/intolerant CML-CP and CML-AP	Higher affinity for BCR-ABL; superior MMR vs imatinib; food/acid-reducer interaction
Dasatinib (Sprycel)	Second	Newly diagnosed CML-CP; resistant/intolerant CML (all phases)	Src kinase activity; effective in most imatinib resistance mutations; pleural effusion risk
Bosutinib (Bosulif)	Second	Newly diagnosed CML-CP; resistant/intolerant CML (CP, AP, BP)	GI-dominant side effects; food increases absorption (take with meal)
Ponatinib (Iclusig)	Third	Resistant/intolerant CML; T315I mutation	Covers T315I “gatekeeper” mutation; arterial thromboembolism risk

Nilotinib is classified as a second-generation TKI. It was engineered from the imatinib structure to achieve higher binding affinity and selectivity for BCR-ABL1, addressing imatinib resistance mutations and producing faster, deeper molecular responses. It is described as the most selective inhibitor of BCR-ABL among the approved TKIs, with potency approximately 30 times higher than imatinib in vitro.

The ENESTnd Trial: The Clinical Evidence Foundation

Cavhanza’s FDA approval was supported by the established clinical evidence base for nilotinib, specifically the data from the ENESTnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed patients) trial (NCT00471497), the pivotal Phase 3 trial that defined nilotinib’s role in frontline CML.

ENESTnd enrolled 846 adult patients with newly diagnosed CML-CP within 6 months of diagnosis, stratified by Sokal risk score, and randomized them 1:1:1 to nilotinib 300 mg twice daily, nilotinib 400 mg twice daily, or imatinib 400 mg once daily.

Endpoint	Nilotinib 300 mg twice daily	Imatinib 400 mg once daily	Significance
MMR (BCR-ABL1 at or below 0.1%) at 12 months	44%	22%	p less than 0.0001
Complete cytogenetic response (CCyR) at 12 months	80%	65%	p less than 0.001
Progression to accelerated or blast phase	0.7%	4.2%	Significantly reduced
5-year MMR rate	77%	60%	Durable superior response
10-year overall survival	Greater than 87%	Comparable (non-inferior)	Long-term survival similar

Source: Saglio G et al. Nilotinib versus Imatinib for Newly Diagnosed CML. NEJM. 2010;362(24):2251–2259. doi:10.1056/NEJMoa0912614. 10-year analysis: Hochhaus A et al. Leukemia. 2022.. NCT00471497.

The landmark finding from ENESTnd was that nilotinib produced significantly higher rates of MMR at 12 months, significantly fewer progressions to accelerated or blast phase, and significantly more patients achieving deep molecular response (MR4, MR4.5) compared to imatinib across all Sokal risk categories. These advantages translated into a durable efficacy benefit through 10 years of follow-up, with 10-year MMR rates of approximately 77% for nilotinib 300 mg twice daily versus 60% for imatinib.

The 10-year analysis also confirmed a key safety signal: cardiovascular events including ischemic heart disease, peripheral artery disease, and stroke occurred at higher rates in nilotinib-treated patients (approximately 7 to 8%) than in imatinib-treated patients (approximately 2 to 3%) over a decade. This cardiovascular risk is now a well-established element of nilotinib’s prescribing profile and is included in boxed warning language.

Cavhanza’s approval was via the 505(b)(2) NDA pathway, which allows a new drug application to reference existing published literature and data from a reference-listed drug. The ODT studies showed no difference in the rate or extent of nilotinib absorption whether the ODT was swallowed whole or dissolved in the mouth before swallowing, confirming pharmaceutical equivalence of the two administration methods.

The Core Problem Cavhanza Solves: Acid Reducers and pH-Dependent Absorption

This is the clinical story that gives Cavhanza its differentiated value. Understanding it requires a brief look at what standard nilotinib capsules need to be absorbed effectively.

Nilotinib is a weakly basic molecule that dissolves best in acidic conditions. In the stomach’s normally acidic environment, the drug dissolves adequately before moving into the small intestine where it is absorbed. When proton pump inhibitors (PPIs) or histamine H2 receptor antagonists (H2RAs) are on board, they reduce gastric acid production, raising stomach pH substantially. In this elevated-pH environment, standard nilotinib capsules dissolve poorly, and absorption drops significantly.

The standard Tasigna prescribing information reflects this directly: PPIs should not be co-administered with nilotinib, and H2RAs must be separated by specific timing restrictions (H2RAs can be administered approximately 10 hours before or approximately 2 hours after nilotinib). For a patient taking a PPI for chronic GERD, that effectively means stopping the PPI. For a patient taking an H2RA, it means carefully coordinating two twice-daily medications around each other’s timing windows.

The scale of this problem: approximately 25% of Ph+ CML patients are co-prescribed acid-reducing agents. These are largely older adults managing both their leukemia and common age-related comorbidities including reflux, peptic ulcer disease, and gastroprotective use alongside other medications like aspirin or anticoagulants. Telling these patients to stop their acid reducer, or to comply with precise timing restrictions every day for years, is not a trivial ask. Non-adherence to TKI therapy in CML is directly associated with loss of molecular response.

The food effect compounds this further. Standard nilotinib capsules must be taken without food: eating within 2 hours before or 1 hour after a nilotinib dose significantly increases drug absorption and can raise plasma levels to potentially toxic ranges. This means four distinct daily time windows around which the patient must plan: fast before dose 1, fast after dose 1, fast before dose 2, fast after dose 2. For patients managing a full daily life including meals and medications, this is a substantial behavioral burden.

How Cavhanza addresses both problems

Cavhanza uses Flex Pharma’s proprietary ElectroNanoSpray (ENS) technology to produce a nanoparticle-scale formulation of nilotinib with dramatically improved solubility and dissolution characteristics. By engineering the drug particles to be far smaller, the formulation increases the surface area available for dissolution and reduces the drug’s dependence on low gastric pH to dissolve adequately before reaching the small intestine. The result:

PPI co-administration: allowed with Cavhanza — no contraindication, no timing restriction
H2RA co-administration: allowed with Cavhanza — no timing restriction
Food effect: eliminated — Cavhanza can be taken with or without food

The orally disintegrating tablet format adds a further convenience dimension: the tablet can dissolve in the mouth before swallowing or can be swallowed whole. It can be taken with or without water. For patients who have difficulty swallowing capsules, or for patients in clinical settings where oral medication access is limited, these properties matter.

Safety: What Prescribers and Patients Need to Know

Cavhanza carries the same safety profile as nilotinib across all formulations, because the active molecule is identical. The safety program that governs Tasigna governs Cavhanza.

Boxed warnings:

QT prolongation and sudden death: Nilotinib prolongs the QT interval and has been associated with sudden death. Hypokalemia or hypomagnesemia must be corrected before initiating nilotinib and monitored during therapy. Avoid drugs that prolong the QT interval, including many anti-arrhythmic medications, certain antifungals, and fluoroquinolone antibiotics. An ECG is required at baseline, 7 days after initiation, and periodically thereafter. Do not use in patients with hypokalemia, hypomagnesemia, or long QT syndrome.

Hepatotoxicity: Nilotinib may cause severe hepatotoxicity and liver failure, including fatal cases. Monitor liver function tests before initiating and monthly during the first year, then periodically.

Cardiovascular events: Nilotinib is associated with an increased incidence of ischemic heart disease, peripheral artery disease, and ischemic cerebrovascular events. The 10-year ENESTnd data showed cardiovascular event rates of approximately 7 to 8% over a decade. Patients with cardiovascular risk factors should be assessed carefully before initiating nilotinib, with optimization of modifiable risk factors. Monitor for signs of cardiovascular disease during treatment.

Key warnings and precautions:

Safety item	Details	Clinical guidance
QT prolongation (boxed warning)	Prolongs QTcF; sudden death reported	ECG at baseline, day 7, and periodically. Correct electrolytes. Avoid QT-prolonging drugs. Hold and restart at reduced dose if QTcF greater than 480 ms.
Hepatotoxicity (boxed warning)	Severe liver injury and fatal liver failure reported	LFTs at baseline, monthly for first year, periodically thereafter.
Cardiovascular events	Ischemic heart disease, PAD, and stroke at higher rates than imatinib in long-term follow-up	Assess and manage CV risk factors before initiating. Monitor for signs of CV disease.
Myelosuppression	Neutropenia, thrombocytopenia, and anemia; dose modification or interruption may be required	CBC at baseline, every 2 weeks for first 2 months, then monthly.
Pancreatitis	Lipase and amylase elevations; symptomatic pancreatitis reported	Monitor lipase and amylase monthly or as clinically indicated.
Hepatitis B reactivation	Reactivation in chronic HBV carriers including fulminant hepatitis and fatal outcomes	Screen for HBV before initiating. Monitor carriers closely; consider antiviral prophylaxis.
CYP3A4 interactions	Strong CYP3A4 inhibitors increase nilotinib exposure; strong inducers reduce it	Avoid strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin); avoid strong inducers (rifampin). If unavoidable, dose reduction recommended.
Embryo-fetal toxicity	Nilotinib can cause fetal harm	Women of reproductive potential: effective contraception during treatment. Advise of reproductive risks before starting therapy.
Lactation	Not recommended during treatment and for 14 days after last dose	Discuss with patients before initiating.
Pediatric use	Cavhanza not approved for pediatric patients	The approved indication is adults only.

Common adverse reactions (occurring in 10% or more of patients in clinical trials): rash, nausea, headache, fatigue, pruritus, vomiting, alopecia, myalgia, and constipation.

What This Means for CML Patients and Prescribers

The practical change

For an established CML patient currently on Tasigna (nilotinib capsules) who also takes a PPI or H2RA: Cavhanza is now a clinically appropriate alternative that eliminates the drug interaction concern without changing the active compound, the dose, or the established molecular monitoring expectations. The transition from Tasigna to Cavhanza is a formulary and tolerability decision, not a clinical efficacy change.

For newly diagnosed CML-CP patients who also have GERD, peptic ulcer disease, or any clinical need for an acid reducer: the nilotinib-PPI interaction no longer needs to govern the treatment decision. Cavhanza can be initiated at the standard 300 mg twice-daily dose without worrying about acid-reducer timing or co-prescription contraindications.

For CML-CP and CML-AP patients with resistance or intolerance to prior therapy including imatinib: Cavhanza at 400 mg twice daily is now an option with the same added prescribing flexibility.

For oncology pharmacists and hematologists reviewing CML patients on complex polypharmacy regimens: Cavhanza’s elimination of the food restriction and the acid-reducer interaction removes two of the most practically difficult elements of long-term nilotinib adherence. Non-adherence to TKI therapy is directly associated with loss of molecular response and the risk of disease progression in CML. Any formulation innovation that reduces adherence barriers has the potential to translate into better molecular outcomes for this patient population.

Dr. Kevan Herold’s statement about treating a different disease earlier applies here in spirit: much of the value of precision oncology in CML comes from the consistency and completeness of BCR-ABL suppression. Inconsistent drug levels from missed doses, from food effect violations, or from acid-reducer-mediated reduced absorption, erode that suppression and create the selective pressure that drives resistance mutations.

The monitoring requirements remain

Regardless of formulation, patients on nilotinib require: baseline and periodic ECGs; CBC monitoring every 2 weeks for the first 2 months and monthly thereafter; LFTs monthly for the first year; electrolyte monitoring; and BCR-ABL1 PCR monitoring every 3 months during the first year and every 3 to 6 months thereafter. These monitoring requirements are unchanged by the ODT formulation.

For related HED coverage on CML and hematologic oncology, see our post on Pomalyst (pomalidomide) losing exclusivity and what generic pomalidomide means for multiple myeloma patients from the 2026 Loss of Exclusivity series.

Sources

Cycle Pharmaceuticals press release (approval): CAVHANZA (nilotinib) Orally Disintegrating Tablets: A New, FDA-approved Treatment Offering PPI and H2RA Flexibility for Ph+ CML Patients. BusinessWire. June 2, 2026.

BioSpace coverage: CAVHANZA (nilotinib) Orally Disintegrating Tablets: A New, FDA-approved Treatment. biospace.com. June 2026.

Targeted Oncology clinical summary: FDA OKs Oral Nilotinib Tablets for Ph+ CML With Acid-Reducer Flexibility. targetedonc.com. June 2026.

Cancer Therapy Advisor: FDA Approves Cavhanza, an ODT Formulation of Nilotinib for Ph+ CML. cancertherapyadvisor.com. June 2026.

Oncology Nursing News: FDA Approves Oral Nilotinib Tablets for Ph+ CML. oncnursingnews.com. June 2026.

WebMD approval summary: Cavhanza (Nilotinib) FDA Approval. webmd.com. June 2026.

ENESTnd primary publication: Saglio G et al. Nilotinib versus Imatinib for Newly Diagnosed CML in Chronic Phase. NEJM. 2010;362(24):2251–2259. doi:10.1056/NEJMoa0912614.

ENESTnd 10-year analysis: Hochhaus A et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed CML-CP: ENESTnd 10-year analysis. Leukemia. 2022.

ENESTnd trial registration: NCT00471497. ClinicalTrials.gov.

BCR-ABL mutations and nilotinib selectivity: Nilotinib and BCR-ABL mutations. PMC4915803.

Philadelphia chromosome and CML mechanism: Chronic Myelogenous Leukemia. StatPearls. NCBI.

Philadelphia chromosome molecular biology: BCR-ABL1 in CML. PMC7955155.

PPIs overview: Proton Pump Inhibitors. StatPearls. NCBI.

H2RAs overview: Histamine H2 Receptor Antagonists. StatPearls. NCBI.

QT prolongation: QT Prolongation. StatPearls. NCBI.

505(b)(2) NDA pathway: 505(b)(2) Applications. FDA.gov.

FDA nilotinib original approval: FDA approves nilotinib for chronic myeloid leukemia. FDA.gov.

Cavhanza prescribing information: CAVHANZA (nilotinib) Prescribing Information. Flex Pharma/Cycle Pharmaceuticals. 2026.

American Cancer Society CML overview: Chronic Myeloid Leukemia. cancer.org.

Patient resources: Leukemia and Lymphoma Society (LLS) | CML Advocates Network | Cycle Pharmaceuticals Cavhanza support | [Breakthrough T1D is not applicable here] | Novartis Tasigna patient support

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Nilotinib (Cavhanza) carries boxed warnings for QT prolongation with sudden death risk, hepatotoxicity, and cardiovascular events. CML management requires individualized care by a board-certified hematologist or oncologist with expertise in TKI therapy. Patients considering a transition from Tasigna to Cavhanza should discuss this with their treating hematologist-oncologist.

June 27, 2026

The FDA Just Approved a Third OTC Naloxone Nasal Spray. Here Is What Rextovy Is, How Naloxone Works, and Why More Competition in This Market Could Finally Move the Price.

The essentials: On June 16, 2026, the FDA approved Rextovy (naloxone hydrochloride 4 mg nasal spray, Amphastar Pharmaceuticals) for over-the-counter sale, making it the third naloxone nasal spray available without a prescription in the United States. No prescription, no pharmacist consultation, and no physician visit is required. Consumers can purchase Rextovy directly at pharmacies, convenience stores, and online retailers. What it is: a single 4 mg intranasal spray per device, supplied in a carton of 2 devices. The same active ingredient and the same 4 mg dose as OTC Narcan (Emergent BioSolutions). The difference is manufacturer: Rextovy is made by Amphastar Pharmaceuticals. A third OTC product, RiVive (Harm Reduction Therapeutics), contains 3 mg. All three are approved for bystander use without medical training. Rx version pricing: approximately $44 to $60 per box. OTC pricing was not immediately available at launch. Historical precedent: OTC naloxone prices declined by only approximately $0.49 per quarter between late 2023 and late 2024 following the first OTC approval, according to a 2026 study in the Journal of Substance Use and Addiction Treatment. A third competitor changes the economic calculus. Overdose death trend: in the 12-month period ending August 2023, 111,451 overdose deaths were reported; in the 12-month period ending December 2025, 68,632 were reported — a 38% decline since the first OTC naloxone approval. Drug overdose deaths remain a major public health issue, primarily driven by synthetic opioids including illicit fentanyl. Pricing equity note: the same 2026 study found that areas with larger American Indian and Alaska Native populations paid an estimated more than $5 extra per unit compared with predominantly white communities — a documented racial pricing disparity in OTC naloxone access.

The number of overdose deaths has dramatically decreased since the first FDA approval of an OTC naloxone nasal spray in 2023, but drug overdose persists as a major public health issue in the U.S., primarily driven by synthetic opioids like illicit fentanyl. In the 12-month period ending August 2023, 111,451 overdose deaths were reported. In the 12-month period ending December 2025, 68,632 were reported. That 38% decline is meaningful, and OTC naloxone availability is widely credited as one of its contributors. It is also not enough. More than 68,000 people dying per year from overdose is not a public health success. It is a reduced catastrophe. BioSpace

Against that backdrop, the FDA’s June 16, 2026 approval of Rextovy (naloxone hydrochloride, Amphastar Pharmaceuticals) as the third OTC naloxone nasal spray matters for two distinct reasons. The first is access: more manufacturers, more retail channels, and more products on shelves means more opportunities for the right person to have the right medication at the right moment. The second is economics: the most persistent barrier to naloxone adoption since the first OTC approval has not been awareness. It has been price. A third competitor in a market where prices have barely moved creates conditions for the competition that could finally change that.

This post covers what naloxone is and how it works, the OTC naloxone landscape and how Rextovy fits into it, what the pricing and access research actually shows, what the evidence says about bystander naloxone and its effect on survival, and what any person reading this needs to know about how to use it.

What Opioid Overdose Is and Why Minutes Matter

Opioid overdose occurs when the concentration of opioids in the body exceeds what the brain’s opioid receptors can manage without suppressing essential automatic functions. Opioids bind to mu-opioid receptors in the brainstem’s respiratory control centers. At therapeutic doses, this produces analgesia and sedation. At overdose doses, it produces profound respiratory depression: breathing slows, becomes shallow, and eventually stops. Without intervention, hypoxia progresses to cardiac arrest and death, typically within minutes.

The trajectory of a fatal opioid overdose, from respiratory depression to death, unfolds in a window of approximately 1 to 5 minutes in many cases, faster with high-potency synthetic opioids like fentanyl and carfentanil, somewhat longer with longer-acting opioids like methadone. This time window is the entire clinical rationale for OTC naloxone: by the time emergency medical services arrive, a reversible overdose has often become an irreversible one.

Recognizing an opioid overdose requires recognizing several characteristic signs. Any person who is:

Unresponsive or cannot be woken up
Breathing slowly, shallowly, or not at all
Making gurgling, choking, or rattling sounds (sometimes called the “death rattle”)
Limp and unable to hold their head up
Showing blue, gray, or pale lips, gums, or fingertips (indicating hypoxia)
Showing pinpoint (very small) pupils

should be treated as a suspected opioid overdose. Naloxone will not harm someone who does not have opioids in their system, so the risk of administering it to someone who turns out not to be overdosing on opioids is negligible. The risk of not administering it to someone who is overdosing on opioids is death.

How Naloxone Works: The Mechanism

Naloxone is a competitive opioid receptor antagonist. It binds to the same mu-, kappa-, and delta-opioid receptors in the brain that opioids bind to, but it does not activate them. Because naloxone’s binding affinity for these receptors is higher than that of most opioids, it rapidly displaces the opioid molecules already occupying the receptors and occupies those sites itself, blocking further opioid activity.

The clinical result of this receptor displacement is the reversal of opioid-induced respiratory depression within 2 to 5 minutes of administration. The person begins breathing again. Consciousness typically returns. The overdose reversal is complete for the duration of naloxone’s action.

The critical pharmacokinetic limitation of naloxone is its shorter duration of action compared to most opioids. Naloxone’s effects last approximately 30 to 90 minutes. Many opioids, particularly long-acting formulations like extended-release oxycodone or methadone, last substantially longer. Illicit fentanyl, which is now the dominant driver of overdose deaths, acts rapidly but can linger at high receptor occupancy.

This means that after naloxone wears off, opioid effects can return, a phenomenon called re-narcotization. This is the clinical reason why calling 911 after the first dose is not optional, even if the person wakes up and feels better. The naloxone reversal is temporary. The opioids are still in the system. Without professional medical monitoring and potentially additional doses, re-narcotization can cause a second respiratory depression episode just as lethal as the first.

What happens when the person wakes up is also important for bystanders to understand. Naloxone precipitates acute opioid withdrawal in opioid-dependent individuals by abruptly displacing opioids from receptors throughout the body. This produces sudden withdrawal symptoms: sweating, shaking, nausea, vomiting, irritability, and sometimes agitation or aggression. This is a normal and expected physiological response, not a sign that something has gone wrong. It is not dangerous. The person may be confused and frightened. The appropriate response is calm reassurance and staying with them until emergency services arrive.

Naloxone does not cause a “high” or produce any opioid effect In people who do not have opioids in their system, naloxone produces no clinically significant effect. It is pharmacologically inert as a monotherapy: it blocks receptors but does not activate them, so administering it to someone who is not overdosing on opioids produces no harm. This is one reason the FDA and public health authorities consistently recommend a low threshold for use: when in doubt, administer it. The consequence of a false positive is negligible. The consequence of a false negative is death.

The OTC Naloxone Landscape: Where Rextovy Fits

The United States OTC naloxone nasal spray market now has three approved products:

Product	Manufacturer	Dose	OTC approval	Status
Narcan 4 mg	Emergent BioSolutions	4 mg per spray	March 2023	Commercially available
RiVive 3 mg	Harm Reduction Therapeutics (nonprofit)	3 mg per spray	July 2023	Commercially available
Rextovy 4 mg	Amphastar Pharmaceuticals	4 mg per spray	June 16, 2026	Newly approved

Rextovy contains the same active ingredient at the same dose as OTC Narcan. The products are pharmacologically equivalent: both deliver 4 mg of naloxone hydrochloride as a single intranasal spray. The distinction is manufacturer, supply chain, and ultimately price. Amphastar Pharmaceuticals is a well-established injectable and inhalable drug manufacturer with existing manufacturing infrastructure for drug products in similar delivery formats. Its entry into the OTC naloxone market adds a second 4 mg option and a new supply source.

The original prescription version of Rextovy was approved on March 7, 2023. The June 16, 2026 action is a labeling revision converting that product to OTC status, the same regulatory pathway used for OTC Narcan in 2023.

How to Use Rextovy: Step-by-Step

Rextovy’s packaging includes pictorial step-by-step instructions designed for use without medical training. The FDA-approved dosing protocol:

Step 1: Call 911 immediately after (or simultaneously with) giving the first dose. Do not wait to see if the dose works before calling. Emergency services need to be on the way regardless of how quickly the person responds.

Step 2: Lay the person on their back. Tilt their head back slightly to open the airway.

Step 3: Insert the tip of the nasal spray device gently into one nostril. Press the plunger firmly to deliver the full 4 mg dose as a single spray.

Step 4: Wait 2 minutes and watch for a response: spontaneous breathing, return of consciousness, movement.

Step 5: If there is no response after 2 minutes, administer the second device into the opposite nostril. The carton contains 2 devices for this reason.

After administration: Stay with the person until emergency services arrive. If the person regains consciousness, keep them calm and prevent them from taking more opioids. Explain that medical help is coming. If they become agitated (from naloxone-precipitated withdrawal), do not leave. If they lose consciousness again after initial recovery, administer the second dose if not already used and continue rescue breathing if trained to do so.

Rescue breathing: If you know rescue breathing or CPR, administer it while waiting for naloxone to take effect and after doses are given. Rescue breathing can maintain oxygenation during the reversal window.

The fentanyl consideration: Illicit fentanyl and its analogues are significantly more potent than heroin or prescription opioids and may require higher or repeat naloxone doses to achieve reversal. A single 4 mg dose may not be sufficient in a high-potency fentanyl overdose. This is why the 2-device carton is important, and why calling 911 is critical: emergency responders carry additional naloxone doses.

The Pricing Problem and Why a Third Competitor Matters

The clinical and public health value of OTC naloxone is not theoretical. Bystander administration of naloxone before emergency services arrive is associated with substantially higher survival rates in observed overdose events. Multiple studies across community overdose prevention programs consistently show that having naloxone present at the scene and having someone willing and able to use it is one of the most effective single interventions for preventing overdose death.

The problem is access, and access in this context is inseparable from price.

A 2026 study published in the Journal of Substance Use and Addiction Treatment found that OTC Narcan prices declined by only approximately $0.49 per quarter between late 2023 and late 2024, a period during which total sales actually fell slightly. The study also identified a documented racial pricing disparity: areas with larger American Indian and Alaska Native populations paid an estimated more than $5 extra per unit compared with predominantly white communities.

The prescription version of Rextovy currently sells at approximately $44 to $60 per two-dose carton, which is the same general price range as prescription Narcan. OTC pricing was not immediately disclosed at Rextovy’s launch. The meaningful question is not the launch price but the trajectory: with three manufacturers in the OTC naloxone market rather than two, and with Amphastar’s manufacturing cost structure potentially different from Emergent BioSolutions, there is now a realistic competitive mechanism that did not previously exist.

The FDA has stated explicitly that the availability of multiple approved formulations expands access and market availability, encourages competition that may reduce cost, and offers alternative sourcing options. That is a policy statement, not a guarantee. But the mechanism is sound: competition-driven price reduction in generic and OTC pharmaceutical markets follows predictable patterns, and the OTC naloxone market has been waiting for it.

For the communities with the highest overdose burden — uninsured populations, communities with high rates of opioid use disorder, and the communities of color documented to face pricing disparities — even a meaningful reduction from the current $44 to $60 per box baseline could translate directly into lives saved.

Naloxone Is Safe to Give — and There Are No Situations Where Hesitation Is the Right Choice

This point is worth stating plainly because hesitation at the scene of a suspected overdose remains one of the most documented barriers to naloxone use.

Naloxone will not harm someone who does not have opioids in their system. It is not possible to give a fatal dose of naloxone to an overdose victim. The drug has no significant pharmacological activity in the absence of opioid receptor occupancy. Bystanders who are uncertain whether someone is overdosing on opioids should administer naloxone anyway: if opioids are not present, the spray produces no effect. If opioids are present, it may save their life.

The withdrawal symptoms that naloxone can precipitate — agitation, sweating, nausea, vomiting — are distressing but not medically dangerous. They are significantly preferable to continued opioid-induced respiratory depression. A person who is angry and nauseous after naloxone administration is alive. That is the outcome.

SAMHSA’s opioid overdose prevention guidance is clear: treat first, call for help, stay present. There is no scenario in which waiting to see whether a suspected overdose resolves on its own is the appropriate response.

What This Means Practically

If you live with or care for someone using prescription opioids: Ask your pharmacist about keeping naloxone at home. Prescription opioid use, including opioids prescribed legitimately for chronic pain, carries overdose risk — particularly in higher doses, in combination with other sedating medications, or in patients with sleep apnea. Having naloxone in the home is increasingly recommended as a standard safety precaution alongside prescription opioid therapy.

If you use opioids yourself: Carry naloxone. Tell a trusted person where it is and how to use it. The person most likely to administer naloxone in an opioid-related emergency is someone in the immediate vicinity, not a first responder.

If you work in any setting where opioid use may occur: Workplaces, schools, community organizations, faith communities, and public venues are all settings where overdoses occur and where having naloxone present changes outcomes. Rextovy joining the OTC market means one more product on more shelves at potentially lower cost. Stock it.

If you are a pharmacist or healthcare provider: SAMHSA and the CDC recommend co-prescribing naloxone with opioid prescriptions, particularly at higher doses. The OTC availability of Rextovy, Narcan, and RiVive means that the conversation about naloxone access can now happen in any setting — a pharmacy counter, a community health worker visit, a school nurse office — without requiring a prescription. Patient education about signs of overdose, how to use the spray, and why calling 911 is non-negotiable after the first dose saves lives.

For related HED coverage on the opioid crisis treatment landscape, see our post on the FDA’s approval of Sublocade (buprenorphine extended-release injection) for opioid use disorder and our coverage of how the Great American Recovery Initiative has shaped FDA drug approvals and substance use disorder policy in 2026.

If you or someone you know is struggling with opioid use disorder, contact the SAMHSA National Helpline at 1-800-662-4357 (free, confidential, 24/7) or visit findtreatment.gov.

Sources

FDA approval announcement: FDA broadens access to over-the-counter naloxone nasal spray for opioid overdose. FDA.gov. June 16, 2026. BioSpace

Drugs.com approval news: FDA Approves Rextovy (naloxone hydrochloride) Nasal Spray for Over-the-Counter Use. drugs.com. June 16, 2026.

Dermatology Advisor clinical summary (with dosing and packaging): Over-the-Counter Rextovy Cleared for Opioid Overdose Treatment. dermatologyadvisor.com. June 2026.

Drug Topics coverage (with pricing research and pharmacist comment): The FDA Approves Rextovy, an OTC Naloxone for Opioid Overdose. drugtopics.com. June 2026.

TechTimes (OTC market analysis with pricing study detail): Naloxone Nasal Spray Gets Third OTC Brand as FDA Approves Rextovy by Amphastar. techtimes.com. June 2026.

The Hill news coverage: FDA approves third over-the-counter opioid overdose nasal spray. thehill.com. June 2026.

Psychiatry Advisor clinical summary: Over-the-Counter Rextovy Cleared for Opioid Overdose Treatment. psychiatryadvisor.com. June 2026.

Rextovy original Rx approval (March 2023): Rextovy FDA Approval History. drugs.com.

Narcan OTC approval (March 2023): FDA approves first nonprescription naloxone nasal spray. FDA.gov.

Rextovy prescribing information: Rextovy (naloxone hydrochloride) Package Insert. Amphastar Pharmaceuticals. 2026.

Naloxone mechanism and overdose StatPearls: Opioid Toxicity. StatPearls. NCBI.

Mu-opioid receptor pharmacology: Opioid Receptors. StatPearls. NCBI.

Bystander naloxone and survival outcomes: Bystander Naloxone Administration and Opioid Overdose Outcomes. PMC9388745.

CDC naloxone consumer guidance: Naloxone for Opioid Overdose. CDC.

SAMHSA opioid overdose guidance: Opioid Overdose Prevention. SAMHSA.

SAMHSA National Helpline: SAMHSA National Helpline. 1-800-662-4357.

Find treatment: findtreatment.gov. SAMHSA.

Patient resources: National Alliance for Eating Disorders Helpline: 1-866-662-1235 (removed — not relevant to this post) | 988 Suicide and Crisis Lifeline: call or text 988 | SAMHSA National Helpline: 1-800-662-4357 | Harm Reduction Coalition | Next Distro (mail-based naloxone access)

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Rextovy is an over-the-counter emergency medication for suspected opioid overdose. Administering naloxone does not replace calling 911: emergency medical services must be contacted immediately after any suspected overdose. Naloxone is a temporary reversal agent; professional medical evaluation and monitoring are required after administration. If you or someone you know is struggling with opioid use disorder, call the SAMHSA National Helpline at 1-800-662-4357.

June 26, 2026

Type 1 Diabetes Has Never Had a Disease-Modifying Therapy That Works After Diagnosis. Tzield Just Changed That. Here Is What the PROTECT Trial Data Shows.

The essentials: On June 12, 2026 (announced June 13), the FDA granted accelerated approval to Tzield (teplizumab-mzwv, Sanofi) for a new indication: to delay the decline in endogenous (the patient’s own) insulin production in pediatric patients aged 8 through 17 years recently diagnosed with Stage 3 type 1 diabetes (T1D). This is the first FDA-approved disease-modifying therapy for recently diagnosed Stage 3 type 1 diabetes. Prior to this approval, there was no treatment capable of altering the course of T1D after clinical diagnosis. Critical time window: treatment must be initiated within 8 weeks of Stage 3 T1D diagnosis. This is an acute clinical opportunity: families and pediatric endocrinologists need to be aware that this window exists and act accordingly. Regulatory pathway: accelerated approval based on C-peptide (a surrogate marker of beta-cell function reasonably likely to predict clinical benefit). A post-approval confirmatory study, the Phase 3 BETA-PRESERVE trial, is ongoing. The clinical basis: Phase 3 PROTECT trial (NCT03875729), 328 youth with Stage 3 T1D enrolled within 6 weeks of diagnosis. Two 12-day IV infusion courses (at baseline and at week 26). Primary endpoint: stimulated C-peptide AUC at 78 weeks, a validated surrogate of beta-cell function. Teplizumab significantly preserved C-peptide versus placebo at 78 weeks. Clinically meaningful beta-cell function maintained in 94.9% of teplizumab-treated patients versus 79.2% of controls. Supporting outcomes: better HbA1c, more time-in-range, less insulin use, and lower hypoglycemia favored teplizumab numerically, though without statistical significance for each. Tzield is not effective as a disease-modifying therapy in non-autoimmune dysglycemic conditions: it only works when the underlying cause is immune-mediated beta-cell destruction. Key safety warnings: cytokine release syndrome (CRS), lymphopenia, viral reactivation including EBV and CMV (most serious cases in patients who continued treatment despite persistent severe lymphopenia). Tzield’s complete indication picture after June 2026: Stage 2 T1D (delay of Stage 3 onset) in patients aged 1 year and older; Stage 3 T1D (delay of insulin production decline) in patients aged 8 to 17 years recently diagnosed.

Type 1 diabetes is an autoimmune disease in which the immune system destroys the insulin-producing beta cells of the pancreas. For almost the entirety of its known history, nothing in medicine could change that course after it began. Insulin was discovered in 1921 and saved countless lives, but it did not address the underlying immune attack. Immunosuppressive agents reduced beta-cell destruction in small studies but caused unacceptable side effects. The disease progressed. Eventually, the beta cells were gone.

Teplizumab (Tzield) was the first drug to change any part of that story. Its original approval in November 2022 for Stage 2 T1D (the pre-symptomatic stage, before diagnosis) demonstrated that a 14-day course of IV treatment could delay the onset of clinical diabetes by approximately two years in at-risk individuals. That was extraordinary. But it left open a question: what about the children who were already diagnosed?

On June 12, 2026, the FDA answered that question. Tzield received accelerated approval for use after diagnosis, specifically to delay the decline of the patient’s own insulin production in children and adolescents aged 8 to 17 who have been recently diagnosed with Stage 3 T1D. It is the first disease-modifying therapy ever approved for recently diagnosed type 1 diabetes. There has never been anything like it before.

This post covers the staged model of type 1 diabetes and why it matters clinically, how teplizumab’s CD3 mechanism works to modulate the autoimmune attack, what the PROTECT trial showed, what the accelerated approval pathway means for the evidence base, what the 8-week treatment window requires from families and clinicians, and what this approval means for the type 1 diabetes community.

The Staged Model of Type 1 Diabetes: Why the Stage Matters

Type 1 diabetes is not a single event. It is a continuum of progressive autoimmune destruction of pancreatic beta cells that begins years before clinical diagnosis and continues afterward. The staged model, developed by the American Diabetes Association and JDRF (now Breakthrough T1D), provides a framework that has reshaped how clinicians and researchers understand and now treat the disease.

Stage	Definition	What it means clinically
Stage 1 T1D	Two or more positive islet autoantibodies; normoglycemia; no symptoms	Beta-cell autoimmunity established; at high risk for progression; no metabolic dysfunction yet
Stage 2 T1D	Two or more positive islet autoantibodies; dysglycemia (glucose abnormalities without meeting diabetes criteria); no symptoms	Beta-cell loss accelerating; progression to Stage 3 virtually certain without intervention; Tzield approved here (Stage 2 in patients aged 1 year and older)
Stage 3 T1D	Two or more positive autoantibodies plus symptomatic hyperglycemia meeting diabetes diagnostic criteria	Clinical diabetes: the stage families recognize as “diagnosis.” Beta-cell function still partially preserved at this point; Tzield now approved here in patients aged 8 to 17 years recently diagnosed

The critical insight embedded in this staging model, and the reason the June 2026 approval matters so much, is that Stage 3 T1D does not begin with zero remaining beta cells. At the time of clinical diagnosis, a meaningful fraction of insulin-producing capacity is still present. The autoimmune attack has been ongoing for years, but it has not yet completed its work. There is a window, measured in weeks to months after clinical diagnosis, during which intervention to slow or interrupt the immune destruction of the remaining beta cells is still biologically possible and clinically meaningful.

That window is exactly what teplizumab’s new indication targets.

Why preserving residual beta-cell function matters clinically Even partial preservation of the patient’s own insulin production, measured as C-peptide secretion, translates into tangible clinical advantages that insulin therapy alone cannot replicate. Patients with measurable residual beta-cell function consistently show better HbA1c levels, more time in glycemic range, lower insulin requirements, and meaningfully reduced frequency of severe hypoglycemia compared to patients with no endogenous insulin production. The pancreas’s own insulin secretion is exquisitely responsive to real-time blood glucose fluctuations in a way that no external insulin replacement strategy, including advanced closed-loop systems, can fully replicate. This is the clinical rationale for C-peptide preservation as both a trial endpoint and a treatment goal: it is not an abstract biomarker. It is a direct predictor of quality of life, safety, and long-term diabetes outcomes.

How Teplizumab Works: The CD3 Mechanism

Teplizumab is a humanized monoclonal antibody that targets CD3, a protein complex on the surface of T cells. Understanding why blocking CD3 helps preserve beta cells requires a brief look at the immunology of type 1 diabetes.

In type 1 diabetes, autoreactive CD8+ cytotoxic T cells and CD4+ helper T cells infiltrate the pancreatic islets and selectively destroy the beta cells that produce insulin. These T cells recognize beta-cell antigens (such as glutamic acid decarboxylase and insulin itself) as foreign and mount a sustained immune attack. The attack is not a single event; it is an ongoing, progressive destruction that continues over years and accelerates toward the time of clinical diagnosis and beyond.

CD3 is a component of the T-cell receptor complex: it is the intracellular signaling module that transduces the activation signal when a T cell’s antigen receptor binds its target. By binding CD3, teplizumab modulates T-cell activation without completely eliminating T cells from the circulation. This partial modulation is important: unlike conventional immunosuppressants that broadly suppress all T cell activity (creating broad susceptibility to infection), teplizumab’s mechanism selectively tolerizes the autoreactive T cells most responsible for beta-cell destruction while preserving broader immune function.

The proposed mechanism includes several complementary effects: induction of partially exhausted or tolerogenic T cells that suppress the autoimmune response; preferential depletion of effector T cells in the inflamed islets; and expansion of regulatory T cells that actively suppress autoimmunity. The net result, observed in both the original Stage 2 trials and now in the Stage 3 PROTECT trial, is a slower rate of beta-cell destruction measurable as preserved C-peptide secretion over years of follow-up after the treatment is complete.

Teplizumab is administered as a 14-day intravenous infusion course, not as an ongoing therapy. Two courses are given: one at baseline (treatment initiation) and one at week 26 (6 months later). After that, no further doses are required. The immune reprogramming established by the two courses appears to produce durable benefit, as evidenced by the persistent C-peptide preservation observed in PROTECT through 78 weeks after enrollment.

The PROTECT Trial: What the Evidence Shows

Design

PROTECT (NCT03875729) was a Phase 3, randomized, double-blind, placebo-controlled multinational trial specifically designed to evaluate teplizumab in newly diagnosed Stage 3 T1D. The trial enrolled 328 children and adolescents (teplizumab n=217, placebo n=111) within 6 weeks of Stage 3 T1D diagnosis.

Treatment regimen: Two 12-day intravenous infusion courses of teplizumab or placebo: one at baseline and one at week 26, in addition to standard diabetes care (insulin therapy and glucose monitoring).

Primary endpoint: Stimulated C-peptide area under the curve (AUC) at 78 weeks, measured during a mixed meal tolerance test (MMTT). C-peptide is co-secreted with insulin from beta cells; its level in the blood is a direct measure of functional beta-cell mass, unaffected by exogenous insulin administration.

Primary endpoint results

Teplizumab significantly preserved stimulated C-peptide versus placebo at 78 weeks. C-peptide is a validated surrogate endpoint for beta-cell function that is reasonably likely to predict clinical benefit, which is the evidentiary standard for accelerated approval.

Secondary and supporting outcomes

Outcome	Teplizumab	Placebo	Notes
Clinically meaningful beta-cell function maintained at 78 weeks	94.9%	79.2%	Clinically significant difference; higher proportion preserved residual function
HbA1c	Numerically favored teplizumab	Reference	Did not reach statistical significance
Time in range	Numerically favored teplizumab	Reference	Did not reach statistical significance
Insulin dose	Numerically lower with teplizumab	Reference	Did not reach statistical significance
Hypoglycemia	Numerically lower with teplizumab	Reference	Did not reach statistical significance

Source: Ramos EL, Dayan CM, Chatenoud L, et al. Teplizumab and beta-cell function in newly diagnosed type 1 diabetes. NEJM. 2023;389(23):2151–2161. doi:10.1056/NEJMoa2306691. PROTECT NCT03875729.

The finding that 94.9% of teplizumab-treated patients maintained clinically meaningful beta-cell function compared to 79.2% of controls at 78 weeks is clinically important. It means that a substantially higher proportion of treated children preserved enough of their own insulin production to realize the downstream glycemic benefits associated with residual beta-cell function.

The secondary outcome numerical trends (better HbA1c, more time in range, less insulin needed, less hypoglycemia) are directionally consistent with what prior research has shown about the clinical value of C-peptide preservation, even without reaching individual statistical significance. They support the clinical plausibility of the C-peptide surrogate endpoint.

Dr. Kevan Herold, MD, C.N.H. Long Professor of Immunobiology and Medicine at Yale School of Medicine and co-author of the PROTECT trial, has stated that practically all patients with new-onset Stage 3 T1D should be offered therapy unless there is an underlying condition that would prevent drug administration, describing the absence of other disease-modifying alternatives for T1D as the defining context for this recommendation.

The accelerated approval basis and confirmatory study

The FDA granted this approval under the accelerated approval pathway, based on C-peptide as a surrogate endpoint reasonably likely to predict clinical benefit. This is the same pathway used for many rare disease and serious condition approvals where waiting for long-term clinical outcome data would delay access to potentially beneficial therapies.

The BETA-PRESERVE trial (NCT05902884), a Phase 3 confirmatory study, is ongoing to verify the clinical benefit of C-peptide preservation in terms of direct patient outcomes including HbA1c, time in range, insulin requirements, and hypoglycemia frequency. Continued approval is contingent on the confirmatory study verifying this clinical benefit.

The 8-Week Treatment Window: What This Means Practically

The approved indication specifies patients recently diagnosed with Stage 3 T1D. Breakthrough T1D has clarified this as within the last 8 weeks of Stage 3 diagnosis. This is not an administrative convenience: it is a biological reality. The earlier treatment is initiated after clinical diagnosis, the more residual beta-cell function remains to preserve. Waiting months after diagnosis substantially reduces the potential benefit.

This 8-week window creates a specific and urgent clinical requirement: families and pediatric endocrinologists must be aware of Tzield’s availability at the time of diagnosis, not months later. For families receiving a new T1D diagnosis in a child or adolescent, this means:

Ask the diagnosing pediatric endocrinologist at the initial appointment whether Tzield is appropriate for your child
If your child is aged 8 to 17, was diagnosed within the past 8 weeks, and has confirmed autoimmune T1D, the conversation about Tzield should happen now, not at the 3-month follow-up visit
A referral to an academic center or JDRF-connected care team with experience in disease-modifying therapy may be appropriate if the diagnosing center is not yet familiar with the treatment protocol

The two 12-day IV infusion courses require IV access and monitoring during infusions, which means this is not a home therapy. It requires an infusion center or hospital setting, coordination of insurance authorization, and scheduling. These logistics take time, making awareness at diagnosis critical for staying within the treatment window.

Tzield’s Complete Indication Picture After June 2026

Two approvals and one significant expansion have occurred in 2026:

Indication	Population	Approval date
Delay onset of Stage 3 T1D	Adults and pediatric patients aged 1 year and older with Stage 2 T1D	November 2022 (original); expanded to ages 1 to 7 in April 2026 (previously 8 and older)
Delay decline in insulin production in recently diagnosed Stage 3 T1D	Pediatric patients aged 8 to 17 years within 8 weeks of Stage 3 T1D diagnosis	June 12, 2026 (accelerated approval)

The Stage 2 expansion to children as young as 1 year (April 2026, based on PETITE-T1D study data) and the Stage 3 approval (June 2026, PROTECT) together mean that teplizumab is now available across the full spectrum of high-risk and newly diagnosed pediatric T1D, from presymptomatic at-risk toddlers through adolescents at clinical diagnosis.

Safety: What the Prescribing Information and Trial Data Show

Teplizumab’s safety profile is driven by its mechanism of CD3-directed T-cell modulation during 12-day IV infusion courses. The adverse event profile in PROTECT was consistent with the previously characterized teplizumab dataset from over 900 patients across the development program.

Warnings and key adverse events:

Cytokine release syndrome (CRS): A class effect of CD3-directed therapies. CRS occurs during the infusion course and is characterized by fever, nausea, headache, fatigue, myalgia, and other systemic symptoms. In teplizumab trials, CRS is generally mild to moderate and managed with premedication (acetaminophen and antihistamines) and supportive care during infusion. Severe CRS has been reported and requires prompt management. Infusion settings must be equipped to manage CRS.

Lymphopenia: T-cell depletion is expected with teplizumab and is part of its mechanism. Severe lymphopenia requires close monitoring. The most serious viral reactivation events observed in the clinical program occurred in patients who continued therapy despite persistent, severe lymphopenia. Current guidance requires dose interruption or discontinuation in the setting of persistent severe lymphopenia.

Viral reactivation: Serious, life-threatening cases of Epstein-Barr virus (EBV) and cytomegalovirus (CMV) reactivation have been reported. Most serious cases occurred in patients with persistent, severe lymphopenia who continued treatment. Viral reactivation surveillance before and during treatment is essential.

Other adverse events reported in PROTECT: Lymphopenia (expected), cytopenias (reductions in other blood cell types), gastrointestinal symptoms, rash, transaminase elevations, and headache. These were generally consistent with the expected immunomodulatory effects of the drug.

Pre-treatment requirements:

Screening for EBV and CMV serostatus before initiating treatment
Complete blood count monitoring before and during treatment courses
Premedication before infusions to reduce CRS severity
Avoid live vaccines during and after treatment until lymphocyte recovery is confirmed

Contraindications:

Active serious infection
Immunocompromised patients are at increased risk; careful benefit-risk assessment required
Tzield is not effective as a disease-modifying therapy in non-autoimmune dysglycemic conditions: laboratory confirmation of autoimmune etiology (positive islet autoantibodies) is a clinical prerequisite

What This Means for Families and Clinicians

For families of a child recently diagnosed with T1D

If your child is aged 8 to 17 and has been diagnosed with type 1 diabetes within the past 8 weeks, Tzield is now an FDA-authorized option that deserves immediate discussion with your pediatric endocrinologist. This is not a therapy to consider “later.” The 8-week window is real and it closes.

Questions to ask your endocrinology team:

Has my child had autoantibody testing that confirms autoimmune T1D?
Are we within 8 weeks of diagnosis?
Is Tzield appropriate for my child given their health history?
Where can we receive the infusion courses?
What is the prior authorization process with our insurance?

The Breakthrough T1D website and JDRF Tzield resources provide current information for families navigating this decision. Sanofi’s Tzield support program (1-800-633-1610) provides information about access, insurance navigation, and referral to treatment centers.

For pediatric endocrinologists

This approval creates a new, urgent clinical protocol: at the time of Stage 3 T1D diagnosis in any patient aged 8 to 17, the Tzield conversation should occur within the first visit or at minimum within the first week of diagnosis. This is the same urgency model used for conditions like acute lymphoblastic leukemia, where initiating disease-modifying treatment in the correct window fundamentally alters long-term outcomes.

The treatment infrastructure requirements (IV infusion over 12 consecutive days, monitoring for CRS and lymphopenia, EBV/CMV screening) mean that systems-level readiness at pediatric endocrinology centers is important. Centers not currently equipped to administer teplizumab should establish referral pathways to centers that are.

The broader significance

Dr. Aaron J. Kowalski, PhD, CEO of Breakthrough T1D, described the approval as providing “a novel therapy that targets the autoimmune and progressive nature of stage 3 type 1 diabetes,” noting that approximately 64,000 people are diagnosed with T1D every year in the United States. For the pediatric portion of that population, a brief window of opportunity now exists to alter the course of the disease in a way that was not previously possible.

Type 1 diabetes has been managed for over 100 years with increasingly sophisticated insulin replacement. This is the first time a treatment has been approved that goes beyond replacement to address the underlying autoimmune destruction. It is a genuinely historic moment for the T1D community.

For related HED coverage on other disease-modifying therapies and autoimmune conditions, see our post on Ocrevus (ocrelizumab) receiving pediatric approval for relapsing-remitting multiple sclerosis, another CD20-directed therapy that alters the course of an autoimmune disease, and our post on Awiqli, the first once-weekly basal insulin for type 2 diabetes, for context on how the insulin therapy landscape continues to evolve alongside disease-modifying approaches.

Sources

FDA approval announcement: FDA approves new indication for Tzield (teplizumab) for certain pediatric patients with recently diagnosed Stage 3 type 1 diabetes. FDA.gov. June 12 (announced June 15), 2026.

Sanofi press release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes. Sanofi. June 12, 2026.

Drugs.com approval news: Sanofi’s Tzield Approved in the US as the First Disease-Modifying Therapy for Patients Recently Diagnosed with Stage 3 Type 1 Diabetes. drugs.com. June 13, 2026.

FDA plain language summary: FDA approves drug for pediatric stage 3 type I diabetes. FDA.gov. June 2026.

Pharmacy Times clinical review: FDA Approves Teplizumab-mzwv for Children With Newly Diagnosed Stage 3 Type 1 Diabetes. pharmacytimes.com. June 2026.

Patient Care Online clinical summary (with investigator cautions): FDA Expands Teplizumab Approval for Pediatric Stage 3 Type 1 Diabetes. patientcareonline.com. June 2026.

Healio endocrinology coverage: FDA approves Tzield to treat children and adolescents with stage 3 type 1 diabetes. healio.com. June 2026.

Pediatric Endocrine Society clinical summary: Teplizumab Approval Expanded to Stage 3 Type 1 Diabetes (Ages 8-17). pedsendo.org. June 2026.

Breakthrough T1D community update: Tzield approved for stage 3 T1D in the U.S. breakthrought1d.org. June 2026.

BioPharm International coverage: FDA Expands Pfizer’s Hympavzi Approval… (note: cross-reference; not directly cited for Tzield)

Sanofi Stage 2 expansion (April 2026, ages 1-7): Sanofi’s Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children. sanofi.com. April 22, 2026.

PROTECT trial primary publication: Ramos EL, Dayan CM, Chatenoud L, et al. Teplizumab and beta-cell function in newly diagnosed type 1 diabetes. NEJM. 2023;389(23):2151–2161. doi:10.1056/NEJMoa2306691.

PROTECT trial registration: NCT03875729. ClinicalTrials.gov.

BETA-PRESERVE confirmatory trial registration: NCT05902884. ClinicalTrials.gov.

Teplizumab mechanism review: Teplizumab in Type 1 Diabetes. PMC9356435.

T1D staging scientific statement: Staging Presymptomatic Type 1 Diabetes. Diabetes. 2015;64(8):2541–2550.

T1D StatPearls: Type 1 Diabetes Mellitus. StatPearls. NCBI.

NIDDK T1D overview: Type 1 Diabetes. NIDDK.

Accelerated approval pathway: Accelerated Approval. FDA.gov.

EBV: Epstein-Barr Virus. StatPearls. NCBI.

CMV: Cytomegalovirus. StatPearls. NCBI.

Tzield prescribing information: TZIELD (teplizumab-mzwv) Prescribing Information. Sanofi. 2026.

Patient resources: Breakthrough T1D (JDRF) | American Diabetes Association: Type 1 | Sanofi Tzield patient support: 1-800-633-1610 | NIDDK Type 1 Diabetes

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Tzield (teplizumab-mzwv) is indicated for recently diagnosed Stage 3 T1D in pediatric patients aged 8 to 17 years within 8 weeks of diagnosis. It is not effective in non-autoimmune dysglycemic conditions. Treatment requires IV infusion and monitoring in a qualified clinical setting. Families should consult with a board-certified pediatric endocrinologist immediately after a child’s Stage 3 T1D diagnosis to determine eligibility and timing within the treatment window.

June 25, 2026

Ebglyss Can Now Be Given Every 8 Weeks Instead of Every 4. For Patients With Moderate-to-Severe Atopic Dermatitis, That Is a Meaningful Change. Here Is What the Science Shows.

The essentials: On June 9, 2026, the FDA approved a new maintenance dosing regimen for Ebglyss (lebrikizumab-lbkz, Eli Lilly): one injection of 250 mg every 8 weeks (Q8W) for adults and adolescents aged 12 years and older weighing at least 40 kg (approximately 88 lbs) with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical prescription therapies. This is a new dosing regimen approval, not a new drug or new indication. Ebglyss was originally approved in September 2024 for the same population with a once-every-4-weeks (Q4W) maintenance regimen. The complete dosing schedule with the Q8W option: induction with 500 mg (two 250 mg injections) at weeks 0 and 2, then 250 mg every 2 weeks through week 16 or until adequate clinical response is achieved, followed by maintenance dosing of either 250 mg Q4W or 250 mg Q8W. What makes the Q8W approval clinically notable: Ebglyss is now the only FDA-approved biologic for atopic dermatitis that offers as few as 6 maintenance injections per year without a mandatory requirement for concomitant topical therapy from treatment initiation. No other approved AD biologic currently combines both of these features. The evidence basis: longitudinal exposure-response modeling and the Q8W ADjoin extension (NCT04392154), a 32-week open-label study evaluating Q8W and Q4W dosing in patients who had completed the 100-week ADjoin long-term study. No new safety signals were identified. No patients discontinued due to adverse events through 32 weeks. Important interpretive caveat: extension participants had already received approximately 100 weeks of lebrikizumab therapy before entering the Q8W study. The real-world applicability to newly initiating patients who transition to Q8W earlier has not been directly studied.

Atopic dermatitis is not a rash. It is a chronic, relapsing immune-mediated inflammatory disease of the skin that affects an estimated 16 million adults in the United States, more than 10% of the adult population, and a substantially higher proportion of children. At its severe end, atopic dermatitis produces relentless itch, disrupted sleep, cracked and weeping skin, and a psychological burden documented to rival conditions such as psoriasis and chronic pain. For adults and adolescents with moderate-to-severe disease inadequately controlled by topical therapies, systemic treatments including biologics are increasingly the standard of care.

Ebglyss (lebrikizumab), an IL-13 inhibitor, was approved in September 2024 with a once-monthly (Q4W) maintenance dosing schedule. On June 9, 2026, the FDA approved an expanded maintenance option: one injection every 8 weeks (Q8W), allowing eligible patients to reduce their annual injection burden from 13 to as few as 6 after completing induction. That numerical change from 13 to 6 injections per year is not a trivial reduction in the context of a disease that will require ongoing management for most patients indefinitely.

This post covers what atopic dermatitis is, how IL-13 drives its pathology and why blocking it works, what the ADjoin extension data supports, what the competitive significance of the Q8W approval is, and what patients and prescribers need to know about the dosing schedule in practice.

What Atopic Dermatitis Is and Why Moderate-to-Severe Disease Requires Systemic Therapy

Atopic dermatitis is a chronic inflammatory skin disease driven by dysfunction in both the skin barrier and the immune system. The two abnormalities are interconnected: a defective epidermal barrier, often related to mutations in the gene encoding filaggrin, allows allergens, irritants, and microorganisms to penetrate the skin, triggering and sustaining a type 2 (Th2-skewed) immune response. The resulting cytokine cascade, dominated by IL-4, IL-13, and IL-31, drives ongoing skin inflammation, barrier disruption, and the hallmark symptom of atopic dermatitis: intense, persistent itch.

The Th2-skewed immune response in atopic dermatitis is what has made this disease amenable to targeted biologic therapy. The first approved biologic for AD, dupilumab (Dupixent), targets both IL-4 and IL-13 by blocking the shared IL-4 receptor alpha chain. Lebrikizumab takes a more targeted approach: it binds specifically and exclusively to IL-13.

Why moderate-to-severe atopic dermatitis requires more than topical therapy

Topical corticosteroids and calcineurin inhibitors (tacrolimus, pimecrolimus) are effective for mild to moderate disease but have significant limitations in moderate-to-severe disease. Long-term topical corticosteroid use carries risks of skin atrophy, striae, and hypothalamic-pituitary-adrenal axis suppression with extensive application. The emotional and logistical burden of applying topical agents to extensive, inflamed skin multiple times daily is substantial, particularly for patients with involvement of difficult-to-treat areas such as the face, neck, and skin folds.

For patients whose disease is not adequately controlled by topical prescription therapies, systemic options including biologics targeting IL-4/IL-13 signaling (dupilumab, tralokinumab, lebrikizumab) and the JAK inhibitor class (upadacitinib, abrocitinib, baricitinib) represent the current standard. No mandatory concomitant topical therapy requirement at treatment initiation is a practical advantage for patients with extensive or difficult-to-treat distribution.

The Science: How IL-13 Drives Atopic Dermatitis and Why Blocking It Works

Interleukin-13 (IL-13) is a cytokine produced primarily by activated Th2 T cells, innate lymphoid cells type 2 (ILC2), and mast cells in atopic skin. It is the dominant driver of multiple pathological processes in atopic dermatitis:

Skin barrier disruption: IL-13 suppresses the expression of filaggrin, loricrin, and other structural proteins essential for the epidermal barrier. By reducing barrier protein synthesis, IL-13 perpetuates the permeability defect that allows allergen penetration and drives the cycle of sensitization and immune activation.

Itch: IL-13 directly stimulates sensory nerve fibers and primes skin-resident cells to release histamine and other pruritogens, contributing directly to the intense itch that is the defining symptom of atopic dermatitis.

Inflammation: IL-13 activates keratinocytes, fibroblasts, and other skin cells to produce chemokines and adhesion molecules that recruit additional immune cells to the skin, amplifying the local inflammatory response.

IgE production: IL-13 cooperates with IL-4 to drive B cell class switching to IgE production, the antibody class responsible for atopic sensitization.

Lebrikizumab is a high-affinity human monoclonal antibody that binds specifically to IL-13 itself, rather than to the IL-4/IL-13 shared receptor that dupilumab targets. By capturing circulating IL-13 before it can engage its receptor, lebrikizumab blocks downstream signaling through both the IL-13Rα1/IL-4Rα heterodimer (the signaling receptor for IL-13 in skin cells) and the IL-13Rα2 decoy receptor. The high binding affinity and specificity for IL-13 means the drug does not affect IL-4 signaling, which distinguishes it from dupilumab pharmacologically, though clinical outcomes in pivotal trials have been broadly comparable in terms of efficacy endpoints.

The structural basis for lebrikizumab’s IL-13 binding has been characterized crystallographically: the antibody binds at a distinct epitope on IL-13 that prevents both IL-13Rα1 and IL-13Rα2 engagement, explaining the completeness of its IL-13 blockade.

The Approved Dosing Schedule: Complete and Correct

With the June 9, 2026 approval, the complete Ebglyss dosing schedule for the approved population (adults and adolescents aged 12 years and older, weight at least 40 kg) is:

Phase	Dose	Frequency
Induction (weeks 0 and 2)	500 mg (two 250 mg injections administered at the same visit)	Two doses, two weeks apart
Maintenance (weeks 2 through 16 or until adequate response)	250 mg single injection	Every 2 weeks (Q2W)
Maintenance (after adequate response achieved, ongoing)	250 mg single injection	Every 4 weeks (Q4W) OR every 8 weeks (Q8W) — patient and clinician choice

The decision between Q4W and Q8W maintenance should be individualized. Patients with robust and sustained response who prefer a less frequent injection schedule are candidates for Q8W. Patients with a history of more frequent flares or less complete response may be better maintained on Q4W. This is a clinical judgment discussion between the patient and their dermatologist.

Annual injection count summary:

Induction (2 visits, 4 injections total across weeks 0 and 2, plus Q2W phase)
Q4W maintenance: approximately 13 injections per year
Q8W maintenance: as few as 6 injections per year

The ADjoin Extension Data: What Supported the Q8W Approval

The Q8W approval was based on two complementary data sources: longitudinal exposure-response modeling and the Q8W ADjoin extension study.

Exposure-response modeling

The pharmacokinetic and pharmacodynamic data from the original lebrikizumab development program, including ADvocate 1 and ADvocate 2 (the pivotal Phase 3 trials), demonstrated that lebrikizumab’s long half-life and sustained IL-13 suppression at Q8W dosing supported the hypothesis that every-8-week dosing could maintain therapeutic drug levels and clinical response in patients who had achieved adequate disease control. Longitudinal exposure-response modeling provides the mechanistic rationale for the regimen; the ADjoin extension provided the confirmatory clinical data.

ADjoin extension (NCT04392154)

The Q8W ADjoin extension was a 32-week open-label study evaluating Q8W and Q4W dosing in adult and adolescent patients who had completed the 100-week ADjoin long-term study. ADjoin itself enrolled completers from four prior Phase 3 trials: ADvocate 1 and 2 (52-week trials), ADore (52-week trial), and ADopt-VA (16-week trial). Patients in the extension received open-label Ebglyss 250 mg, Q8W or Q4W, regardless of their prior dosing interval (Q2W or Q4W) or response status at extension baseline.

Extension safety findings:

No new safety signals identified through 32 weeks of Q8W dosing
No patients discontinued due to adverse events through 32 weeks
Safety profile consistent with the established lebrikizumab dataset

Efficacy:

Disease control was maintained through 32 weeks in both Q8W and Q4W dosing groups
Long-term data from the broader lebrikizumab program show durable disease control for up to 4 years of continuous treatment

Dr. Peter Lio, MD, primary investigator of the ADjoin study and Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University, noted that extending maintenance dosing to every eight weeks represents an important option for patients living with moderate-to-severe atopic dermatitis.

The important interpretive caveat

The patients in the Q8W ADjoin extension had already completed approximately 100 weeks of lebrikizumab therapy before entering the extension. They were therefore a population with demonstrated long-term tolerability and sustained response, representing a selected, treatment-experienced group. The real-world applicability of Q8W dosing in newly initiating patients who have completed induction and transitioned earlier to Q8W maintenance has not been directly studied in a de novo population. Dermatologists should discuss this with patients: the 6-injections-per-year figure applies to patients who have achieved and maintained adequate response; the long-term profile of Q8W in newly initiated patients should be monitored as real-world experience accumulates.

Competitive Context: Where This Places Ebglyss in the AD Biologic Landscape

The atopic dermatitis biologic market in 2026 is the most competitive it has ever been. The approved biologics for moderate-to-severe AD include:

Drug	Target	Approval	Dosing (maintenance)	Mandatory topical
Dupixent (dupilumab, Sanofi/Regeneron)	IL-4Rα (blocks IL-4 and IL-13)	2017 (adults); expanded	Q2W	No
Adbry (tralokinumab, LEO Pharma)	IL-13	2021	Q2W; Q4W option available	No
Ebglyss (lebrikizumab, Lilly)	IL-13	2024	Q4W or Q8W	No

The Q8W approval gives Ebglyss a dosing frequency advantage over dupilumab (Q2W mandatory maintenance) and tralokinumab (Q2W standard, Q4W available for responders). Ebglyss’s Q8W maintenance option of as few as 6 injections per year, without a mandatory concomitant topical therapy requirement, is a combination not currently available with any other approved AD biologic. That distinction is commercially meaningful for Lilly and clinically meaningful for the subset of patients who are well-controlled responders and for whom injection burden influences long-term adherence.

The practical comparison for prescribers: dupilumab has the most extensive long-term evidence base and the broadest approved indication range (including asthma, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, and prurigo nodularis in addition to AD). For patients whose primary driver is AD management and for whom injection frequency is a concern, Ebglyss’s Q8W option is now a differentiating factor worth discussing.

Safety: What Prescribers and Patients Need to Know

The safety profile of lebrikizumab with the Q8W dosing regimen is consistent with the established dataset from the full lebrikizumab clinical program. The most common adverse reactions (occurring in at least 1% of patients) are:

Conjunctivitis: The most characteristic class effect across all IL-4/IL-13 pathway targeting biologics. Conjunctivitis in the lebrikizumab trials occurs at lower rates than typically reported with dupilumab, which is a clinically relevant distinction for patients who have experienced significant eye symptoms on dupilumab. Mild to moderate conjunctivitis should be assessed and treated with ophthalmic supportive care; if severe or persistent, ophthalmology consultation and discussion of dose adjustment are appropriate.

Injection site reactions: Common, typically mild (redness, pain, swelling at the injection site), and generally not requiring discontinuation. Rotate injection sites; abdomen, thigh, and upper arm are acceptable locations.

Herpes zoster: IL-13 pathway inhibition has a low but documented association with herpes zoster (shingles) reactivation. Patients who have not been vaccinated against herpes zoster should discuss vaccination with their dermatologist before initiating long-term biologic therapy for atopic dermatitis.

Contraindications:

Hypersensitivity to lebrikizumab-lbkz or any ingredient in Ebglyss

Live vaccines: As with all biologic therapies, live attenuated vaccines should not be administered during lebrikizumab treatment. Update all vaccines, including zoster vaccine, before initiating therapy.

Pregnancy: The effect of lebrikizumab on a developing fetus is not fully established. Discuss contraception and pregnancy planning with patients of reproductive potential. A pregnancy exposure registry (1-800-545-6962) is available for patients who become pregnant while on Ebglyss.

What This Means for Patients

For patients currently on Ebglyss Q4W who are achieving good disease control, the Q8W option is now available to discuss with their dermatologist. If you have been well-controlled for an extended period on Q4W maintenance and would benefit from a less frequent injection schedule, this is a conversation worth initiating at your next dermatology appointment.

For patients newly initiating Ebglyss: the standard induction and Q2W maintenance schedule remains the starting point. The Q8W option comes after achieving adequate clinical response, which typically occurs by week 16. The dosing path is: start with induction, achieve response, then discuss with your dermatologist whether Q4W or Q8W maintenance fits your response profile and lifestyle.

For patients who have experienced significant conjunctivitis on dupilumab: lebrikizumab’s IL-13-only mechanism (not blocking IL-4) is associated with lower conjunctivitis rates than dupilumab in clinical trials, making it a clinically reasonable alternative for patients where ocular side effects have been a management challenge.

For prescribers: the Q8W approval gives an additional tool for the conversation about long-term maintenance. Patient adherence to any chronic biologic therapy is improved by dosing schedules that fit into normal life rhythms. Six injections per year, administered at home without routine monitoring requirements, is a significantly lighter burden than monthly or biweekly regimens for patients who can achieve and sustain adequate disease control.

For related HED coverage on biologics for inflammatory conditions and the expanding IL-13 inhibitor class, see our post on Fasenra (benralizumab) receiving its new indication for hypereosinophilic syndrome and our post on Xolair (omalizumab) and its biosimilar transition as part of the 2026 LOE series, which covers the broader IgE/type-2 inflammation treatment landscape in which both drug classes operate.

Sources

Lilly FDA approval press release: FDA approves Lilly’s EBGLYSS (lebrikizumab-lbkz) for one maintenance dose every eight weeks. Eli Lilly. investor.lilly.com. June 9, 2026.

Drugs.com approval news: FDA Approves Lilly’s Ebglyss for One Maintenance Dose Every Eight Weeks. drugs.com. June 9, 2026.

HCPLive clinical coverage: FDA Approves Lebrikizumab 8-Week Maintenance Dosing in Atopic Dermatitis. hcplive.com. June 2026.

BioPharm International clinical coverage: FDA Approves Lebrikizumab Every-8-Week Maintenance Dosing for Moderate-Severe Atopic Dermatitis. biopharminternational.com. June 2026.

Contemporary Pediatrics (with investigator caveat): FDA approves lebrikizumab every-8-week maintenance dosing for moderate-to-severe atopic dermatitis. contemporarypediatrics.com. June 2026.

Dermatology Times coverage: Lebrikizumab Earns FDA Approval for Less Frequent, Every-8-Week Maintenance Dosing in AD. dermatologytimes.com. June 2026.

ADjoin extension (NCT04392154): NCT04392154. ClinicalTrials.gov.

Silverberg J et al. (ADjoin Q8W data; Fall Clinical Dermatology Conference 2025): Silverberg J, et al. Lebrikizumab every 8 weeks as maintenance dose provides long-lasting response in patients with moderate-to-severe atopic dermatitis. Fall Clinical Dermatology Conference. 2025.

4-year durability data (Almirall): Lebrikizumab delivered long-term disease control for up to four years in patients with moderate-to-severe atopic dermatitis. Almirall press release. March 27, 2026.

Ebglyss original FDA approval (September 2024): FDA approves lebrikizumab-lbkz for atopic dermatitis. FDA.gov.

Dupixent FDA approval: FDA approves dupilumab for moderate to severe atopic dermatitis. FDA.gov.

Adbry FDA approval: FDA approves tralokinumab-ldrm for atopic dermatitis. FDA.gov.

IL-13 in atopic dermatitis: IL-13 in Atopic Dermatitis. PMC8908499.

Lebrikizumab IL-13 binding mechanism: Okragly A et al. Binding, neutralization and internalization of IL-13 antibody lebrikizumab. Dermatology and Therapy. 2023. doi:10.1007/s13555-023-00947-7.

Lebrikizumab structural basis: Ultsch M et al. Structural basis of signaling blockade by IL-13 antibody lebrikizumab. Journal of Molecular Biology. 2013;425(8):1330-1339. doi:10.1016/j.jmb.2013.01.024.

Atopic dermatitis epidemiology: Atopic Dermatitis. StatPearls. NCBI.

Atopic dermatitis quality of life burden: AD Quality of Life and Burden. PMC7305275.

NIAMS atopic dermatitis overview: Atopic Dermatitis. NIAMS.

Ebglyss prescribing information: EBGLYSS (lebrikizumab-lbkz) Prescribing Information. Eli Lilly. 2026.

Patient resources: National Eczema Association | American Academy of Dermatology: Find a Dermatologist | Lilly Ebglyss patient support

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Decisions about biologic therapy for atopic dermatitis, including the choice between Q4W and Q8W maintenance dosing for Ebglyss, should be made in close consultation with a board-certified dermatologist or allergist familiar with the patient’s disease history, prior treatment response, and overall health profile.

June 24, 2026

Hympavzi Just Became Available to Children as Young as 6 and to Patients With Hemophilia Inhibitors — Two of the Groups Who Have Needed It Most. Here Is What the BASIS Trial Data Shows.

The essentials: On June 8, 2026, the FDA approved an expanded indication for Hympavzi (marstacimab-hncq, Pfizer) to include two additional patient populations: patients aged 12 years and older with hemophilia A or B who have inhibitors, and pediatric patients aged 6 to 11 years with hemophilia A or B with or without inhibitors. Hympavzi was originally approved in October 2024 for patients aged 12 years and older without inhibitors. The complete current indication: routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients aged 6 years and older with hemophilia A (congenital factor VIII deficiency) or hemophilia B (congenital factor IX deficiency), with or without inhibitors. First-in-class designations from the expanded approval: Hympavzi is now the first subcutaneous non-factor therapy available for children aged 6 to 11 years with hemophilia B. Mechanism: Hympavzi targets the Kunitz 2 domain of tissue factor pathway inhibitor (TFPI), a natural anticoagulant that brakes the initiation of coagulation. By inhibiting TFPI, marstacimab restores the coagulation pathway in a way that works regardless of whether the patient is deficient in factor VIII or factor IX, and regardless of whether inhibitory antibodies are present against those factors. This is why it works in both hemophilia A and B, and in patients with inhibitors. The clinical basis: Phase 3 BASIS trial (NCT03938792) inhibitor cohort and Phase 3 BASIS KIDS trial (NCT05611801). BASIS inhibitor cohort: 93% reduction in mean treated annualized bleeding rate (ABR) versus on-demand bypassing agent therapy (1.4 [95% CI 0.9 to 2.3] versus 19.8 [95% CI 16.1 to 24.3]; ratio 0.07 [95% CI 0.04 to 0.12]; p less than 0.0001). BASIS KIDS (ages 6 to 17): mean ABR 1.8 versus historical model-based mean ABR 3.6 with prior routine prophylaxis. Pediatric inhibitor subgroup (ages 6 to under 18; n=14): mean ABR 1.4 (99% CI 0.5 to 4.5) versus historical mean ABR 18.9 (99% CI 14.2 to 25.2). Ages 6 to 11 cohort (n=7): mean ABR 1.3 (99% CI 0.5 to 3.4). Warnings: thromboembolic events occurred in 2 of 259 patients in the open-label extension study; hypersensitivity reactions; embryo-fetal toxicity; increased laboratory values of fibrin D-dimer and prothrombin fragment 1.2. Dosing: once weekly subcutaneous injection; available as 75 mg/0.5 mL and 150 mg/mL prefilled syringe or autoinjector pen. No routine treatment-related laboratory monitoring required.

Hemophilia is, at its core, a disease of imbalance. The coagulation cascade that allows blood to clot and stop bleeding is a tightly regulated system of amplification, and in hemophilia A or B, a critical amplifier is missing or deficient. The consequences, when left untreated or inadequately treated, are relentless: joint bleeds that destroy cartilage and deform limbs, muscle hemorrhages that compress nerves and blood vessels, and intracranial bleeding that can be fatal. For patients with a specific complication called inhibitors, even the standard replacement therapy stops working, leaving them in a position where a category of medications designed to save their lives has become ineffective against their own immune response.

Hympavzi (marstacimab-hncq), originally approved in October 2024, takes an entirely different approach to hemophilia prophylaxis. Rather than replacing the deficient clotting factor, it blocks a natural brake on the coagulation system: tissue factor pathway inhibitor (TFPI). On June 8, 2026, the FDA expanded Hympavzi’s approved indication to two of the groups most in need of this approach: patients with hemophilia A or B who have inhibitors (where factor replacement therapy either cannot work or works inadequately), and children aged 6 to 11 years, the youngest pediatric age group that can benefit from a once-weekly subcutaneous prophylactic therapy.

This post covers what hemophilia is, why inhibitors represent such a significant clinical challenge, how the TFPI mechanism works and why it is effective across both hemophilia types and inhibitor-positive patients, what the BASIS and BASIS KIDS trial data shows, and what the expanded approval means for families and clinicians managing these patients.

What Hemophilia Is: A Brief Overview

Hemophilia is a rare, X-linked recessive bleeding disorder caused by deficiency or dysfunction of specific coagulation factors. Two major types are recognized:

Hemophilia A is caused by deficiency or dysfunction of factor VIII (FVIII). It is the more common type, affecting approximately 1 in 5,000 male births.

Hemophilia B is caused by deficiency or dysfunction of factor IX (FIX). It affects approximately 1 in 25,000 male births.

Both conditions result in a dysfunctional coagulation cascade, the sequential activation of clotting proteins that ultimately converts fibrinogen to fibrin and forms a stable blood clot. Without adequate FVIII or FIX activity, the intrinsic pathway of coagulation cannot amplify adequately, resulting in delayed, insufficient clot formation. Minor injuries that healthy individuals handle without consequence become prolonged bleeding events in hemophilia. Spontaneous joint and muscle bleeds, which occur without obvious trauma, are a hallmark of severe hemophilia and are responsible for the progressive arthropathy (joint destruction) that historically defined the long-term morbidity of the disease.

The standard of care for moderate to severe hemophilia has been prophylactic factor replacement: infusing FVIII or FIX concentrate on a scheduled basis, typically two to three times per week for IV formulations or less frequently for extended half-life products, to maintain factor levels high enough to prevent spontaneous bleeding. This approach has dramatically improved outcomes over the past four decades. It requires, however, venous access and intravenous administration, which is particularly challenging in young children whose veins are small and who may require port placement.

The inhibitor problem

Inhibitors are neutralizing antibodies against the infused clotting factor, most commonly FVIII in hemophilia A. They develop in approximately 30% of patients with severe hemophilia A and in a smaller proportion of hemophilia B patients, typically early in treatment. When inhibitors are present, the infused factor is rapidly neutralized before it can participate in clotting, and standard prophylaxis becomes ineffective.

Managing hemophilia with inhibitors has historically required bypassing agents, products that activate the coagulation cascade at steps downstream of where FVIII and FIX normally act: recombinant factor VIIa (NovoSeven) and activated prothrombin complex concentrate (aPCC, FEIBA). These agents work differently from standard factor replacement and are less precisely dosed, making achieving predictable bleeding protection more challenging. Their use is also expensive, requires intravenous administration, and when used on-demand (only when bleeding occurs) rather than prophylactically, leaves patients with significant residual bleeding burden.

Why non-factor therapies are a breakthrough for inhibitor patients The development of non-factor hemostatic therapies, which restore hemostasis by mechanisms that bypass the deficient factor entirely, represents one of the most significant advances in hemophilia management in decades. Emicizumab (Hemlibra), approved in 2017 for hemophilia A with inhibitors, was the first such therapy and demonstrated dramatic reductions in bleeding rates in a population that had previously had very limited prophylactic options. It works by bridging FIXa and FX, mimicking the co-factor function of FVIII specifically. However, because emicizumab bridges FIXa (factor IX in activated form), it works only in hemophilia A: it provides no benefit in hemophilia B because FIX is not a bridging partner for its mechanism. Marstacimab’s TFPI inhibition mechanism is active in both hemophilia A and hemophilia B regardless of inhibitor status, because it restores hemostasis upstream of where either FVIII or FIX deficiency disrupts the cascade. This is why Hympavzi’s expanded indication covers both hemophilia types and both inhibitor-positive and inhibitor-negative patients.

The Science: How Marstacimab Works

Tissue factor pathway inhibitor (TFPI) is a naturally occurring anticoagulant protein. It functions as a feedback inhibitor of the extrinsic pathway of coagulation: after tissue factor and factor VIIa initiate clotting in response to vascular injury, TFPI rapidly inhibits the TF-FVIIa-FXa complex, effectively braking the initial clotting signal after it has had time to initiate.

In healthy individuals, this brake is appropriate. The extrinsic pathway generates only a small initial burst of thrombin, and the intrinsic pathway (which requires FVIII and FIX) amplifies this initial signal to generate the large amounts of thrombin needed for stable clot formation. When FVIII or FIX is deficient, the initial thrombin burst generated by the extrinsic pathway is inadequate, and the amplification step through the intrinsic pathway cannot compensate. TFPI’s braking of the extrinsic pathway further limits the already insufficient hemostatic response.

Marstacimab is a human monoclonal antibody that targets the Kunitz 2 (K2) domain of TFPI with high specificity. The K2 domain is the site through which TFPI inhibits FXa, a critical downstream clotting protein. By blocking the K2 domain, marstacimab prevents TFPI from inhibiting FXa as efficiently. This allows the coagulation cascade to generate more thrombin from the extrinsic pathway initiation step, partially compensating for the deficient intrinsic amplification. The result is a shift in the coagulation balance toward clot formation even in the absence of adequate FVIII or FIX.

Critically, this mechanism functions regardless of:

Whether the patient is deficient in FVIII (hemophilia A) or FIX (hemophilia B)
Whether inhibitory antibodies are present against FVIII or FIX
The severity of the underlying factor deficiency

Because marstacimab acts on a checkpoint in the coagulation cascade that is common to both hemophilia types and is entirely upstream of where inhibitors act against replacement factors, it provides hemostatic coverage across the full breadth of the expanded indication.

The Original Approval and What the Expansion Adds

Original approval (October 2024)

Hympavzi was initially approved in October 2024 for routine prophylaxis in patients aged 12 years and older with hemophilia A without FVIII inhibitors or hemophilia B without FIX inhibitors, based on the Phase 3 BASIS trial in the non-inhibitor cohort.

The June 2026 expansion

The June 8, 2026 expansion adds two critically important populations:

Population 1: Patients aged 12 years and older with hemophilia A or B who have inhibitors. This is the group with the most limited treatment options prior to this approval, for whom on-demand bypassing agents were often the only recourse for bleeding management.

Population 2: Pediatric patients aged 6 to 11 years with hemophilia A or B, with or without inhibitors. This extends Hympavzi’s reach to younger children, a population in whom venous access for IV therapy is a significant practical challenge, and for whom a once-weekly subcutaneous injection is potentially far more manageable than frequent IV infusions.

Together, the expanded and original indications give Hympavzi a single consolidated label: routine prophylaxis for adults and pediatric patients aged 6 years and older with hemophilia A or B, with or without inhibitors.

The Clinical Evidence: BASIS Inhibitor Cohort and BASIS KIDS

BASIS trial (NCT03938792): the inhibitor cohort data

BASIS (NCT03938792) was a Phase 3, global, open-label trial evaluating marstacimab in patients with hemophilia A or B with and without inhibitors. The trial included an inhibitor cohort of patients who had previously received on-demand (OD) bypassing agent therapy for bleeding episodes. This population represents the clinical severity of inhibitor disease: patients who had not been on prophylaxis and were relying on reactive treatment when bleeds occurred.

The primary efficacy comparison in the inhibitor cohort was marstacimab prophylaxis versus on-demand bypassing agent therapy. The results were striking:

Outcome	Marstacimab prophylaxis	On-demand bypassing agent (historical)	Comparison
Mean treated annualized bleeding rate (ABR)	1.4 (95% CI 0.9 to 2.3)	19.8 (95% CI 16.1 to 24.3)	93% reduction; ratio 0.07 (95% CI 0.04 to 0.12); p less than 0.0001

Source: Clinical Advisor. Hympavzi Gains Expanded FDA Approval for Hemophilia A and B. June 2026. Hematology Advisor. June 2026. Pfizer press release, June 8, 2026.

A 93% reduction in mean treated annualized bleeding rate compared to on-demand bypassing therapy is a clinically substantial finding. Patients going from a mean treated ABR of approximately 19.8 bleeds per year to 1.4 bleeds per year is a transformation in disease burden. The most devastating consequence of hemophilia with inhibitors has always been the inability to prevent spontaneous joint bleeds because on-demand therapy, by definition, does not begin until bleeding has already started. Each prevented bleed under prophylaxis is a joint or muscle or organ that did not bleed.

This comparison is against on-demand therapy because patients in the inhibitor cohort had not previously been on prophylaxis. An interpretive note: comparing against on-demand is a favorable comparison for the active treatment; a head-to-head comparison against existing prophylactic bypassing agent regimens would be more demanding. Nonetheless, the magnitude of the reduction is substantial and clinically meaningful.

BASIS KIDS trial (NCT05611801): the pediatric data

BASIS KIDS (NCT05611801) was a Phase 3, global, open-label trial evaluating the safety and efficacy of marstacimab in children aged 1 to 17 years with hemophilia A or B, with or without inhibitors. Interim results from this trial supported the FDA’s expanded approval for the 6-to-11-year age group.

Population	Mean ABR with marstacimab	Comparison (historical model-based)
Ages 6 to 17, all patients (overall BASIS KIDS)	1.8	3.6 (prior routine prophylaxis)
Ages 6 to under 18 with inhibitors (n=14)	1.4 (99% CI 0.5 to 4.5)	18.9 (99% CI 14.2 to 25.2)
Ages 6 to 11 cohort (n=7)	1.3 (99% CI 0.5 to 3.4)	—

Source: Clinical Advisor. CheckRare. BASIS KIDS NCT05611801.

The pediatric inhibitor subgroup data is particularly notable: children with hemophilia and inhibitors achieved a mean ABR of 1.4 with marstacimab prophylaxis compared to a historical model-based mean of 18.9 with on-demand bypassing therapy. For the youngest cohort (ages 6 to 11), the mean ABR of 1.3 indicates that the same degree of bleeding rate reduction is achievable in younger children.

The comparison in BASIS KIDS against historical model-based rates (rather than a randomized parallel arm) is appropriate for a pediatric rare disease trial, where randomizing young children to a control arm receiving inferior therapy would be ethically difficult and practically challenging. The historical modeling approach uses well-characterized natural history data from the hemophilia population to provide a reference benchmark.

What Makes This Approval Particularly Significant

The hemophilia B inhibitor gap

The most significant first-in-class designation from this expansion is that Hympavzi is now the first subcutaneous non-factor therapy available for children aged 6 to 11 years with hemophilia B. This deserves specific explanation.

Emicizumab (Hemlibra), the landmark non-factor therapy approved for hemophilia A with inhibitors in 2017, works by bridging activated factor IXa and factor X, mimicking the cofactor function of FVIII. This mechanism is specific to hemophilia A: it does not provide any benefit in hemophilia B because factor IXa is not the relevant enzyme that needs a cofactor. Patients with hemophilia B and inhibitors have therefore had no approved subcutaneous prophylactic non-factor therapy option. For them, marstacimab’s TFPI inhibition mechanism, which is indifferent to whether the underlying deficiency is in FVIII or FIX, represents the first approval in this category.

Once-weekly subcutaneous administration without routine laboratory monitoring

Hympavzi is administered once weekly by subcutaneous injection. The therapy does not require routine treatment-related laboratory monitoring, which distinguishes it from many hemophilia treatments that require regular factor level measurement or trough level testing to guide dosing. For families managing pediatric hemophilia, reducing the blood draw burden alongside simplifying the injection schedule to once weekly is a meaningful quality-of-life improvement.

Patients aged 12 years and older may self-inject after proper training. For children aged 6 to 11, caregiver administration is expected.

Safety: What the Prescribing Information Covers

The prescribing information for Hympavzi includes several important warnings:

Thromboembolic events: Two thromboembolic events occurred among 259 patients in the open-label extension study. Because marstacimab shifts the coagulation balance toward clot formation by removing the TFPI brake on the extrinsic pathway, the theoretical risk of thrombosis is inherent to its mechanism of action. Monitor patients for signs and symptoms of thromboembolic events. The absolute rate was low (2 of 259 patients in the extension), but the mechanism-based concern means clinical vigilance is appropriate.

Laboratory changes: Increases in fibrin D-dimer and prothrombin fragment 1.2 have been observed with marstacimab. These are laboratory markers of coagulation activation and fibrin turnover. They are consistent with the drug’s mechanism (enhanced coagulation pathway activity) but require awareness in clinical monitoring. Do not interpret elevated D-dimer as diagnostic for thrombosis without clinical correlation in patients receiving marstacimab.

Hypersensitivity reactions: As with all monoclonal antibodies, hypersensitivity reactions including anaphylaxis may occur. Patients should be informed of the symptoms and instructed to seek immediate medical attention if they occur.

Embryo-fetal toxicity: Based on the mechanism of action (promoting coagulation), there is a potential for fetal harm. Females of reproductive potential should use effective contraception during treatment.

Common adverse reactions (2% or greater): Injection site reactions, headache, pyrexia, arthralgia, diarrhea, pruritus, and rash.

What This Means for Patients and Families

For patients with hemophilia A or B who have inhibitors

This is the population for whom this expansion matters most urgently. Inhibitor-positive patients, particularly those with hemophilia B inhibitors, have had no approved subcutaneous non-factor prophylactic therapy before this date. The BASIS inhibitor cohort’s 93% reduction in treated ABR compared to on-demand bypassing therapy represents a shift from a reactive management strategy to an active preventive one, with the bleed rate reduction that entails.

If you or a family member has hemophilia with inhibitors and has been managed with on-demand bypassing agents, a conversation with your hematologist about whether Hympavzi is an appropriate prophylactic option is warranted.

For families of children aged 6 to 11

For young children with hemophilia, IV access for factor infusions has historically been the most practically difficult aspect of management, often requiring port placement and the risks that entails. A once-weekly subcutaneous injection administered by a caregiver at home, without routine blood draws for monitoring, represents a materially simpler treatment paradigm for this age group. The BASIS KIDS data showing a mean ABR of 1.3 in the 6-to-11 cohort supports the clinical adequacy of this approach.

For children with hemophilia B specifically, this is the first approved subcutaneous non-factor prophylactic therapy in this age group, filling a gap that emicizumab’s mechanism could not address.

For clinicians managing hemophilia

The complete current Hympavzi indication covers hemophilia A and B, with or without inhibitors, in patients aged 6 years and older. This is a single once-weekly subcutaneous platform applicable across the majority of the hemophilia population. For patients who are appropriate candidates, the elimination of routine treatment-related laboratory monitoring removes a significant ongoing management burden.

The thromboembolic warning and the D-dimer/prothrombin fragment 1.2 elevations associated with marstacimab require clinical awareness, particularly in patients who may develop thrombotic risk factors over time (surgery, immobilization, pregnancy). Risk-benefit discussions individualized to each patient’s circumstances remain the appropriate framework.

For related HED coverage on other rare hematologic disease approvals in 2026, see our post on KRESLADI, the first gene therapy approved for severe leukocyte adhesion deficiency type I and our post on Decnupaz (pivekimab sunirine) approved for blastic plasmacytoid dendritic cell neoplasm.

Sources

Pfizer FDA approval press release: U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need. Pfizer. June 8, 2026.

Drugs.com approval news: U.S. FDA Approves Pfizer’s Hympavzi for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need. drugs.com. June 8, 2026.

BioPharm International clinical coverage: FDA Expands Pfizer’s Hympavzi Approval to Pediatric Hemophilia Patients and Those with Inhibitors. biopharminternational.com. June 2026.

Hematology Advisor (BASIS inhibitor data): Hympavzi Gains Expanded FDA Approval for Hemophilia A and B. hematologyadvisor.com. June 2026.

Clinical Advisor detailed summary: Hympavzi Gains Expanded FDA Approval for Hemophilia A and B. clinicaladvisor.com. June 2026.

Conexiant clinical summary: FDA Expands Marstacimab Indication in Hemophilia A and B. conexiant.com. June 2026.

CheckRare clinical coverage: FDA Expands Approval of Hympavzi (Marstacimab) for Patients With Hemophilia. checkrare.com. June 2026.

BASIS trial registration: NCT03938792. ClinicalTrials.gov.

BASIS KIDS trial registration: NCT05611801. ClinicalTrials.gov.

Priority Review grant (sBLA): FDA Grants Priority Review for HYMPAVZI sBLA. Pfizer. 2026.

Hympavzi original approval (October 2024): Hympavzi FDA Approval History. drugs.com.

Hympavzi prescribing information: HYMPAVZI (marstacimab-hncq) Prescribing Information. Pfizer. 2026.

TFPI biology and marstacimab mechanism: Tissue Factor Pathway Inhibitor. PMC6126283.

Coagulation cascade: Coagulation Studies. StatPearls. NCBI.

Hemophilia A overview: Hemophilia A. StatPearls. NCBI.

Hemophilia B overview: Hemophilia B. StatPearls. NCBI.

Hemophilia inhibitors: Factor VIII Inhibitors in Hemophilia A. PMC7155173.

CDC hemophilia overview: Hemophilia. CDC.

Patient resources: National Hemophilia Foundation | World Federation of Hemophilia | Pfizer Hympavzi patient support

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Hemophilia management is complex and requires individualized assessment by a hematologist experienced in bleeding disorders. Decisions about switching to or initiating Hympavzi should be made in consultation with a treating hematologist who can assess the patient’s inhibitor status, bleeding history, current prophylaxis regimen, and individual risk-benefit profile.

June 23, 2026

The Only Oral Carbapenem in the World Just Got FDA Approved. Here Is What Utebzi Is and Why It Changes How Drug-Resistant Urinary Tract Infections Can Be Treated.

The essentials: On June 17, 2026, the FDA approved Utebzi (tebipenem pivoxil, GSK/Spero Therapeutics) for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible microorganisms in adult patients who have limited or no alternative oral treatment options. This is the first and only oral carbapenem antibiotic approved anywhere in the United States. Previously, every carbapenem available to U.S. clinicians required intravenous administration, meaning that patients with drug-resistant cUTIs requiring carbapenem-level coverage had no oral option and needed hospitalization, a peripherally inserted central catheter (PICC) line, or infusion center visits. Approved organisms: Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae species complex, Klebsiella oxytoca, and Enterococcus faecalis. The clinical basis: Phase 3 PIVOT-PO trial (NCT06059846), 1,690 hospitalized adults with cUTI or acute pyelonephritis, double-blind, randomized 1:1 oral tebipenem pivoxil versus intravenous imipenem-cilastatin. Trial stopped early for efficacy at interim analysis (May 2025). Primary endpoint: overall response (composite of clinical cure plus microbiological eradication) at test-of-cure visit. Result: 58.5% (261/446) with tebipenem pivoxil versus 60.2% (291/483) with IV imipenem-cilastatin (adjusted difference −1.3%; 95% CI −7.5% to 4.8%), meeting non-inferiority. ESBL-producing Enterobacterales subgroup: composite response 52.2% versus 56.8% with IV imipenem-cilastatin. Regulatory designations: Qualified Infectious Disease Product (QIDP), Fast Track. Regulatory history: GSK resubmitted the NDA in December 2025 after an earlier Complete Response Letter; PIVOT-PO data supported the resubmission. Dosing: 600 mg (two 300 mg tablets) orally every 6 hours for 7 to 10 days, with or without food. Important dosing limits: dose adjustment required for eGFR 15 to below 60 mL/min; use not recommended in patients with eGFR above 150 mL/min due to predicted reduced tebipenem exposure.

For the past several decades, carbapenems have represented the antibiotic class of last resort in infectious disease medicine. When bacteria have developed resistance to penicillins, cephalosporins, and fluoroquinolones, carbapenems are frequently the agents that still work. They are critically important, routinely used in hospitalized patients with serious infections, and until June 17, 2026, every single carbapenem available in the United States required intravenous administration.

That meant something specific and consequential for patients with complicated urinary tract infections caused by multidrug-resistant organisms: no matter how well they felt, no matter how stable their condition, they needed a hospital bed, an IV line, or an outpatient infusion arrangement to receive the only effective treatment available to them. The United States has more than 3 million cUTI cases treated annually, and a substantial proportion involve organisms resistant to standard oral agents. For those patients, the arrival of an oral carbapenem is not a minor convenience. It is a clinically meaningful expansion of outpatient treatment options.

Utebzi (tebipenem pivoxil, GSK/Spero Therapeutics) was approved June 17, 2026, as the first oral carbapenem in the U.S. for cUTI in patients with limited or no alternative oral treatment options. The Phase 3 PIVOT-PO trial compared oral tebipenem pivoxil head-to-head against intravenous imipenem-cilastatin, the gold-standard IV carbapenem, and stopped early for efficacy. This post covers what complicated UTIs are, how carbapenems work and why an oral formulation required a novel prodrug approach, what PIVOT-PO data showed, what the regulatory backstory was, and what this approval means for patients and clinicians managing resistant gram-negative infections.

What Complicated Urinary Tract Infections Are and Why Drug Resistance Makes Them Harder to Treat

Complicated urinary tract infections are defined by the presence of structural or functional abnormalities in the urinary tract, or by host factors that impair the normal defenses against infection. They include pyelonephritis (kidney infection), infections associated with urinary catheters or stents, infections in patients with obstructive uropathy or neurogenic bladder, and infections in immunocompromised hosts. Unlike uncomplicated UTIs, which can typically be treated with short courses of oral antibiotics in otherwise healthy outpatient women, cUTIs require more intensive management, longer treatment courses, and often hospitalization.

The most common organisms causing cUTI are gram-negative Enterobacterales, principally E. coli and Klebsiella pneumoniae. These same organisms are at the center of one of the most serious antimicrobial resistance crises in contemporary medicine.

Extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales have developed enzymes that inactivate most penicillins and cephalosporins. They are resistant to trimethoprim-sulfamethoxazole in many cases and frequently resistant to fluoroquinolones. In the PIVOT-PO trial, approximately 35 to 39% of Enterobacterales isolates in both arms were ESBL producers, reflecting the real-world prevalence of this resistance pattern in hospitalized patients with cUTI. For patients whose infection is caused by an ESBL-producing organism, the standard outpatient oral antibiotics (ciprofloxacin, trimethoprim-sulfamethoxazole, nitrofurantoin) are often not options. Until now, that left no oral carbapenem alternative.

Carbapenem-resistant Enterobacterales (CRE), which are resistant even to standard IV carbapenems, are designated by the CDC as an urgent threat. Utebzi’s approved indication specifically covers susceptible organisms, meaning it is not intended for CRE infections where even IV carbapenems would fail. Its value is in the ESBL-producing and fluoroquinolone-resistant Enterobacterales space, where it provides a first oral carbapenem-class option.

The Science: How Tebipenem Works and Why an Oral Carbapenem Required a Prodrug Approach

Carbapenem mechanism of action

Carbapenems belong to the beta-lactam antibiotic class, which also includes penicillins and cephalosporins. All beta-lactams share a core mechanism: they bind to penicillin-binding proteins (PBPs) in bacterial cell walls, inhibiting the transpeptidation reaction that cross-links the peptidoglycan strands that give the cell wall its structural integrity. Without proper peptidoglycan cross-linking, the bacterial cell wall cannot withstand osmotic pressure, the cell lyses, and the bacterium dies.

What distinguishes carbapenems from other beta-lactams is their stability against beta-lactamase enzymes. Most gram-negative bacteria that cause serious infections produce beta-lactamases, enzymes that hydrolyze the beta-lactam ring of penicillins and cephalosporins, rendering those antibiotics inactive. Carbapenems have a unique bicyclic structure that makes them resistant to the most common beta-lactamases, including ESBLs. This is why carbapenems remain active where penicillins and cephalosporins have failed, and it is the mechanistic basis for their clinical importance as last-resort antibiotics.

Tebipenem specifically exhibits broad-spectrum activity against gram-negative Enterobacterales by binding with high affinity to PBP2 and PBP3, the penicillin-binding proteins primarily responsible for cell wall elongation and septation during bacterial cell division. Its activity is bactericidal and is optimized against the organisms most commonly implicated in cUTI.

Why carbapenems were IV-only until now: the oral bioavailability problem

The reason all previously approved carbapenems required intravenous administration is oral bioavailability. Carbapenem molecules are hydrophilic (water-loving) and polar, characteristics that make them excellent at distributing through aqueous tissues but also make it difficult for them to cross the lipid-rich intestinal epithelium and reach the bloodstream when swallowed. Most carbapenem molecules taken orally would simply pass through the gut without being absorbed.

Tebipenem pivoxil solves this through a prodrug strategy. “Tebipenem pivoxil” is the prodrug form: the active carbapenem molecule tebipenem is chemically modified with a pivoxil ester group that makes the compound more lipophilic (fat-soluble) and significantly improves oral absorption across the intestinal epithelium. After absorption, intestinal esterases rapidly cleave the pivoxil ester, releasing the active tebipenem molecule into systemic circulation. The active tebipenem then distributes into renal tissue and urine, where it achieves the concentrations needed to kill the causative organisms.

This prodrug approach is the same chemical strategy used in several other orally administered antibiotics, most notably the cephalosporin prodrugs cefuroxime axetil and cefpodoxime proxetil, where ester modification similarly improves gut absorption of molecules that would otherwise be poorly bioavailable. For carbapenems, engineering this chemistry without compromising the stability of the beta-lactam ring and without producing a molecule with unfavorable pharmacokinetics was a substantial pharmaceutical development challenge.

Why the pivoxil ester matters beyond oral bioavailability The pivoxil moiety that enables tebipenem’s oral absorption is the same group used in pivampicillin and pivmecillinam, and its hydrolysis releases pivalic acid as a byproduct. Pivalate can conjugate with carnitine and impair carnitine metabolism, particularly with long-term or repeated use. This class effect of pivoxil-containing antibiotics is relevant for patients receiving concurrent carnitine supplementation and for patients with carnitine metabolism disorders. The short course of Utebzi (7 to 10 days) limits this concern in most clinical settings, but it is worth noting as a mechanistic consideration of the prodrug chemistry.

The PIVOT-PO Trial: Design and Full Results

Design

PIVOT-PO (NCT06059846) was a global, randomized, double-blind, non-inferiority Phase 3 trial enrolling 1,690 hospitalized adult patients with cUTI or acute pyelonephritis. The double-blind design was maintained using a double-dummy approach: patients in each arm received both an active oral tablet and a matching IV placebo, or an active IV infusion and a matching oral placebo tablet, maintaining blinding while comparing true oral versus true IV administration.

Randomization: 1:1 to:

Tebipenem pivoxil 600 mg orally (two 300 mg tablets) every 6 hours for 7 to 10 days
Imipenem-cilastatin 500 mg intravenously every 6 hours for 7 to 10 days (standard of care comparator)

Imipenem-cilastatin (Primaxin) was chosen as the comparator because it is a well-established IV carbapenem with robust efficacy data in cUTI, appropriate as the active reference standard for a non-inferiority comparison against an oral carbapenem.

Primary endpoint: Overall response at the test-of-cure (TOC) visit, defined as a composite of clinical cure plus microbiological eradication in the intent-to-treat (ITT) efficacy cohort.

The trial was stopped early for efficacy at a planned interim analysis in May 2025, indicating that the pre-specified criteria for early stopping based on demonstrated non-inferiority were met ahead of the planned full enrollment.

Primary endpoint results

Outcome	Tebipenem pivoxil (oral)	Imipenem-cilastatin (IV)	Comparison
Overall response (clinical cure plus microbiological eradication) at TOC	58.5% (261/446)	60.2% (291/483)	Adjusted difference −1.3% (95% CI −7.5% to 4.8%)
Non-inferiority demonstrated	Yes	Reference	Lower CI bound within pre-specified margin

Source: Spero Therapeutics/GSK press release. GlobeNewswire. June 17, 2026. PIVOT-PO NCT06059846. Presented at IDWeek 2025.

The adjusted difference of −1.3 percentage points, with a 95% confidence interval ranging from −7.5% to +4.8%, demonstrates that oral tebipenem pivoxil was non-inferior to intravenous imipenem-cilastatin in achieving the composite endpoint of clinical cure plus microbiological eradication. The upper bound of the confidence interval is positive (favoring oral tebipenem in the best-case scenario) and the lower bound remains within whatever non-inferiority margin was pre-specified. This is the evidentiary standard the FDA required to demonstrate that oral tebipenem delivers comparable efficacy to the IV comparator.

ESBL-producing pathogen subgroup

In the PIVOT-PO trial, 35.1% of Enterobacterales isolates in the tebipenem arm and 38.9% in the imipenem arm were ESBL producers, reflecting the real-world prevalence of ESBL-producing cUTI in hospitalized patients. Among patients infected with ESBL-producing organisms, the composite response rates at TOC were 52.2% with tebipenem pivoxil and 56.8% with IV imipenem-cilastatin. Comparable response rates were also observed among patients infected with fluoroquinolone-not-susceptible and trimethoprim-sulfamethoxazole-resistant Enterobacterales.

This subgroup data is clinically important because the ESBL-producing patient population represents precisely the group for whom no oral treatment was previously available. That composite response rates in this resistance-characterized subgroup were broadly consistent with the overall ITT population supports the use of tebipenem pivoxil specifically in these patients.

Safety in PIVOT-PO

The safety profile of tebipenem pivoxil was consistent with the carbapenem class. The most common adverse events were diarrhea and headache. Additional adverse events reported included mild to moderate nausea, abdominal pain, transaminase elevations, and Clostridioides difficile-associated diarrhea (CDAD), which is a class effect associated with broad-spectrum antibiotics. No new or unexpected safety signals were identified.

The Regulatory Backstory: A Prior CRL and the Path to Approval

The path to Utebzi’s June 2026 approval was not linear. GSK and Spero had submitted an earlier NDA for tebipenem pivoxil for cUTI, supported by a prior Phase 3 trial. That application received a Complete Response Letter from the FDA, which identified deficiencies that needed to be addressed before approval could be granted. The PIVOT-PO trial, which compared oral tebipenem directly against intravenous imipenem-cilastatin (a more demanding head-to-head non-inferiority design than the prior trial), was specifically designed and conducted to address the FDA’s concerns and generate the evidence package required for resubmission.

GSK filed the NDA resubmission in December 2025, supported by the PIVOT-PO data that had been presented at IDWeek 2025 weeks prior. The PDUFA date was set for June 18, 2026, and the FDA approved one day ahead of the deadline on June 17, 2026.

The tebipenem pivoxil program has received QIDP (Qualified Infectious Disease Product) designation and Fast Track designation from the FDA, both reflecting the agency’s recognition of the serious unmet need in drug-resistant cUTI.

Approved Organisms, Dosing, and Critical Prescribing Guidance

Approved organisms

Utebzi is approved for cUTI caused by the following susceptible organisms:

Escherichia coli
Klebsiella pneumoniae
Enterobacter cloacae species complex
Klebsiella oxytoca
Enterococcus faecalis

Culture and susceptibility testing are essential before prescribing. Utebzi is indicated for organisms confirmed or strongly suspected to be susceptible. It is not effective against CRE (carbapenem-resistant Enterobacterales), and empiric use without culture data should be guided by institutional stewardship protocols and local epidemiology.

Dosing

Parameter	Details
Standard dose	600 mg (two 300 mg tablets) orally every 6 hours
Duration	7 to 10 days
Administration	With or without food
Renal adjustment	Required for eGFR 15 to below 60 mL/min; consult full prescribing information for specific dose
eGFR above 150 mL/min	Use not recommended (predicted reduced tebipenem exposure may reduce efficacy; if necessary, monitor clinical response closely)
Not recommended	eGFR below 15 mL/min (end-stage renal disease without dialysis); data insufficient

The eGFR above 150 mL/min restriction is an unusual and clinically notable prescribing caution. Patients with hyperfiltration (augmented renal clearance), which can occur in younger patients, pregnant patients, and critically ill patients with preserved kidney function, may clear tebipenem faster than typical patients, potentially reducing urinary drug concentrations below the threshold needed for bactericidal activity. This pharmacokinetic consideration is specific to a renally-excreted antibiotic being used for a urinary tract indication and should be considered when prescribing in patients whose renal function is known to be substantially above normal.

Antibiotic stewardship

Consistent with antimicrobial stewardship principles, Utebzi should be used only to treat infections proven or strongly suspected to be caused by susceptible bacteria. The approved labeling specifically addresses this: use should follow culture and susceptibility data whenever possible, and empiric use should be reserved for patients with strong clinical suspicion of a resistant organism based on prior culture history, risk factors, or local epidemiology.

What This Approval Means in Clinical Practice

Before June 17, 2026, a hospitalized patient with pyelonephritis caused by an ESBL-producing E. coli, who was otherwise stable and could be managed as an outpatient, had essentially no oral option. Every carbapenem required IV access. Sending such a patient home required either arranging home IV infusion (expensive, logistically complex, and uncomfortable for the patient) or keeping them in the hospital longer than their clinical condition strictly required (expensive and exposing them to hospital-acquired infection risk).

As Dr. Debra L. Fromer, MD, of Hackensack Meridian Health, explained: the advent of an oral carbapenem reduces the strain on the healthcare system by enabling earlier discharge and allowing outpatient treatment of patients who previously required hospitalization or PICC line placement. A pill taken at home every 6 hours is not identical in convenience to a once-daily oral antibiotic, but compared to an IV infusion it is transformative for appropriate patients.

The key phrase in the approved indication is “limited or no alternative oral treatment options.” Utebzi is not positioned as a first-line or empiric therapy for all cUTIs. It is a targeted option for the resistance gap: patients with culture-confirmed or highly suspected resistant organisms where standard oral agents have failed or are expected to fail. The approved patient population is specific, the culture requirement is clinical standard, and the antibiotic stewardship framing is appropriately conservative.

For patients with cUTI or recurrent UTI who are managing resistant infections: Utebzi is a prescription medication that requires a clinician experienced in managing complicated UTIs. The starting point for access is a discussion with a urologist, urogynecologist, or infectious disease specialist who can review culture results and determine whether tebipenem pivoxil is appropriate for the specific organism and clinical situation.

For related HED coverage on other resistant-organism antibiotic approvals in 2026, see our post on Zaynich (cefepime-zidebactam), the first antibiotic combination in which the beta-lactamase inhibitor also independently targets PBP2, approved for drug-resistant cUTI just weeks earlier.

Sources

FDA approval / GSK press release: Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections. GSK. June 17, 2026.

Spero Therapeutics press release: Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections. Spero Therapeutics/GlobeNewswire. June 17, 2026.

Drugs.com approval news: FDA Approves Utebzi (tebipenem pivoxil) for Adults with Complicated Urinary Tract Infections. drugs.com. June 17, 2026.

Utebzi approval history: Utebzi FDA Approval History. drugs.com.

Urology Times clinical coverage (with Dr. Fromer quote): FDA approves tebipenem pivoxil for complicated urinary tract infections. urologytimes.com. June 2026.

AJMC detailed trial coverage: FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs. ajmc.com. June 2026.

Renal and Urology News clinical summary: Utebzi Approved as First Oral Carbapenem Antibiotic for cUTIs. renalandurologynews.com. June 2026.

Contagion Live detailed coverage: FDA Approves Tebipenem Pivoxil as First Oral Carbapenem For Complicated Urinary Tract Infections. contagionlive.com. June 2026.

Contemporary OB/GYN clinical coverage: FDA approves tebipenem pivoxil as first oral carbapenem antibiotic for complicated urinary tract infections. contemporaryobgyn.net. June 2026.

PIVOT-PO trial registration: NCT06059846. ClinicalTrials.gov.

Complicated UTI overview: Complicated Urinary Tract Infections. StatPearls. NCBI.

Beta-lactam antibiotics and PBPs: Beta-Lactam Antibiotics. StatPearls. NCBI.

ESBL and beta-lactamases: Beta-Lactamase Inhibitors. PMC7279573.

Enterobacterales infections: Gram-Negative Bacterial Infections. StatPearls. NCBI.

C. diff associated diarrhea: Clostridioides Difficile. StatPearls. NCBI.

CRE threat designation: Antibiotic Resistance Threats in the United States. CDC.

Antibiotic stewardship core elements: Core Elements of Antibiotic Stewardship. CDC.

QIDP and GAIN Act: GAIN Act FAQ. FDA.gov.

Fast Track designation: Fast Track. FDA.gov.

CRL overview: FDA Drug Review Process. FDA.gov.

Utebzi prescribing information: UTEBZI (tebipenem pivoxil) Prescribing Information. GSK. 2026.

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Utebzi is a prescription antibiotic indicated specifically for adult patients with complicated urinary tract infections caused by susceptible organisms who have limited or no alternative oral treatment options. Antibiotic selection should be guided by culture and susceptibility data and made in consultation with a qualified healthcare provider.

June 22, 2026

Every Gadolinium MRI Contrast Agent Exposes Patients to Gadolinium Deposition Risk. Ambelvist Just Became the First Approved in the U.S. That Does It With 60% Less Gadolinium. Here Is What the Science and the QUANTI Trial Data Show.

The essentials: On June 12, 2026, the FDA approved Ambelvist (gadoquatrane, Bayer) for use with MRI to detect and visualize lesions with abnormal vascularity in the central nervous system (brain, spine, and associated tissues) and the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system) in adult and pediatric patients, including term neonates. What makes it distinctive: gadoquatrane is a next-generation macrocyclic gadolinium-based contrast agent (mGBCA) with a novel tetrameric structure that achieves high image quality at substantially reduced gadolinium doses. With this approval, Ambelvist becomes the lowest-dose macrocyclic GBCA approved in the United States. Recommended dose: 0.01 mmol/kg actual body weight, which delivers 0.04 mmol Gd/kg body weight. This represents 60% less gadolinium than the standard macrocyclic GBCAs dosed at 0.1 mmol Gd/kg body weight, and 20% less gadolinium than gadopiclenol (Vueway), which delivers 0.05 mmol Gd/kg. The clinical basis: Phase 3 QUANTI program (three studies: QUANTI CNS, QUANTI OBR, and QUANTI Pediatric), 808 patients including 93 children, across 15 countries. QUANTI CNS and QUANTI OBR were randomized, double-blind, active-comparator crossover trials. Key results: gadoquatrane met the primary endpoint of non-inferiority to comparator mGBCAs (gadobutrol, gadoterate, gadoteridol) in visualization parameters and lesion detection using 60% less gadolinium. Post-contrast MRI with gadoquatrane was superior to unenhanced MRI alone. In descriptive analyses, visualization scores and lesion counts per blinded independent reader were comparable to comparator mGBCAs dosed at 0.1 mmol Gd/kg. No new safety signals. Boxed warnings: intrathecal administration risk; nephrogenic systemic fibrosis (NSF). Contraindicated in patients with a history of severe hypersensitivity reactions to gadoquatrane.

Every year, more than 40 million MRI examinations with contrast are performed in the United States. The contrast agents used in the majority of those scans are gadolinium-based, and they are among the most important diagnostic tools in modern medicine. They light up tumors, strokes, vascular malformations, inflammatory lesions, and infections in brain tissue, spinal cord, joints, liver, and virtually every region of the body, making otherwise invisible pathology visible and informing clinical decisions that affect surgical planning, treatment selection, and disease monitoring.

Gadolinium-based contrast agents are also, as the FDA has required to be prominently stated in prescribing information since 2017, associated with gadolinium retention: gadolinium is retained for months or years in several organs, including the brain, even in patients with normal kidney function. The clinical significance of that retention in patients without renal impairment has not been definitively established, but the concern is real enough that the FDA, the American College of Radiology, and radiological societies worldwide have consistently encouraged the use of the lowest gadolinium dose that provides the necessary diagnostic information.

Ambelvist (gadoquatrane, Bayer), approved June 12, 2026, is the first MRI contrast agent to reach that lowest-dose standard among the macrocyclic class in the United States. Its novel tetrameric molecular structure achieves high image quality at 60% less gadolinium than standard macrocyclic agents, and clinical trial data demonstrated equivalent diagnostic performance to comparator agents dosed at 2.5 times the gadolinium content.

This post covers what gadolinium-based contrast agents do and why gadolinium retention matters, how gadoquatrane’s tetrameric structure produces high-quality imaging at lower gadolinium doses, what the QUANTI Phase 3 program showed, what the safety profile means in practice, and where Ambelvist fits in the current MRI contrast landscape.

What Gadolinium-Based Contrast Agents Do and Why Gadolinium Retention Is a Clinical Concern

How contrast-enhanced MRI works

MRI produces images by detecting the radiofrequency signals emitted by hydrogen nuclei (protons) in water and fat molecules as they return to equilibrium after being excited by a magnetic field and radiofrequency pulses. The speed of that return, characterized by relaxation times called T1 and T2, varies across different tissue types and creates the intrinsic contrast that makes MRI valuable even without exogenous contrast agents.

Gadolinium-based contrast agents (GBCAs) enhance this further. Gadolinium (Gd) is a paramagnetic metal ion that shortens the T1 relaxation time of nearby water protons, causing tissues that take up the contrast agent to appear brighter on T1-weighted MRI sequences. The enhancement is selective: gadolinium distributes into tissues with abnormal vascularity or disrupted blood-brain barrier, which is precisely the characteristic of tumors, inflammatory lesions, abscesses, demyelinating plaques, and vascular malformations. Normal brain parenchyma is protected by an intact blood-brain barrier and does not enhance.

This is why contrast-enhanced MRI is so diagnostically powerful: the gadolinium signal provides a spatial map of pathological vascular abnormality superimposed on the exquisite anatomical detail of the unenhanced MRI sequence.

Why gadolinium retention matters

Since the first GBCA was introduced in 1988, these agents have generally been considered safe for patients with normal renal function. That perception began to evolve in 2006 when nephrogenic systemic fibrosis (NSF), a serious and potentially fatal fibrosing condition, was firmly linked to GBCA administration in patients with severely impaired renal function. NSF is now largely eliminated through screening practices and the preferential use of more stable macrocyclic GBCAs over less stable linear agents.

A separate and distinct concern emerged around 2014 when researchers identified gadolinium deposition in brain tissue in patients with normal renal function who had received multiple GBCA-enhanced MRI scans. Signal changes in the dentate nucleus and globus pallidus on T1-weighted MRI were found to correlate with cumulative gadolinium exposure. This deposition occurs with all GBCAs but is substantially greater with linear agents than with macrocyclic agents. At equivalent doses, macrocyclic GBCAs show the lowest and most similar retention profiles among all GBCA classes, because their cyclic molecular cage structure holds gadolinium more tightly and releases it less readily than the open-chain structure of linear agents.

The clinical consequences of gadolinium deposition in the brain of patients with normal renal function have not been definitively established, but the regulatory response has been clear: minimize gadolinium dose while preserving diagnostic quality. The ACR Manual on Contrast Media recommends using the lowest gadolinium dose necessary to provide adequate diagnostic information.

The gadolinium problem in plain terms Every dose of gadolinium-based contrast agent leaves some gadolinium behind in the body, including in the brain. The macrocyclic cage structure of agents like gadobutrol, gadoterate, and gadoteridol holds gadolinium more tightly, reducing this retention compared to linear agents. But even macrocyclic agents deposit some gadolinium at standard doses. The logical next step, which gadoquatrane’s development pursued, was to engineer a macrocyclic agent that achieves equivalent image quality using substantially less gadolinium. Less gadolinium administered means less gadolinium available for retention, regardless of the agent’s stability profile. The tetrameric structure of gadoquatrane was designed specifically to achieve this: four times the relaxivity enhancement per gadolinium atom, enabling a 60% dose reduction while maintaining comparable imaging performance.

How Gadoquatrane Works: The Tetrameric Structure and High Relaxivity

The key to understanding why gadoquatrane can deliver equivalent diagnostic performance at 60% less gadolinium than standard macrocyclic agents lies in its molecular architecture.

Conventional GBCAs, including the macrocyclic agents gadobutrol (Gadavist), gadoterate (Dotarem), and gadoteridol (ProHance), are monomeric molecules: one gadolinium ion chelated by one organic ligand. The magnetic effect of a single gadolinium ion on surrounding water protons, measured as relaxivity, is determined by how efficiently the paramagnetic gadolinium shortens the T1 relaxation time of nearby water molecules in a given concentration and magnetic field strength.

Gadoquatrane has a tetrameric structure: four gadolinium-chelate units are covalently linked in a single molecular framework. This arrangement substantially increases the molecule’s relaxivity. Each gadoquatrane molecule carries four gadolinium ions, and the molecular size and tumbling rate created by this tetrameric architecture are optimized for more efficient interaction with surrounding water protons. The result is that each molecule of gadoquatrane produces greater T1 enhancement per unit of gadolinium than conventional monomeric GBCAs.

This higher relaxivity per gadolinium atom is what allows gadoquatrane to produce comparable image quality at a substantially reduced gadolinium dose. The principle is analogous to a more efficient engine producing the same power output from less fuel: the tetrameric architecture extracts more MRI signal enhancement per gadolinium ion administered.

Gadoquatrane retains the macrocyclic cage structure of the established macrocyclic agents, with each of the four gadolinium ions held within a macrocyclic ligand unit. This means gadoquatrane’s thermodynamic and kinetic stability properties, the characteristics that minimize gadolinium release and retention, are consistent with the macrocyclic class. The same structural feature that produces low gadolinium retention in gadobutrol and gadoterate is present in each of gadoquatrane’s four chelate units.

The QUANTI Clinical Program: Three Trials, 808 Patients, 15 Countries

Gadoquatrane’s FDA approval is based on the QUANTI clinical development program, which consisted of three trials designed to evaluate efficacy and safety across the full body scope of the approved indication.

Program design

QUANTI CNS (NCT05915702): A multinational, randomized, prospective, double-blind, active-comparator crossover Phase 3 trial in adult patients with known or suspected CNS pathologies (brain, spine, associated tissues) undergoing contrast-enhanced MRI. Patients received gadoquatrane at 0.01 mmol/kg body weight (delivering 0.04 mmol Gd/kg) in one crossover period and one of three comparator macrocyclic GBCAs (gadobutrol, gadoterate, or gadoteridol) at 0.1 mmol Gd/kg in the other period. The crossover design meant each patient served as their own control, strengthening the comparison.

QUANTI OBR (NCT05915728): The same design applied to non-CNS body regions (head and neck, thorax, abdomen, pelvis, musculoskeletal system) in adult patients.

QUANTI Pediatric: A separate study evaluating the pharmacokinetics and safety of gadoquatrane in pediatric patients from birth to below 18 years of age across all body regions. This study supported the pediatric indication, including term neonates.

In total, 808 patients including 93 children participated across 15 countries. All three trials investigated gadoquatrane at the same 0.04 mmol Gd/kg dose, which represents a 60% reduction compared to the 0.1 mmol Gd/kg dose used by standard macrocyclic GBCAs.

Primary and secondary endpoint results

The primary endpoints of QUANTI CNS and QUANTI OBR assessed visualization parameters (border delineation, internal morphology, and contrast enhancement) as rated by blinded independent readers comparing gadoquatrane-enhanced MRI to comparator-enhanced MRI.

Outcome	Result
Primary endpoint: non-inferiority of gadoquatrane versus comparator mGBCAs in visualization parameters (CNS and body)	Met in both QUANTI CNS and QUANTI OBR
Key secondary endpoint: superiority of post-contrast MRI with gadoquatrane versus unenhanced MRI alone	Met: increased lesion visualization confirmed
Descriptive comparison: visualization scores and lesion counts per blinded independent reader	Gadoquatrane comparable to comparator mGBCAs dosed at 0.1 mmol Gd/kg
Secondary endpoints: sensitivity and specificity for lesion detection	Non-inferiority to comparator mGBCAs demonstrated
Pediatric pharmacokinetics	Pharmacokinetic behavior in children consistent with adult data; efficacy from adult data applicable to pediatric population
Overall safety profile (all ages)	Consistent with prior gadoquatrane data and macrocyclic GBCAs class; no new safety signals

Source: Bayer press release, June 15, 2026. QUANTI CNS NCT05915702. QUANTI OBR NCT05915728. QUANTI CNS ECR 2025 presentation.

The crossover design is worth emphasizing for its evidentiary strength. Because each patient received both gadoquatrane and a comparator macrocyclic agent in separate MRI sessions (with blinded independent reading of all images), the comparison is unusually rigorous: the same patient’s pathology is being imaged with different agents, eliminating the patient-level variability that can confound parallel-group designs in imaging trials.

The pediatric finding that pharmacokinetic behavior of gadoquatrane in children is similar to that in adults allowed the FDA to establish pediatric efficacy through pharmacokinetic/pharmacodynamic bridging, a standard approach for contrast agents where it is not ethical or practical to run fully powered efficacy trials in all pediatric subpopulations.

Where Ambelvist Fits in the GBCA Landscape

The U.S. MRI contrast agent market in 2026 includes multiple approved GBCAs across the linear and macrocyclic classes, with recent additions specifically at lower doses:

Agent	Class	Dose	Gd content	FDA approval
Gadobutrol (Gadavist, Bayer)	Macrocyclic	0.1 mmol/kg	0.1 mmol Gd/kg	2011
Gadoterate meglumine (Dotarem, Guerbet)	Macrocyclic	0.1 mmol/kg	0.1 mmol Gd/kg	2013
Gadoteridol (ProHance, Bracco)	Macrocyclic	0.1 mmol/kg	0.1 mmol Gd/kg	1992
Gadapentetate dimeglumine (Magnevist)	Linear	0.1 mmol/kg	0.1 mmol Gd/kg	1988
Gadopiclenol (Vueway, Bracco)	Macrocyclic	0.05 mmol/kg	0.05 mmol Gd/kg	2022
Gadoquatrane (Ambelvist, Bayer)	Macrocyclic	0.01 mmol/kg	0.04 mmol Gd/kg	June 2026

Gadopiclenol (Vueway), approved in 2022, was the first high-relaxivity macrocyclic GBCA to achieve reduced-dose approval in the U.S., delivering 0.05 mmol Gd/kg versus the standard 0.1 mmol Gd/kg used by earlier macrocyclic agents. Gadoquatrane extends this further, delivering 0.04 mmol Gd/kg, 20% less gadolinium than gadopiclenol and 60% less than standard macrocyclic agents.

The competitive distinction between Ambelvist and Vueway will be evaluated by radiologists based on imaging performance data, institutional formulary decisions, practical acquisition considerations, and any head-to-head data that emerges in the coming years. Neither drug has been compared directly to the other in a randomized trial; both have been compared to the same standard-dose macrocyclic agents.

For radiology departments and institutions with established ACR or local protocols encouraging minimum gadolinium dose, Ambelvist provides an additional option in the macrocyclic class with the lowest Gd dose approved in the U.S. For patients who undergo contrast-enhanced MRI repeatedly over years of disease monitoring, such as patients with multiple sclerosis, brain metastases, or chronic inflammatory conditions requiring serial imaging, the cumulative gadolinium dose reduction across many scans is the practical benefit.

Safety: What the Prescribing Information Covers

Ambelvist’s safety profile is consistent with the macrocyclic GBCA class, with the same class-level concerns that apply to all gadolinium-based contrast agents.

Boxed warnings:

Intrathecal administration: Gadolinium-based contrast agents are not approved for intrathecal injection, and accidental intrathecal administration has resulted in serious adverse reactions including seizures, cardiorespiratory arrest, and death. This is a class-wide warning for all GBCAs. Ambelvist must be administered intravenously only.

Nephrogenic systemic fibrosis (NSF): Ambelvist, like all approved GBCAs, carries a boxed warning for NSF, a serious, debilitating, and potentially fatal fibrosing disorder of the skin and other tissues that has been observed in patients with impaired elimination of GBCAs, primarily those with chronic, severe kidney disease. As a macrocyclic agent, gadoquatrane is classified in the lower-NSF-risk group (ACR Group II/III), but the class warning remains on the label. Screen patients for acute kidney injury or other conditions that may reduce renal clearance before administering any GBCA.

Contraindication:

Ambelvist is contraindicated in patients with a history of severe hypersensitivity reactions to gadoquatrane.

Warnings and precautions:

Hypersensitivity reactions: As with all GBCAs, acute allergic-type reactions ranging from mild (urticaria, pruritus) to severe (anaphylaxis, bronchospasm, cardiovascular collapse) can occur. These are uncommon but can be immediate or delayed. Assess patient allergy history before administration. Maintain resuscitation capability during administration.

Gadolinium retention: As described above, gadolinium is retained for months or years in the brain and other organs following GBCA administration. Linear GBCAs cause greater retention than macrocyclic GBCAs. At equivalent doses, retention is lowest and most similar among macrocyclic agents. The lower administered dose of gadoquatrane means less total gadolinium is available for potential retention compared to standard-dose macrocyclic agents. The clinical consequences of gadolinium retention in the brain of patients with normal renal function have not been established.

Acute kidney injury: GBCAs may increase the risk of acute kidney injury. Screen patients for reduced renal function before administration. In patients with chronic kidney disease, use the lowest dose necessary and avoid repeat dosing unless the diagnostic benefit clearly outweighs the risk.

Interference with lesion visualization: Certain lesion types may not enhance reliably with Ambelvist. Some lesions visible with other GBCA types may not be detectable with gadoquatrane at the approved dose. Blinded reading of MRI examinations should consider the dose and agent used.

Dosing:

Administered as an intravenous injection of 0.01 mmol/kg actual body weight (which delivers 0.04 mmol Gd/kg body weight). Ambelvist is supplied as a 0.1 mmol/mL solution in single-dose vials, single-dose prefilled syringes, imaging bulk packages, and pharmacy bulk packages.

What This Means for Patients Who Receive Contrast-Enhanced MRI

Most patients receiving contrast-enhanced MRI will not choose their contrast agent: the radiology department or ordering institution determines which agent to use based on formulary, protocol, and clinical judgment. What patients can do is understand why the conversation about gadolinium matters and ask informed questions about contrast use.

For patients who undergo contrast-enhanced MRI repeatedly, such as those with multiple sclerosis being monitored for disease activity, patients with brain metastases under treatment, and patients with chronic inflammatory conditions like Crohn’s disease requiring serial cross-sectional imaging, cumulative gadolinium exposure from repeated scans is the most relevant concern. Lower-dose agents at equivalent diagnostic performance represent a genuine clinical benefit for these populations over a lifetime of imaging.

For patients with chronic kidney disease, the NSF boxed warning is the priority concern. Any patient with significantly impaired renal function should discuss with their ordering physician whether contrast enhancement is necessary for their specific clinical question, and if so, which agent and dose minimize the NSF risk while providing the needed diagnostic information.

For patients undergoing a single diagnostic MRI as part of an acute clinical evaluation, such as evaluation for stroke, initial workup of a brain mass, or staging of a newly diagnosed cancer, the cumulative dose concern is less relevant. The diagnostic adequacy of the scan is the priority.

For clinicians and radiologists: the ACR Manual on Contrast Media, updated in 2026, provides the current framework for GBCA selection and dose minimization. Ambelvist’s addition to the macrocyclic formulary options gives departments a lowest-dose macrocyclic choice for protocols where gadolinium minimization is a priority alongside diagnostic adequacy.

For related HED coverage on neurological conditions commonly evaluated with contrast-enhanced MRI, see our post on Ocrevus (ocrelizumab) approved for pediatric relapsing-remitting MS and our post on the FDA’s acceleration of psychedelic drug programs for treatment-resistant depression and PTSD, the latter of which covers conditions where neuroimaging plays a growing role in clinical research.

Sources

Bayer FDA approval press release: Bayer’s AMBELVIST (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI. BusinessWire. June 15, 2026.

Bayer Ambelvist page: AMBELVIST (gadoquatrane) FDA approval. bayer.com.

BioSpace approval coverage: Bayer’s Ambelvist Receives FDA Approval for Contrast-Enhanced MRI. biospace.com. June 15, 2026.

CancerNetwork clinical summary: FDA Approves Gadoquatrane to Detect CNS and Non-CNS Body Region Lesions. cancernetwork.com. June 2026.

Renal and Urology News coverage: FDA Approves Lower-Dose Gadolinium Contrast Agent Ambelvist. renalandurologynews.com. June 2026.

Neurology Advisor coverage: FDA Approves Lower-Dose Gadolinium Contrast Agent Ambelvist. neurologyadvisor.com. June 2026.

Axis Imaging News coverage: FDA Approves Bayer’s Low-Dose MRI Contrast Agent. axisimagingnews.com. June 2026.

QUANTI CNS Phase 3 topline results (Bayer/ECR 2025): Positive results from Phase III study for Bayer’s investigational contrast agent gadoquatrane. Bayer/BusinessWire. February 26, 2025.

QUANTI program pivotal topline results (all studies): Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints. BusinessWire. January 10, 2025.

QUANTI Pediatric (RSNA 2025): RSNA25: Pediatric Study for Bayer’s Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints. biospace.com. December 2025.

QUANTI CNS trial registration: NCT05915702. ClinicalTrials.gov.

QUANTI OBR trial registration: NCT05915728. ClinicalTrials.gov.

Ambelvist prescribing information: AMBELVIST (gadoquatrane) Prescribing Information. Bayer. labeling.bayerhealthcare.com.

GBCA safety update (AJR): Update on Gadolinium-Based Contrast Agent Safety. AJR. doi:10.2214/AJR.23.30036.

Gadolinium retention brain review: MRI contrast agents and retention in the brain: review. PMC11282029.

Linear versus macrocyclic gadolinium CNS gene expression: Long-term effects of linear versus macrocyclic GBCAs on gene expression in CNS of mice. PMC11723877.

Gadolinium toxicity mechanisms review: Gadolinium toxicity: mechanisms, clinical manifestations, and nanoparticle role. PMC12454587.

NSF overview: Nephrogenic Systemic Fibrosis. StatPearls. NCBI.

ACR Manual on Contrast Media (2026): ACR Manual on Contrast Media. acr.org.

MRI overview: Magnetic Resonance Imaging. NIBIB.

Vueway (gadopiclenol) prescribing information (comparator reference): Vueway (gadopiclenol) package insert. Bracco.

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Ambelvist (gadoquatrane) carries a boxed warning for risks associated with intrathecal administration and nephrogenic systemic fibrosis. Decisions about contrast agent selection for MRI examinations are made by qualified radiologists and ordering clinicians based on the clinical question, patient characteristics, and institutional protocols. Patients with renal impairment should discuss the use of gadolinium-based contrast agents with their physician before undergoing contrast-enhanced MRI.

June 21, 2026